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Hemostasis and thrombosis 
Under normal conditions the blood is maintained in a fluid state, but after vascular 
damage the hemostatic system functions to arrest hemorrhage by inducing the formation 
of a clot. When the hemostatic balance is disturbed in intact vessels, thrombosis may 
occur with vascular occlusion as a result. In the arterial system, thrombosis is 
characterized predominantly by platelets (so-called white thrombus), while thrombi in the 
venous system are rich in fibrin and erythrocytes (so-called red thrombi).
1
   
The main trigger for the formation of a thrombus after arterial injury is endothelial 
damage, as a consequence of which flowing blood comes into contact with extracellular 
matrix components, such as collagen, laminin, fibronectin and von Willebrand factor 
(vWF).
2,3
 Platelets play a fundamental role in the ensuing (patho)physiological 
processes. In the classical concept of thrombus formation, platelets adhere to the 
subendothelial structures, become activated and accumulate into a growing platelet 
aggregate (platelet plug). Subsequent activation of the coagulation cascade via exposure 
of tissue factor is considered to lead to the formation of thrombin and fibrin, which 
stabilizes the thrombus and forms a clot.
4
 However, new intravital technologies in 
examining thrombus formation in vivo have demonstrated that platelet aggregate 
formation and fibrin clot formation locally overlap and occur almost simultaneously.
5
 
Another classical concept is that platelets activated by thrombin and collagen stimulate 
the coagulation cascade by providing a membrane surface for the assembly of 
coagulation factors.
6
 As a consequence, platelet activation and coagulation are highly 
interdependent processes, occurring simultaneously and stimulating each other.
7
 In spite 
of major achievements in this area during the last decades, there is still incomplete 
understanding of the precise interaction mechanisms of platelet activation and 
coagulation. 
Arterial and venous thrombosis are usually treated with anti-platelet and anti-
coagulation medication, respectively. Only few studies have been performed with 
combinations of this medication and not all had a positive outcome. Hence, better 
understanding of the ways how platelets influence the coagulation system and vice versa 
is required for more effective treatment of cardiovascular diseases. 
To provide background information, the remaining part of this chapter will focus on 
the platelet agonists and signaling pathways that are relevant for the interactions of 
platelets and coagulation. In addition, a brief outline will be given of the coagulation 
cascade. Extensive overviews of the roles of platelets in thrombus formation and 
coagulation, as well as the classical signaling mechanisms involved, are given 
elsewhere.
3,8
 
Platelet activation by soluble agonists 
The serine protease thrombin plays a central role in coagulation by converting fibrinogen 
to fibrin and, in addition, it is among the most potent activators of platelets.
9
 Thrombin 
provokes a shape change of platelets, secretion of granules and activation of integrin 
αIIbβ3 which mediates platelet aggregation. Thrombin exerts these effects by interacting 
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with G protein-coupled protease-activated receptors (PARs).
10
 Human platelets express 
the isoforms PAR1 and PAR4
11,12
, while mouse platelets express PAR3 and PAR4.
13
 
Both PAR1 and PAR4 contain their own receptor-activating ligand. Thrombin cleaves the 
N-terminal exodomain at an arginine residue, which then unmasks a new N-terminus 
serving as tethered ligand for the receptors.
14
 It has been established that PAR1 
mediates human platelet activation at low thrombin concentrations, whereas PAR4 
activation requires high concentrations of thrombin. Activation of PARs in mouse 
platelets occurs slightly different than in human platelets as PAR3 is not cleaved by 
thrombin, but functions as a cofactor for PAR4 to promote its cleavage and activation at 
low thrombin concentrations.
10
 
Once cleaved by thrombin, both PAR1 and PAR4 activate heterotrimeric G proteins 
of the G13 and Gq families (Figure 1A). Activation of G13 stimulates the Rho/Rho-
kinase-mediated signaling pathway, which mediates reorganization of the actin 
cytoskeleton and results in platelet shape change. Gq activation stimulates the β isoform 
of phospholipase C, resulting in the formation of diacylglycerol (DAG) and inositol 1,4,5-
triphosphate (IP3) from phosphatidylinositol-(4,5)-biphosphate (PIP2). DAG activates 
protein kinase C, a key signaling protein in platelets, as well as the Rap1b exchange 
factor, CalDAG-GEF.
15
 The other second messenger IP3 releases Ca
2+ 
from intracellular 
stores, primarily the endoplasmatic reticulum, by interacting with IP3 receptor channels. 
Once the intracellular Ca
2+
 stores are depleted, Ca
2+ 
entry from the extracellular medium 
is activated.
16-18
 The identity of the Ca
2+
 entry channels has for long remained unclear. 
Recently, a role for STIM and Orai proteins have been identified in Ca
2+
 entry.
19,20
 Early 
 
 
Figure 1. Thrombin- and ADP-induced signaling pathways in platelets. (A) The thrombin 
receptors PAR1 and PAR4 and the ADP receptor P2Y1 couple to Gq and activate phospholipase Cβ 
(PLCβ), which leads to the formation of inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). 
IP3 releases Ca
2+
 from the intracellular stores and DAG activates protein kinase C (PKC) and the 
guanine nucleotide exchange factor, CalDAGGEF. (B) The other ADP receptor P2Y12 couples to Gi, 
which on the one hand activates phosphoinositide 3-kinase (PI3-K) and Akt and on the other hand 
inhibits adenylyl cyclase, thereby decreasing the formation of cAMP and inhibiting protein kinase A 
(PKA). Activation of these Gq-coupled pathways results in platelet activation and aggregation via 
integrin αIIbβ3. 
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data suggested that PARs might also couple to the Gi protein, but current evidence 
shows that Gi signaling in response to thrombin occurs indirectly via ADP, which is 
released upon platelet stimulation.
10,21
 Thromboxane A2, autocrine produced by 
phospholipase A2 and cyclooxygenase activation, signals via Gq-coupled receptors in a 
similar way as thrombin. 
Another positive feedback mediator of platelet activation is ADP, which is released 
from the dense granules. Two G protein-coupled receptors for ADP are present on 
platelets, namely P2Y1 and P2Y12. The P2Y1 receptor couples to Gq and signals in the 
same way as PAR1/4 (Figure 1A). On the contrary, the P2Y12 receptor couples to Gi and 
inhibits adenylyl cyclase, the enzyme that produces cAMP and activates protein kinase A 
(PKA).
21,22
 In addition, Gi signaling also results in stimulation of phosphoinositide 3-
kinase (PI3-K), which forms phosphatidylinositol 3,4,5-trisphosphate (PIP3) to activate 
downstream signaling targets, including protein kinase B/Akt (Figure 1B).
22,23
 Using 
these two signaling pathways the P2Y12 receptor functions to complete platelet 
aggregation and potentiate platelet secretion.
24
 Especially the β- and γ-isoforms of PI3-K 
mediate ADP-induced aggregation.
25
 It is still unclear whether PI3-K isoforms also 
influence other platelet functions than aggregation. In addition to ADP, platelets secrete 
ATP which activates the ligand-gated cation channel P2X1 and thereby induces fast Ca
2+
 
entry.
22
 It has been shown that P2X1 participates in shape change and aggregation in 
response to collagen.
26
   
Platelet activation by adhesive agonists 
Collagens are richly present in the vessel wall. They become exposed to the blood 
stream upon vascular injury, and support platelet adhesion and activation. The most 
abundant fibrillar collagens in the vessel wall, types I and III, are also adhesive for 
platelets.
27
 Two major collagen receptors are implicated in platelet-collagen interaction, 
i.e. integrin α2β1 and glycoprotein VI (GPVI), with the latter being the dominant receptor 
in inducing signaling.
28
 The signaling pathways are extensively described elsewhere.
29
 
Briefly, GPVI associates with the Fc receptor (FcR) γ-chain that contains an 
immunoreceptor tyrosine-based activation motif (ITAM). Collagen causes cross-linking of 
GPVI, which induces tyrosine phosphorylation of the FcR γ-chain ITAM by the Src 
kinases, Fyn and Lyn (Figure 2A). This leads to recruitment of the SH2 domain-
containing Syk, which by downstream signaling results in the formation of a large 
activation complex.
27
 This complex includes adapter proteins that act as docking sites for 
effector enzymes, such as phospholipase Cγ2 (PLCγ2) and PI3-K. The adapter proteins 
LAT, SLP-76 and Gads have a partly overlapping role herein. Similarly to PLCβ, PLCγ2 
releases Ca
2+
 from the internal stores via PIP2 cleavage and IP3 formation. Evidence has 
been presented for a LAT-independent way of PLCγ2 activation, but the mechanism is 
still unclear. In addition, it is proposed that PLCγ1 can act as a backup effector if PLCγ2 
is absent.
29,30
   
Another important adhesive receptor is integrin αIIbβ3 which is required for platelet 
aggregation and spreading on extracellular matrices. Both the αIIb and the  
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Figure 2. Signaling pathways to Ca
2+
 release in platelets adhered to collagen or fibrinogen. 
(A) Collagen clusters glycoprotein VI (GPVI), which then associates with the Fc receptor (FcR) 
γ-chain. Phosphorylation events by the Src kinases Fyn and Lyn leads to recruitment of Syk and 
phosphorylation of the transmembrane adapter protein LAT. LAT serves as a docking site for 
phospholipase Cγ2 (PLCγ2), which causes IP3 formation and release of Ca
2+
. (B) Fibrinogen binds 
to and clusters integrin αIIbβ3. Integrin clustering results in activation of Src, which is bound to the 
β3 tail, and subsequent activation of Syk. PLCγ2 is activated, likely via Syk, and Ca2+ is released 
from the internal stores.  
 
β3-chains consist of a large extracellular moiety and a short cytoplasmic tail. Integrin 
αIIbβ3 is capable of bidirectional signaling, as specific proteins can bind to the 
intracellular or extracellular moieties and cause functional changes.
31,32
 Activation of the 
thrombin, ADP or collagen receptors increases the activation state of integrin αIIbβ3, via 
the signaling pathways mentioned above. This ‘inside-out’ signaling causes a reversible 
conformational transition in αIIbβ3 to allow binding of the ligands, fibrinogen and von 
Willebrand factor.
33
 A critical step herein appears to be interaction of the actin-associated 
protein talin with the β3 chain.34 On the other hand, ligand binding to αIIbβ3 and 
subsequent integrin clustering provokes ‘outside-in’ signals that in turn promote actin 
cytoskeletal reorganization and granule secretion. Outside-in signaling involves 
activation of Src and Syk kinases, which in turn stimulate the effector proteins PLCγ2 and 
PI3-K (Figure 2B). Src kinase is constitutively associated with the β3 cytoplasmic tail and 
becomes activated when fibrinogen clusters αIIbβ3. Syk is then recruited to the β3 tail 
and is activated by Src. It is proposed that Syk plays a role in the phosphorylation of 
PLCγ2.30,31 Outside-in signaling pathways independent of Syk have also been described 
and involve tyrosine phosphorylation of the β3-integrin tail and the proteins Shc, Dok2 
and myosin.
30,35
 Functional platelet responses of outside-in signaling are only limitedly 
investigated, but include spreading on a fibrinogen surface and clot retraction.
36
 Although 
many proteins interact with αIIbβ3, their functions remain to be explored.31  
Coagulation and the platelet procoagulant response 
Blood coagulation occurs by a series of enzymatic reactions in which zymogens of serine 
proteases are converted into active coagulation factors (enzymes), which eventually lead 
to the formation of thrombin and fibrin. The presence of many positive and negative 
Chapter 1  
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feedback loops makes the coagulation system quite complex.
37
 For the purpose of this 
thesis, only a simplified figure is given in Figure 3. One way to initiate the coagulation 
process is by exposure of tissue factor (extrinsic pathway).
38
 Tissue factor is expressed 
on vascular cells or present in the blood in an encrypted form.
39
 Once exposed and 
active, it forms a complex with factor VIIa and activates factors X and IX to Xa and IXa, 
respectively. With factor VIIIa as a cofactor, factor IXa can activate factor X, whereas 
factor Va functions as a cofactor for factor Xa in the conversion of prothrombin into 
thrombin.
2,40
  Thrombin amplifies its own formation by activating factors V, VIII and XI, 
although the physiological relevance of this way of factor XI activation is recently 
debated.
41
 Fibrin formed by thrombin stabilizes the thrombus. 
The alternative way to trigger coagulation (contact activation or intrinsic pathway) 
involves factor XII. This is supposed to start when factor XII comes into contact with 
negatively charged surfaces, e.g. subendothelial matrix proteoglycans, 
glycosaminoglycans and collagens (Figure 3).
42
 However, which is the main 
physiological activator of factor XII is still debated.
43
 Artificial negatively charged 
materials like kaolin and glass are used as non-physiological activators of this pathway in 
clotting assays. At these surfaces, factor XII is converted into its activated form with the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Simplified overview of extrinsic and intrinsic pathways of thrombin generation. The 
extrinsic pathway is initiated by complex formation of tissue factor with factor (F)VIIa. Subsequent 
activation of FIX and FX results in the conversion of prothrombin into thrombin. The intrinsic 
pathway is initiated by contact of FXII with negatively charged surfaces, involving prekallikrein (PK) 
and high molecular weight kininogen (HMWK). FXII-induced activation of FXI leads to the activation 
of FIX and FX, and eventually thrombin is formed. Thrombin leads to activation of platelets as well 
as the conversion of fibrinogen into fibrin. The formation of thrombin is greatly accelerated on the 
procoagulant surface (PS exposure) of activated platelets. The platelets assemble into a thrombus 
that is stabilized by fibrin. Positive feedback loops and anticoagulant factors are not indicated. For 
further details, see text. 
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help of kallikrein and high molecular weight kininogen. The majority of prekallikrein in 
blood is bound to high molecular weight kininogen. High molecular weight kininogen 
functions as a cofactor as it simultaneously binds to prekallikrein and negatively charged 
surfaces. Binding of FXII to negatively charged surfaces leads to autoactivation. The 
conversion of prekallikrein to kallikrein is catalyzed by factor XIIa and then kallikrein can 
activate factor XII again.
43
 In its active form factor XII activates factor XI and 
subsequently factor IX, which as described above results in factor X activation and 
thrombin formation.
42
 Traditionally, the tissue factor pathway is considered to be the 
most important initiator of coagulation since deficiency in factor VII or tissue factor is 
associated with severe hemorrhage
44,45
, while deficiency in FXII is not related to a 
bleeding phenotype.
46
 However, this concept was challenged by a report that factor XII-
deficient mice showed greatly reduced thrombus formation in various models of 
experimental arterial and venous thrombosis.
47
  
Platelets stimulate coagulation by providing a phospholipid surface, at which 
coagulation factors can assemble and become activated. In resting platelets the 
procoagulant phospholipids, phosphatidylserine (PS) and phosphatidylethanolamine 
(PE) are present in the inner leaflet of the plasma membrane. Upon platelet activation 
PS and PE become exposed from the inner to the outer leaflet, likely by scramblase 
activity.
48
 Especially the negatively charged PS supports the Ca
2+
-dependent formation 
of the tenase complex, consisting of factors IXa and VIIIa, and the prothrombinase 
complex with factors Xa and Va. Co-localization of these procoagulant complexes on the 
platelet surface accelerates the formation of thrombin dramatically. It has been shown 
that PS exposure on the platelets is induced by a prolonged rise in intracellular Ca
2+ 
concentration.
8,49
 Ca
2+
 ionophore followed by complement membrane attack complex 
C5b-9 appeared to be most effective in evoking PS exposure.
7
 Early evidence already 
described that activation of platelets with the physiological agonists thrombin or collagen 
increased PS exposure moderately, but simultaneous stimulation with thrombin and 
collagen was very potent in causing PS exposure.
6
 At present, the thrombin receptor 
PAR1 and collagen receptor GPVI are believed to be the major receptors responsible for 
inducing platelet procoagulant activity.
50-52
 However, during in vivo thrombus formation 
few platelets become exposed to both thrombin and collagen and therefore it is likely that 
other agonists also are involved in platelet procoagulant activity. Additional agonists and 
signaling pathways remain to be elucidated.   
Aims and outline of the thesis 
This thesis focuses on novel interaction mechanisms of platelet signaling and 
coagulation which may play an important, hitherto undiscovered role in thrombosis and 
hemostasis. Following the introductory chapter 1, the role of platelets in venous and 
arterial thrombosis is discussed in a short review presented in chapter 2. Starting from 
the premise that activation of platelets and coagulation are cooperative processes; this 
review paper considers that platelets should play a role in venous thrombosis. In the next 
chapters, it was investigated by which mechanisms platelets can affect thrombin 
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generation and coagulation. Insight into these processes can give information on the 
efficacy of antiplatelet treatment in the prevention of thrombosis. In chapter 3 the role of 
the platelet agonist, ADP, and of the purinergic P2Y1 and P2Y12 receptors was examined 
with regards to the procoagulant effect of platelets. For patients at thrombotic risk, the 
result of anti-P2Y12 treatment was assessed on platelet-dependent thrombin generation 
using calibrated automated thrombography (CAT). This work revealed that ADP, acting 
via P2Y12, exerts a procoagulant effect particularly by enhancing Ca
2+
 fluxes in platelets. 
Chapter 4 subsequently describes a dual signaling mechanism, by which P2Y12 can 
synergize with thrombin to increase the Ca
2+
 and procoagulant responses. Purinergic 
receptor stimulation leads to integrin αIIbβ3 activation, while blockade of this integrin 
suppresses platelet-mediated procoagulant activity. In chapter 5 it was therefore 
investigated, by which signaling mechanism αIIbβ3 is capable to contribute to the 
coagulation process. The second part of this thesis examines how collagen can 
contribute to the roles of platelets in thrombin generation and thrombus formation. In 
chapter 6 it is hypothesized that collagen has an additional function beyond stimulation 
of the platelet GPVI receptors. By using blood from mice deficient in coagulation factor XI 
or XII, or mice lacking signaling proteins of the GPVI cascade, it appeared that collagen 
in addition is capable to stimulate the intrinsic pathway of coagulation. The novel findings 
of this thesis are critically discussed in relation to the current literature in chapter 7, 
where also possible clinical implications are described. 
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The blood coagulation system serves at least two main functions in physiology: 
controlling bleeding due to trauma and protecting the organism against infections as part 
of the innate immune system.
1
 These functions are accomplished by multiple interactions 
between cellular elements (platelets, leukocytes and endothelial cells) and proteins of 
the coagulation and fibrinolytic pathways. In case of bleeding, the traditional view is that 
the cells provide the first line of defence, i.e. aggregated platelets form the primary 
hemostatic plug after which the coagulation process permits fibrin clot formation 
(secondary hemostasis). The modern view is slightly different in the sense that we 
consider these mechanisms as cooperative and acting in parallel, in fact behaving as an 
integrated cell-protein clotting machinery. Why and how, then, have platelets and the 
coagulation system still different functions? 
Excessive activity of the blood coagulation system can result in excess fibrin 
formation at sites of blood stasis or vascular damage, where it is potentially harmful. This 
situation may lead to venous thrombosis, in which a fibrin and cellular meshwork partially 
or completely obstructs a major vein. On the other hand, rupture of an atherosclerotic 
plaque can result in arterial thrombosis. Thrombosis by itself is a cause of serious clinical 
complications; venous thrombosis leads to pulmonary embolism and post-thrombotic 
syndrome, while arterial thrombosis causes impaired oxygenation of a critical organ, 
resulting in e.g. a myocardial infarction or stroke. 
From early studies by Virchov and other pathologists it is known that venous and 
arterial thrombi typically differ in their composition. While venous thrombi appear as ‘red’ 
clots due to numerous red cells intermingled with fibrin, arterial thrombi are ‘white’ in 
appearance due to a predominance of platelets with associated fibrin.
2
 Consequently, it 
has been surmised for long that particularly platelets play a distinct role in the thrombotic 
processes, in the sense that their participation is critically important in arterial 
thrombosis, but not apparent in venous thrombosis.
3,4
 This corresponds well to the 
experimental evidence ex vivo that tissue factor is a primary trigger for thrombus 
formation under (coagulant) conditions resembling those of venous thromboembolism.
5
 
Also, at high shear-rate conditions, as in (stenotic) arteries, collagen with deposited von 
Willebrand factor (vWF) is known to be an initial trigger for platelet tethering and 
adhesion, which predisposes for the formation of platelet-rich thrombi with a typical 
‘arterial’ composition.
6,7
 However, the recognition that also blood-borne tissue factor can 
promote for arterial thrombus formation 
8
 has changed this black-white view. 
Presently, we have considerable knowledge of the molecular mechanisms of the 
interactions of platelets and the coagulation system.
9
 Activated platelets expose 
procoagulant phospholipids, which enhance the generation of factor Xa and thrombin by 
several magnitudes.
10
 Since thrombin is one of the most potent platelet agonists, this 
procoagulant activity of platelets results in a positive feedback loop of platelet activation, 
thrombin generation and fibrin formation.
11
 Platelets already respond at very low (sub-
nanomolar) concentrations of thrombin via their receptors (PARs), i.e. well before fibrin 
starts to be formed. It is thus inevitable that all platelets become in an activated state at 
sites of venous thrombosis, where locally quite high levels of thrombin can be reached. 
This would imply that platelet procoagulant activity is a potent driving force for the 
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thrombin generation in venous thrombosis, although this has not yet been demonstrated. 
Thus, simply the fact that thrombin is formed in thrombotic veins predicts that platelets 
will contribute to the thrombotic process. All of this does not necessarily mean that weak 
platelet antagonists (like aspirin) effectively affect the thrombotic process; for instance, 
the tissue factor (blood-borne?) induced thrombin generation can locally be too high to 
be inhibited by weak antiplatelet agents whereas anticoagulant medication is still 
effective.  
In experimental animal studies, the effect of platelet inhibitors on venous thrombosis 
indeed depends on the model chosen. In general, stasis-induced thrombi are insensitive 
to platelet inhibition, e.g. with aspirin, while inflammation related models (applying an 
inflammatory stimulus) may be more dependent on platelet function.
3
 The clearest 
influence of platelet inhibitors is observed in models where the venous wall is directly 
damaged by mechanical or other forces. Under those conditions, platelets likely interact 
with subendothelial collagen and vWF, facilitating their adherence and activation, while 
aspirin or ADP receptor blockers inhibit the venous thrombus formation.
12
 Thus, following 
the argumentation above, while thrombin will activate platelets at the thrombotic sites 
under all these conditions, platelet inhibitors seem to be most effective in situations 
where a direct trigger for platelet activation is present (LPS, collagen, vWF). 
Translating these animal experiments to the clinical situation, the efficacy of 
antiplatelet therapy in venous thrombosis may similarly depend on the underlying cause. 
Thus, stasis dependent thrombosis during prolonged physical immobilization or gradual 
occlusion of a vein may be less inhibitable with platelet antagonists than trauma induced 
thrombosis. 
Is this argumentation of any clinical relevance? We believe it is for the following 
reasons. First, there is an ongoing debate about the importance of platelet inhibitors in 
the prevention of venous thromboembolism (VTE), where advocates claim that the 37% 
or 53% risk reduction observed in a meta-analysis of platelet inhibition in preventing 
deep venous thrombosis and pulmonary embolisms, respectively, is highly relevant.
13
 In 
contrast, in a recent position paper other investigators indicate that this antithrombotic 
effect of platelets inhibitors is of limited clinical importance as compared to the more 
effective low molecular weight heparins.
14
 Here, better knowledge of the platelet triggers 
in relation to venous thrombosis under different conditions may help to clarify the clinical 
arguments. Also, the use of platelet antagonists with an anticoagulant effect such as 
clopidogrel
15,16
 and integrin blockers
17
 should be considered. Second, and related, there 
is still a need for simple ways of preventing venous thrombosis in conditions like 
prolonged immobilization during long-term transportation such as flying. Here, it would 
be very helpful to estimate how effective aspirin (or perhaps even better other platelet 
inhibitors with anticoagulant effect) might be in limiting the risks, but it is unlikely that 
clinical trials will be able to answer the question, because of the low incidence of clinical 
VTE and consequently huge study samples required. Third, new proposals for classifying 
idiopathic VTE
18
 may take into account the likely presence of a platelet trigger. 
Finally, to answer the question what is the role of platelets in venous 
thromboembolism? Most likely, this role is considerable, but effective inhibition may need 
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the use of combination medication of anticoagulants and antiplatelet agents, particularly 
those which also have an anticoagulant potential such as clopidogrel and integrin 
blockers. 
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Abstract 
Activated platelets participate in arterial thrombosis by forming aggregates and 
potentiating the coagulation through exposure of procoagulant phosphatidylserine. The 
function of the two receptors for ADP, P2Y1 and P2Y12, is well-established in 
aggregation, but is incompletely understood in the platelet procoagulant response. We 
established that, in PRP from healthy subjects, ADP accelerated and potentiated tissue 
factor-induced thrombin generation exclusively via stimulation of P2Y12 and not via P2Y1 
receptors. The P2Y12 receptors also mediated the potentiating effect of PAR1 stimulation 
on thrombin generation. Furthermore, ADP enhanced in a P2Y12-dependent manner the 
Ca
2+
 response induced by thrombin, which was either added externally or generated in-
situ. This ADP effect was in part dependent of phosphoinositide 3-kinase and was 
paralleled by increased phosphatidylserine exposure. In PRP from (young) patients with 
either stroke or type-II diabetes, platelet-dependent thrombin generation was similarly 
enhanced by ADP or SFLLRN as in healthy subjects. In PRP from stroke patients of 
older age, the P2Y12-mediated contribution to thrombin generation was variably reduced 
by two weeks of clopidogrel medication. Remaining P2Y12 activity after medication 
correlated with remaining P2Y12-dependent P-selectin exposure, i.e. Ca
2+
-dependent 
secretion, likely due to incomplete antagonism of P2Y12 receptors. Together, these 
results indicate that physiological platelet agonists amplify phosphatidylserine exposure 
and subsequent thrombin generation by release of ADP and P2Y12-receptor stimulation. 
This P2Y12 response is accomplished by a novel Ca
2+
 signaling pathway. It is similarly 
active in platelets from control subjects and patients at thrombotic risk. Finally, the 
thrombogram method is useful for measuring incomplete P2Y12 inhibition with 
clopidogrel. 
Introduction 
Platelet activation and blood coagulation are mutually stimulatory processes in 
hemostasis and thrombosis.
1,2
 When stimulated with agonists that cause a prolonged 
elevation in cytosolic [Ca
2+
]i such as collagen or calcium ionophore, platelets respond by 
exposing procoagulant phosphatidylserine (PS) at their outer surface.
3
 The resulting PS-
exposing membrane provides assembly sites for tenase and prothrombinase complexes 
from the coagulation system, which result in a vast acceleration of thrombin generation.
4
 
Conversely, once formed, thrombin is a potent physiological agonist, acting through the 
platelet Gq/12-coupled receptors, PAR1 and PAR4.
5
 Most likely because thrombin 
induces only transient, spiking Ca
2+
 mobilisation in platelets,
6
 by itself it is no more than 
weakly active in causing PS exposure and stimulating prothrombinase activity.
4,7
 
Recent evidence indicates that release of endogenously stored ADP is a key event in 
platelet aggregation in response to physiological agonists such as thrombin or 
collagen.
8,9
 The pro-aggregatory effect of ADP in platelets involves two purinergic 
receptors, P2Y1 and P2Y12.
10,11
 The same receptors mediate the formation of platelet 
thrombi in blood flowing over a collagen surface.
12,13
 P2Y1, which is coupled to Gq 
(similarly as PAR1 and PAR4) triggers the classical pathway of intracellular Ca
2+
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mobilisation and subsequent store-regulated Ca
2+
 influx by activating phospholipase Cβ. 
The P2Y12 receptor acts via a Gi-coupled pathway that inhibits adenylyl cyclase and, as 
a result, lowers cyclic-AMP levels. Similarly as with adrenaline, this cyclic-AMP lowering 
can result in increased Ca
2+
 signal generation.
14
 In addition, P2Y12 stimulates a 
phosphatidyl inositol 3-kinase (PI3-K) pathway, putatively involving the γ-isoform of PI3-
K, which is known to be activated by βγ regulatory subunits released from Giα.15 Activity 
of PI3-K completes the ADP-induced aggregation by enhancing the secretion reaction 
and activating integrin αIIbβ3.9,16 
A number of earlier and recent studies indicate that ADP release and P2Y12 receptor 
stimulation contribute to thrombin generation and coagulation.
17-20
 This finding raises a 
number of important questions. Because during the coagulation process high levels of 
thrombin are formed, which are sufficiently high to fully activate both PAR1 and PAR4, it 
is unclear how the released ADP can bypass or enhance the effects of PAR stimulation 
on platelets. Further, since platelet procoagulant activity is a Ca
2+
-dependent process, it 
is tempting to infer that ADP contributes to thrombin generation by increased Ca
2+
 
signaling, but whether this is indeed the case and by which signaling pathways, are 
questions that are still unanswered. Another unresolved issue is whether or not ADP 
contributes to coagulant activity by surface exposure of PS or integrin activation.
17,18,21
 
Better knowledge of the mechanism of ADP-stimulated procoagulant activity is of 
considerable interest, as P2Y12 is the target of antithrombotic drugs like clopidogrel.
22-24
 
Clopidogrel is currently administered as a substitute for aspirin to patients with 
increased atherothrombotic risk. Differently from inhibiting thromboxane formation with 
aspirin, clopidogrel treatment may reduce not only platelet aggregation, but also platelet-
dependent coagulant activity. There is evidence for the presence of hyperactive platelets 
with increased procoagulant activity in patients with ischemic stroke.
25
 Similarly, 
increased platelet reactivity, e.g. via ADP receptors, may contribute to the 
hypercoagulable state in type-II diabetes mellitus.
26
 This suggests that anti-P2Y12 
medication would be particular helpful for these patients. On the other hand, recent 
aggregation measurements indicate that the inhibitory effect of clopidogrel intake is not 
always complete, but the effect on P2Y12-mediated procoagulant activity was not 
investigated.
27
 
Here, we investigated the procoagulant effect of ADP receptors under conditions of 
coagulation using the newly developed thrombogram method, which allows continuous 
measurement of the thrombin generation in coagulating platelet-rich plasma (PRP).
28
 We 
found that ADP, exclusively acting via P2Y12, stimulated the thrombin-forming process by 
a hitherto unrecognised Ca
2+
 response and stimulation of PS exposure. In platelets from 
patients with stroke or type-II diabetes mellitus, P2Y12 caused an unchanged, enhancing 
effect on thrombin generation which, however, was quite variably suppressed by 
clopidogrel intake. 
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Materials and methods 
Subjects 
For comparative thrombin generation studies, blood was taken from 11 healthy subjects, 
who were free from medication for at least two weeks. Blood was also taken from 11 
young patients with stroke, aged 32 to 51 years (median 47 years). Other blood samples 
were obtained from 9 stroke patients of older age, i.e. 60 to 74 years (median 65 years), 
who were subsequently advised to take clopidogrel for two weeks (75 mg daily); a 
second blood sample was obtained at the end of this period to monitor the efficacy of this 
intervention. These patients had experienced an ischemic stroke at 3-12 months earlier 
(lesion proven by computer tomography or magnetic resonance imaging). Stroke 
patients did not use anti-platelet or anti-coagulant medication other than aspirin; 8 out of 
9 older patients and 9 out of 11 young patients used statins. Finally, blood was taken 
from 12 patients with confirmed type-II diabetes mellitus, aged 26 to 73 years (median 56 
years). All participating subjects gave full informed consent. The studies were approved 
by the local medical ethical committee. 
Materials 
ADP, apyrase, bovine serum albumin (BSA), adrenaline, thrombin, MRS2179 (MRS) and 
wortmannin were obtained from Sigma (St. Louis, MO, USA). PAR1 peptide SFLLRN 
and fluorescent thrombin substrate, Z-Gly-Gly-Arg aminomethyl coumarin (Z-GGR-
AMC), were from Bachem (Bubendorf, Switzerland). Recombinant human tissue factor 
was from Dade Behring (Marburg, Germany); acetylsalicylic acid (aspirin) from 
Genfarma (Maarssen, The Netherlands); Fura-2 pentaacetoxymethyl ester (Fura-2 AM) 
from Molecular Probes (Leiden, The Netherlands). AR-C69931MX (AR-C) was kindly 
provided by Astra-Zeneca (Charnwood, UK). Fluorescent-labelled and unlabelled 
annexin-A5 were obtained from Nexins Research (Hoeven, The Netherlands). 
Monoclonal antibody against P-selectin labelled with fluorescein isothiocyanate (anti-
CD62P FITC) came from Immunotech (Marseille, France); FITC-labelled antibody PAC-1 
against activated integrin αIIbβ3 was from Becton Dickinson (San Jose, CA, USA). 
Human thrombin calibrator was from Thrombinoscope (Maastricht, The Netherlands); 
ancrod came from NIBSC (Hertfordshire, UK). 
Isolation of platelets 
Blood was drawn with a 1.2-mm needle, dripping freely into open tubes (first 2.5 mL of 
blood was discarded), and collected in 1/10 volume of 129 mM trisodium citrate. PRP 
was obtained by 15-min centrifuging at 240 g. Platelet-poor plasma (PPP) was prepared 
by centrifuging PRP twice at 2630 g for 10 min. Platelet count in PRP was determined 
with a thrombocounter (Coulter Electronics, Luton, UK) and normalised with autologous 
PPP. 
To obtain washed platelets, blood was collected into 1/6 volume of acid-glucose 
solution (ACD, 80 mM trisodium citrate, 52 mM citric acid and 180 mM glucose). PRP, 
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prepared by centrifugation, was incubated with 2.5 µM Fura-2 AM at 37°C for 45 min. 
After addition of ACD solution and apyrase (0.1 U/mL ADPase), platelets were 
centrifuged at 800 g for 15 min, and after a wash step resuspended in Hepes buffer pH 
7.45 (10 mM Hepes, 136 mM NaCl, 2.7 mM KCl, 2 mM MgCl2, 0.1% glucose and 0.1% 
BSA).
 
Thrombin generation measurements 
Normalised PRP was preincubated with indicated inhibitors and/or activators. After 10 
min, coagulation was initiated with tissue factor/CaCl2, and thrombin generation was 
continuously measured at 37°C.
19
 Briefly, 80 µL of PRP (150 x 109 platelets/L) were 
pipetted into a polystyrene 96-wells plate (Immulon 2HB, Dynex Technologies, Chantilly, 
VA, USA). Wells contained 20 µL tissue factor (6 pM) in buffer A (20 mM Hepes, 140 mM 
NaCl and 5 mg/mL BSA at pH 7.35). The plate was pre-heated to 37°C for 5 min in a 
fluorescence well-plate reader. Coagulation was started by adding 20 µL of Z-GGR-AMC 
(2.5 mM), dissolved in buffer B (20 mM Hepes, 140 mM NaCl, 100 mM CaCl2, 60 mg/mL 
BSA at pH 7.35). After 10 s shaking, fluorescence from cleaved AMC was measured at 
excitation and emission wavelengths of 368 and 460 nm, respectively. Fluorescence 
measurements were with a Fluoroskan Ascent well-plate reader (Themolab Systems, 
Helsinki, Finland), equipped with Thrombinoscope software. An internal thrombin 
calibrator was used to give corrected curves of thrombin generation.
29
 Alternatively, 
where indicated, fluorescence accumulation was measured with a Spectramax well-plate 
reader (Molecular Devices, Sunnyvale, CA, USA). In this case, first-derivative traces 
were directly converted into nanomolar concentrations of thrombin,
28
 by post-hoc 
calibration based on normal pool plasma. Peak height, time-to-peak and area-under-the-
curve (i.e., endogenous thrombin potential, ETP) were used as principal parameters 
determining thrombin generation curves. 
Cytosolic Ca
2+
 measurements 
Washed, Fura-2 loaded platelets, diluted in Hepes buffer pH 7.45 to 100×10
9
 platelets/L, 
were used for [Ca
2+
]i measurements, as described elsewhere.
30
 Before administrating 
agonist, 1 mM CaCl2 was added. Changes in Fura-2 fluorescence were measured under 
stirring at 340 and 380 nm excitation by ratio fluorometry. After correction for background 
fluorescence, ratio values were converted into levels of [Ca
2+
]i; both maximal rises in 
[Ca
2+
]i and [Ca
2+
]i-time integrals (5 min) were determined.
6
 
Flow cytometry 
Washed platelets (100×10
9
 platelets/L) were resuspended in citrate plasma that was 
defibrinated by treatment with 14 µL ancrod (10 U/mL). Coagulation was triggered with 
CaCl2 (16.6 mM); tissue factor (5 pM) was added, as indicated. Exposure of PS was 
determined with flow cytometry after 11 min of activation, using FITC-labelled annexin 
A5.
21
 Flow cytometry was also used to measure P-selectin exposure and integrin αIIbβ3 
activation, using FITC-labelled anti-CD62 and FITC-labelled PAC-1 antibodies, 
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respectively.
31
 PRP (300×10
9
 platelets/L) was 10-times diluted with Hepes buffer pH 
7.45 and activated with indicated agonists for 10 min. 
Statistics 
Statistical analysis was performed using the independent-samples t-test to compare 
independent variables, and the paired-samples t-test to compare effects of interventions. 
SPSS 11.0 software was used. Data are presented as means±SEM. However, where 
data from various individuals were compared, data are given as means±SD. 
Results 
Enhancement of thrombin generation by PAR1 or ADP receptor stimulation is 
exclusively mediated by P2Y12 receptor 
Recent reports indicate that thrombin generation in coagulating PRP is in part mediated 
by ADP release and P2Y12 stimulation.
18,19
 To confirm this, effects of ADP receptor 
antagonists on thrombin generation curves were determined in citrate PRP from healthy 
subjects that was triggered with CaCl2 and a low concentration of tissue factor (1 pM). 
Preincubation of PRP with the selective P2Y12 antagonist AR-C diminished and delayed 
the time-to-peak of thrombin formation from 24±1.3 to 30±2.1 min (mean±SEM, n=5) 
(Fig. 1A). Similar effects were obtained at doses of 1-30 µM AR-C, in agreement with the 
high affinity of this compound for P2Y12 (10
-9
 M range). In contrast, the P2Y1 antagonist 
MRS, which has a lower receptor affinity and was therefore used at higher 
concentrations (50-200 µM), was unable to suppress thrombin generation, but even 
caused weak stimulation. An explanation for the lack of inhibitory effect of P2Y1 
antagonism by MRS could be its low affinity or fast desensitisation of the receptor under 
coagulant conditions. To check this, platelet shape change (which is a P2Y1-mediated 
response) was monitored by turbidometry under the same experimental conditions. 
Addition of MRS (50 µM) resulted in 50% reduction of the shape change occurring 
immediately at the onset of coagulation (PAR1 activity likely accounting for the remaining 
shape change). This indicates that released ADP can trigger for P2Y1 signaling in 
thrombin-generating plasma. 
Thrombin generation in PRP can be enhanced by prior stimulation of platelet PAR1 
with SFLLRN.
19
 We examined whether endocrine ADP contributes to this enhancement. 
Pretreatment of PRP with AR-C but not with MRS resulted in substantial antagonism of 
the potentiating effect of 15 µM SFLLRN (Fig. 1B). Activation with SFLLRN significantly 
shortened the time-to-peak with 13±2.9% (mean±SEM, n=10), while conversely AR-C 
but not MRS prolonged the time-to-peak with 27±4.7%. The latter effect was seen both 
with and without SFLLRN (Fig. 1C,D). These results indicate that a considerable part of 
the enhanced thrombin generation by PAR1 stimulation is de facto mediated by ADP 
release and P2Y12 activity. 
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Figure 1. Contribution of autocrine ADP to enhancement of thrombin generation by PAR1 
stimulation. PRP (150×10
9
 platelets/L) from healthy subjects was preincubated with vehicle 
(control), AR-C69931MX (AR-C, 30 µM) and/or MRS2179 (MRS, 50 µM) for 15 min, as indicated. 
The PRP was then stimulated with SFLLRN (15 µM) or vehicle (control) for 10 min. Thrombin 
generation was measured in the presence of Z-GGR-AMC (0.42 mM, f.c.), CaCl2 (16.6 mM) and 
tissue factor (1.0 pM). Shown are representative, calibrated thrombin generation curves in the 
absence (A) or presence (B) of SFLLRN. (C,D) Quantitative effect of ADP on time-to-peak values 
relative to the control condition. Data are means±SEM (n=5-10), *p≤0.05 vs. condition without 
antagonist, 
x
p≤0.05 vs. condition with SFLLRN. 
 
In following experiments, PRP was activated with ADP itself and the effect on 
thrombin generation was measured. Sub-maximal enhancing effects were obtained with 
ADP at a concentration of 20 µM, causing a 30±1.5% increase in thrombin peak height 
and a 25±3.1% shortening in time-to-peak (Fig. 2A,B). Preincubation with 30 µM AR-C 
abolished the ADP effect, while MRS was ineffective. Notably, MRS still failed to inhibit, 
when administered at a 50x higher concentration than ADP. Preincubation of PRP with 1 
µM wortmannin, an inhibitor of the PI3-K pathway implicated in P2Y12 signaling,
9
 also 
antagonised the ADP effect on thrombin generation; peak levels reduced with 22±9.5%. 
Furthermore, preincubation with PS-scavenging annexin-A5 abrogated all (ADP effects 
on) thrombin formation (Fig. 2A). 
Unlike reported by others,
18
 we were unable to detect surface exposure of PS on 
washed platelets that were stimulated with thrombin. However, when thrombin formation 
in defibrinated PRP was triggered with CaCl2, platelets readily exposed PS, as detected 
with FITC-labelled annexin A5 (Fig. 2C). Addition of ADP increased the fraction of PS-
exposing platelets, while AR-C abrogated this ADP effect. When thrombin formation was  
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Figure 2. P2Y12 receptor mediates enhancing effect of ADP on thrombin generation by 
increasing PS exposure. (A) Effect of AR-C (30 µM) or annexin-A5 (10 µg/mL) on ADP-enhanced 
thrombin generation. PRP was stimulated with ADP (20 µM), and thrombin generation was 
measured after triggering with tissue factor/CaCl2. (B) Quantitative effect of AR-C and MRS on 
thrombogram parameters. Data are expressed as percentages relative to the control condition 
without (ant)agonist (mean±SEM, n=4-7). (C) ADP-enhanced PS exposure during thrombin 
generation. Platelets in defibrinated plasma were untreated or activated with 20 µM of ADP or 
ionomycin before triggering with CaCl2. Exposure of PS was determined by flow cytometry using 
FITC-labelled annexin-A5 after 11 min. Preincubation was with 30 µM AR-C, as indicated. Data are 
means±SEM (n=4). *p≤0.05 vs. condition without (ant)agonist, xp≤0.05 vs. condition with ADP. 
 
enhanced with tissue factor, the fraction of PS-exposing platelets became higher, but the 
effects of ADP and AR-C were maintained (data not shown). Together, these results 
indicate that the potentiating effect of P2Y12 signaling on thrombin generation is likely 
due to increased platelet activation and PS exposure. 
Stimulation of P2Y12 potentiates thrombin-induced calcium signaling  
As prolonged elevation in cytosolic [Ca
2+
]i is needed for PS exposure,
3
 we studied the 
effect of ADP on thrombin-evoked Ca
2+
 responses using Fura-2-loaded platelets. Fig. 3A 
shows that ADP, at a maximally effective dose of 20 µM, increased and prolonged the 
rise in [Ca
2+
]i induced by thrombin (4 nM). Preincubation of platelets with AR-C (30 µM), 
alone or in combination with MRS (50-200 µM), completely abolished this ADP effect 
(Fig. 3B). In agreement with earlier results,
32
 AR-C preincubation also decreased the 
Ca
2+
 response evoked by ADP alone. Quantitative analysis indicated that AR-C lowered 
the maximal and integrated [Ca
2+
]i rises evoked by thrombin with 17±4.3% and  
Platelet P2Y12 receptors and thrombin generation 
 35 
M
a
x
im
a
l 
ri
s
e
 i
n
 [
C
a
2
+
] i
 (
%
 o
f 
c
o
n
tr
o
l)
50
100
150
AR-C
MRS
- + + - + +
- - + - - +
Thrombin
ADP
+ + + + + +
- - - + + +
* x x
A B
C
In
te
g
ra
te
d
 r
is
e
 i
n
 [
C
a
2
+
] i
 (
%
 o
f 
c
o
n
tr
o
l)
40
80
120
160
AR-C
MRS
- + + - + +
- - + - - +
Thrombin
ADP
+ + + + + +
- - - + + +
**
*
x
x
D
Time (s)
0 200 400
[C
a
2
+
] i
 (
n
M
)
0
200
400
600
800 Thrombin ± ADP
+ ADP
- ADP
Time (s)
0 200 400
[C
a
2
+
] i
 (
n
M
)
0
200
400
600
800 Thrombin + ADP
+ AR-C
+ AR-C/MRS
 
Figure 3. ADP enhances thrombin-induced Ca
2+
 response via P2Y12 stimulation. (A) Fura-2-
loaded platelets were activated with thrombin (4 nM) with/without ADP (20 µM) (arrow). (B) Platelets 
were preincubated with AR-C (30 µM) with/without MRS (50 µM), and subsequently activated with 
thrombin and ADP. Representative traces are given of changes in [Ca
2+
]i. (C,D) Shown is 
stimulating effect of ADP on maximal [Ca
2+
]i rise and on [Ca
2+
]i-time integral. Data are means±SEM 
(n=3-5) relative to the condition of thrombin alone. *p≤0.05 vs. condition with thrombin, xp≤0.05 vs. 
condition with thrombin and ADP. 
 
34±3.4%, whereas it reduced the [Ca2+]i rises evoked by thrombin plus ADP with 25±2.8 
and 53±5.6%, respectively (Fig. 3C,D). Notably, the potentiating effect of ADP persisted 
at thrombin concentrations as high as 40 nM: integrated [Ca
2+
]i rises then increased with 
22% in comparison to those of thrombin alone. 
To approach conditions of coagulation, [Ca
2+
]i rises were also measured during in 
situ thrombin generation. Fura-2-loaded platelets were incubated with a mixture of tissue 
factor, factor VII, factor X and prothrombin. The resulting continuous formation of 
thrombin caused a gradual increase in [Ca
2+
]i (Fig. 4A). Addition of ADP again enhanced 
the Ca
2+
 response, once more in a P2Y12 manner (Fig. 4A,B). This ADP effect was most 
probably not mediated by a Gi-mediated decrease in cyclic-AMP level, because 
preincubation with 10 µM adrenaline, sufficient to cause maximal lowering of cyclic-
AMP,
14
 did not influence the ADP stimulation of the Ca
2+
 signal with thrombin: ADP 
addition increased the maximal and integrated [Ca
2+
]i rises with 15% and 29%, 
respectively, in comparison to thrombin/adrenaline. On the other hand pretreatment with 
100 nM wortmannin, inhibiting PI3-K, partly abolished the stimulating effect of ADP:  
Chapter 3 
 36 
A B
Time (s)
0 200 400 600
[C
a
2
+
] i
 (
n
M
)
0
500
1000
- ADP
+ ADP
ADP
Time (s)
0 200 400 600
[C
a
2
+
] i
 (
n
M
)
0
500
1000
ADP
+ AR-C
+ AR-C/MRS
 
Figure 4. ADP enhances Ca
2+
 responses induced by thrombin generated in situ. Fura-2-loaded 
platelets were incubated with a mixture of tissue factor (10 pM), factor VII (10 pM), factor X 
(100 nM) and prothrombin (1 µM), and changes in [Ca2+]i were measured. Thrombin generation was 
triggered with CaCl2 (t=0), after which ADP (20 µM) or vehicle was added (arrow). (A) 
Representative traces of effect of ADP on Ca
2+
 response; (B) effect of preincubation with 30 µM 
AR-C and/or 50 µM MRS. Thrombin concentrations after 5 and 10 min amounted to 10 and 36 nM, 
respectively. 
 
when compared to ADP/thrombin alone, maximal and integrated [Ca
2+
]i rises decreased 
with 7±4.6% and 24±6.1%, respectively. 
Unaltered enhancement of thrombin generation by ADP in PRP from patients with 
stroke or diabetes mellitus 
To determine possibly altered ADP effects on platelet procoagulant activity, thrombin 
generation was measured in PRP from groups of young and older patients with stroke 
and PRP from patients with type-II diabetes mellitus. In the absence of ADP, tissue 
factor-triggered thrombin generation (thrombin peak level or area-under the curve) was 
higher in PRP from the older patients with stroke and in PRP from diabetic patients, in 
comparison to a group of healthy subjects (Table 1). As we have indicated before, inter-
individual variation in thrombogram characteristics is mostly explained by variation in 
plasma coagulant activity, and no more than little by variable platelet activation.
19
 
Therefore, to determine possible variation in agonist-induced platelet procoagulant 
activity, thrombogram curve shifts were examined after preactivation of the PRP with 
ADP or SFLLRN. On average, in all groups, these agonists caused a similar increase in 
thrombin peak height and a similar decrease in time-to-peak (Fig. 5A,B). This points to 
normal responsiveness of the patient platelets to the stimulating effects of ADP and 
SFLLRN under coagulant conditions. The patients with stroke all used aspirin but, as 
shown before,
19
 thrombin generation curves are only little affected by aspirin treatment. 
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Table 1. Thrombogram characteristics of PRP from healthy subjects and patients with stroke 
or diabetes mellitus. 
Subject (n) Thrombin peak 
(nM) 
Time to peak 
(min) 
ETP 
(nM×min) 
Healthy controls (11) 78.2 ± 23 31.2 ± 7.9 1667 ± 331 
Young stroke patients (11) 92.4 ± 30 25.9 ± 7.9 1726 ± 430 
Other stroke patients (9) 119 ± 22* 26.5 ± 6.0 1868 ± 377 
Diabetic patients (12) 104 ± 25* 30.8 ± 7.2 1960 ± 293* 
 
Thrombin generation was measured in normalised PRP (150×10
9
 platelets/L, f.c.), with post-hoc 
calibration. Shown are mean values±SD of thrombin peak-height, time-to-peak and area-under-the-
curve (ETP). All stroke patients had aspirin medication, other subjects were free from medication. 
*p≤0.05 vs. healthy controls. 
 
 
 
 
Figure 5. Potentiation of thrombin generation by ADP and SFLLRN in PRP from healthy 
subjects and patients. PRP was obtained from healthy subjects, young stroke (YS) patients, 
stroke patients of older age (OS), and type-II diabetic patients (see Table 1). Platelets in PRP were 
activated for 10 min with 20 µM ADP or 15 µM SFLLRN, and then triggered with tissue factor/CaCl2 
for measurement of thrombin generation. Thrombogram data (post-hoc calibration) are given of (A) 
thrombin peak height and (B) time-to-peak relative to control condition without (ant)agonist 
(means±SD, n=8-12). 
Clopidogrel treatment variably abolishes ADP/P2Y12 effects on thrombin 
generation 
Since the ADP-induced effect on thrombin generation completely relies on P2Y12 activity, 
this effect could be used to monitor the efficacy of medication with clopidogrel, which 
gives rise to irreversible blockade of this receptor. In PRP from nine older patients with 
stroke, we were able to investigate this before and after 14 days of clopidogrel 
medication (75 mg/day). In thrombin generation experiments, two sets of conditions were 
compared: first, PRP was activated with ADP before start of thrombin generation, to 
achieve maximal P2Y12 activity; second, the PRP was pretreated with a high dose of AR-
C (30 µM) before activation, sufficient to suppress all ADP-induced effects. The 
percentage effect of AR-C on thrombin peak height was taken as a measure of the P2Y12  
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Figure 6. Variable P2Y12-mediated thrombin generation and platelet activation after 
clopidogrel intervention. Blood was drawn from 9 stroke patients of older age after 14 days of 
clopidogrel medication. To measure P2Y12-mediated activity, PRP was stimulated with ADP (20 µM) 
in the presence or absence of AR-C (30 µM). For the indicated platelet responses, percentage 
effects of AR-C were taken as a measure of relative P2Y12 activity. (A) Typical thrombin generation 
curves for patients with a high (patient A) or low (patient I) remaining P2Y12 response after 
clopidogrel intervention. Thrombin generation in PRP was triggered with tissue factor/CaCl2. (B) 
Variable contribution of P2Y12 to thrombin generation; data from all 9 patients are expressed as 
percentage AR-C effects on thrombin peak height. Number under bars indicate AR-C effects on 
thrombin peak height, P-selectin exposure (% of platelets binding to anti-CD62 FITC) and on 
integrin αIIbβ3 activation (% of platelets binding to PAC-1 FITC). Exposure of P-selectin and integrin 
activation were measured by flow cytometry in diluted PRP, pre-activated with ADP (20 µM) in the 
presence or absence of AR-C (30 µM). (C) Correlations between thrombin generation and flow 
cytometric measurements. 
 
activity in thrombin generation. For all 9 patients, this P2Y12 activity diminished after 
clopidogrel intake from 41±13 to 32±13% (mean±SD, n=9, P=0.057). As a comparison, 
using flow cytometry, ADP-induced effects were determined on platelet activation 
markers in the presence and absence of AR-C. The P2Y12 activity (i.e. percentage effect 
of AR-C) in ADP-induced P-selectin exposure significantly reduced from 44±13 to 
18±11% after clopidogrel treatment. Similarly, the P2Y12 activity in ADP-induced 
activation of αIIbβ3 (using the PAC-1 antibody) reduced from 60±14% to 43±14%, the 
remaining part being attributable to P2Y1 action. 
Most clearly after clopidogrel intake, there was considerable variation in P2Y12 
activity between patients (Fig. 6A). The PRP from one subjects (patient A) hardly 
responded to the presence of ADP or AR-C, while the PRP from another subject (patient 
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I) showed considerable responses to these compounds. Arbitrarily, the patients were 
divided into two about equal groups; one group of patients with a low P2Y12 activity after 
clopidogrel (‘high’ responders) and the other group of patients with high residual P2Y12 
activity (‘low’ responders) (Fig. 6B). Flow cytometric measurements confirmed that these 
groups differed in P2Y12 activity with residual values of P-selectin exposure of 29±7% 
and 11±8%, respectively. There was no such a difference in P2Y12-mediated αIIbβ3 
activation. Notably, comparison of all individual patient data indicated a good correlation 
of P2Y12 activity in thrombin generation with P2Y12 activity in P-selectin exposure (Fig. 
6C). This suggests that either of these parameters can be a suitable marker of 
resistance to clopidogrel intervention. Only in the high-responding group, but not in the 
other group, clopidogrel intake appeared to reduce the P2Y12 activity on thrombin 
generation from 35±3.3 pre-treatment to 23±9.4% post-treatment (P=0.041). Similarly, 
P2Y12-dependent P-selectin exposure was reduced in this group from 43±16 to 11±8.1% 
(P=0.005) and αIIbβ3 activation from 62±16 to 40±18% (P=0.001). Together, the 
thrombin generation measurements point to incomplete, but highly variable effects of 
clopidogrel intake on P2Y12 receptor function in these patients. 
Discussion 
The present data show that platelet stimulation with ADP or SFLLRN results in a 
considerable stimulation of thrombin generation and, thus, coagulant activity in a P2Y12-
dependent manner. Complete abolition of the ADP-mediated effects is obtained with the 
specific P2Y12 antagonist AR-C (from 1 µM), but not with the P2Y1 blocker MRS, 
whereas the latter compound affects platelet shape change under these coagulant 
conditions, proving that the P2Y1 receptor is still signaling. Typically, MRS, when applied 
at concentrations around its Kd value for P2Y1 (10
-5
 M), results in a small, dose-
dependent increase rather than a decrease in thrombin generation, indicating that P2Y1 
is not positively involved in procoagulant activity. We also find that P2Y12 stimulation 
under conditions of thrombin generation leads to increased exposure of PS at the 
platelet outer surface, and that the PS-chelating annexin A5 completely abolishes 
thrombin generation with ADP. Thus, ADP is not only a proaggregatory agonist, but is 
also, exclusively via P2Y12, a potent enhancer of the platelet procoagulant response via 
PS exposure. 
The results of Ca
2+
 measurements provide a first biochemical explanation for the 
procoagulant ADP effect. In spite of the fact that thrombin causes a high Ca
2+
 response 
in platelets, co-stimulation with ADP (via P2Y12) further increases and prolongs this 
thrombin-induced response. It has been proposed that P2Y12 stimulation increases Ca
2+
 
signal generation by lowering cyclic-AMP, e.g. in platelets treated with 
prostaglandins.
33,34
 However, the potentiating effects of ADP on thrombin-induced Ca
2+
 
signaling and PS exposure most probably involve a different pathway, as platelet 
treatment with adrenaline, which maximally lowers cyclic-AMP, fails to abolish the ADP 
effect. The ADP effects are also likely to be independent of platelet aggregation, 
because inhibitors of αIIbβ3 or Src kinases do not influence the Ca2+ responses with 
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ADP/thrombin (data not shown). On the other hand, we found that PI3-K inhibition with 
wortmannin partly inhibited the ADP-enhanced Ca
2+ 
response and thrombin generation. 
This partially agrees with a recent report that P2Y12/PI-3K signaling is involved in the 
Ca
2+
 response evoked by ADP alone.
34
 However, these authors also mentioned a 
modulatory effect of Src kinases, which we could not confirm under the present 
conditions with added thrombin. 
To detect a possibly increased contribution of P2Y12 in thrombin generation, ADP- 
and SFLLRN-induced effects were evaluated in PRP from patients at thrombotic risk, i.e. 
patients with stroke or type-II diabetes mellitus. There was intersubject variation in all 
patient groups, but the stimulating effects of ADP or SFLLRN on thrombin generation 
were nevertheless comparable to those in control PRP from healthy subjects. 
In blood from patients with stroke, ADP/P2Y12-medated thrombin generation was 
measured after a period of clopidogrel intake. In most of the patients, this intervention 
appeared to result in only partial blockade of the ADP/P2Y12 effects on thrombin 
generation. In fact, in only 1 out of 9 patients clopidogrel suppressed thrombin 
generation to a similar degree as AR-C. This variable responsiveness to clopidogrel was 
confirmed by parallel measurements of ADP/P2Y12-mediated P-selectin exposure, which 
is a Ca
2+
-dependent platelet response. These findings are remarkably consistent with a 
recent report, showing a fairly incomplete responsiveness to clopidogrel (in comparison 
to AR-C added in vitro) in patients with ischemic cardiovascular diseases, using an 
indirect assay of P2Y12/Gi-regulated VASP phosphorylation.
35
 In that paper, it was 
concluded that one-third of patients is not protected by the therapy, which also fits with 
our data. The present findings thus underline the notion in several clinical studies that 
resistance to clopidogrel (resulting in variable platelet inhibition) is a common 
phenomenon.
36,37
 A number of explanations for clopidogrel resistance have been put 
forward in the literature, including possible interaction of clopidogrel with statins.
38
 We 
can confirm the partial efficacy of clopidogrel treatment and, furthermore, note that the 
thrombogram method is useful for measuring this. 
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Abstract 
During thrombus formation, thrombin, which is abundantly present at sites of vascular 
injury, activates platelets in part via autocrine produced ADP. We investigated by which 
signaling pathways thrombin and ADP in synergy induced platelet Ca
2+
 elevation and 
procoagulant activity, and we monitored the consequences for the coagulation process. 
Even at high thrombin concentration, autocrine and added ADP enhanced and prolonged 
Ca
2+
 depletion from internal stores via stimulation of the P2Y12 receptors. This P2Y12-
dependent effect was mediated via two distinct signaling pathways. The first is enhanced 
Ca
2+ 
mobilization by the inositol 1,4,5-trisphosphate receptors due to inhibition of protein 
kinase A. The second pathway concerns prolonged activation of phosphoinositide 3-
kinase (PI3-K) and phospholipase C. Experiments with PI3-K isoform-selective inhibitors 
and p110γ deficient platelets demonstrated that the PI3-Kβ and not the PI3-Kγ isoform is 
responsible for the prolonged Ca
2+
 response and for the subsequent increases in 
procoagulant activity and coagulation. Taken together, these results demonstrate a dual 
P2Y12-dependent signaling mechanism, which increases the platelet-activating effect of 
thrombin by prolongation of Ca
2+
 elevation and, thereby, facilitating the coagulation 
process. 
Introduction 
Platelets are activated at sites of vascular injury, and then clump together to form a vaso-
occlusive thrombus. Platelet activation is usually triggered by the exposure of a 
thrombogenic surface like collagen, and continues by the availability of soluble agonists 
that are derived from the injured vessel wall or the activated platelets themselves. One of 
the most potent, soluble platelet-activating agents is thrombin. Intravital imaging studies 
of thrombus formation in damaged mouse arteries indicate that thrombin is rapidly 
formed at thrombotic sites via the tissue factor/factor VIIa pathway of coagulation.
1
 This 
is confirmed by inhibitory studies in various experimental models, showing that thrombin 
generation plays a key, driving role in the thrombotic process.
2-4
 Once thrombin is 
formed, it will inevitably interact with and activate all nearby platelets.
5
 
Thrombin stimulates platelets mostly or only via the protease-activated receptors, 
PAR1/4 on human and PAR3/4 on mouse platelets, which all signal through the G 
proteins, Gq and G12/13.
6,7
 Thrombin evokes multiple responses, such as shape 
change, Ca
2+
 mobilization, secretion, integrin αIIbβ3 activation, and assembly of a 
platelet aggregate.
8
 Furthermore, thrombin enhances the development of platelet 
procoagulant activity.
9
 Particularly, in combination with collagen, it causes a prolonged 
elevation in cytosolic [Ca
2+
]i, which leads to the exposure of phosphatidylserine (PS) at 
the platelet outer membrane. This provides a procoagulant surface, upon which 
coagulation factors assemble to produce factor Xa and thrombin. Hence, the generation 
of initial traces of thrombin via the tissue factor/factor VII pathway leads to a strong 
positive feedback loop, where thrombin activates platelets, platelets become 
procoagulant, and more thrombin is formed at the surface of these platelets.
9,10
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Although ADP is considered to be a weak agonist, studies with human and mouse 
platelets have indicated that it does play an important role in thrombus formation.
11,12
 
Being secreted from platelets in large amounts, ADP functions as an autocrine agonist 
sustaining many activation processes. Secreted ADP binds to the P2Y1 and P2Y12 
purinergic receptors, and triggers shape change, Ca
2+
 mobilization and platelet 
aggregation.
13-15
 The P2Y1 receptors are linked to Gq, but they evoke much weaker 
responses than thrombin receptor activation.
16
 The result is limited activation of 
phospholipase C, leading to formation of inositol 1,4,5-trisphosphate (InsP3) and InsP3 
receptor-mediated elevation in [Ca
2+
]i. The P2Y12 receptors are coupled to Gi and signal 
in a different way. Both in human and mouse platelets, P2Y12 induces Gi-dependent 
inhibition of adenylyl cyclase and consequent down-regulation of cAMP.
13,17
 In this way, 
(autocrine produced) ADP can relieve the platelet-inactivating effect of cAMP and its 
effector, protein kinase A (PKA).
14
 Also downstream of Gi, P2Y12 receptors stimulate the 
less well understood phosphoinositide 3-kinase (PI3-K) pathway, which leads to αIIbβ3 
integrin activation and platelet aggregation.
18
 We and others have shown that both the 
PI3-Kβ and PI3-Kγ isoforms contribute to the P2Y12-mediated stabilization of platelet 
aggregates under static and shear conditions.
19-21
 
Recently, it was established that P2Y12 signaling is implicated in the stimulating effect 
of thrombin on PS exposure and procoagulant activity of platelets.
5,22,23
 We hence 
hypothesized that the thrombin and P2Y12 receptors signal in a synergistic way towards 
this platelet response. Since elevation in [Ca
2+
]i is a key feature in PS exposure, we 
started to investigate how thrombin and ADP receptor stimulation co-operate to induce 
Ca
2+
 mobilization and to provoke platelet procoagulant activity. We found that autocrine 
released ADP via P2Y12 causes a marked prolongation of the [Ca
2+
]i elevation even with 
high doses of thrombin. Subsequently, using platelets that were co-stimulated with fixed 
concentrations of thrombin and ADP we unraveled the signaling mechanism underlying 
this P2Y12 effect. The results point to a dual regulatory pathway evoked by P2Y12. It 
involves increased InsP3 receptor function due to inactivation of the cAMP/PKA route. 
This effect is accompanied by prolongation of thrombin/ADP-evoked phospholipase C 
activity and Ca
2+
 mobilization in a way controlled by PI3-Kβ. 
Materials and methods 
Animals 
Animal experiments were approved by the local animal experimental committees. 
Wildtype control (p110γ+/+) and PI3-Kγ deficient (p110γ-/-) mice, with identical genetic 
backgrounds, were generated as described.
21,41
 
Materials 
Human α-thrombin (3270 NIH units/mg, 12,750 units/mL, 1.12 µM) was obtained from 
Enzyme Research Laboratories. Fura-2, Fura red and Oregon green (OG)-BAPTA 
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acetoxymethyl esters (AM) as well as non-esterified Fluo-3 were from Molecular Probes; 
ultra-pure calcium-free water was from Baker Analytical. Cangrelor (AR-C69931MX, AR-
C) was kindly provided by The Medicines Company. Fluorescent thrombin substrate, Z-
Gly-Gly-Arg aminomethyl coumarin (Z-GGR-AMC) was from Bachem; recombinant 
human tissue factor from Dade Behring; and human thrombin calibrator from Synapse. 
InsP3 was from Alexis Biochemicals; tirofiban from Merck, Sharp and Dohme; Akt 
inhibitor and LY294002 from Calbiochem. ET-18-OCH3, manoalide, U73122 and 
U73343 came from Biomol. PI3-K isoform-specific inhibitors were kind gifts of Baker 
Heart Institute, i.e. TGX221, selective for the PI3-Kβ isoform (p110β), and AS252424, 
selective for PI3-Kγ (p110γ), both synthesized as described.21,42 Fluorescent-labeled 
annexin A5 was obtained from Nexins Research. Other materials were from Sigma. 
Platelet preparation and isolation 
Blood was taken from healthy volunteers, who gave full informed consent; subjects were 
free from medication for at least two weeks. Blood was collected into 1/6 volume of acid-
citrate glucose solution (ACD, 80 mM trisodium citrate, 52 mM citric acid and 180 mM 
glucose). Human platelet-rich plasma (PRP) was obtained by 15-min centrifuging at 240 
g. Blood from mice was collected and handled as described.
3
 Murine PRP was prepared 
by centrifuging blood at 280 g for 3 min, and centrifuging the upper phase once more at 
625 g for 10 s. Platelet counts were determined with a thrombocounter (Coulter 
Electronics). 
Platelet shape change was measured in PRP or washed platelets by turbidometry in 
the presence of tirofiban to prevent aggregation. Shape change evoked by up to 20 µM 
ADP was not significantly (<10%) influenced by AR-C in the range of 1-30 µM, indicating 
that AR-C did not interfere with the P2Y1-dependent response. 
Measurements of cytosolic Ca
2+
 in intact and permeabilized platelets 
To measure [Ca
2+
]i in intact human platelets, PRP was incubated with the fluorescent 
probe Fura-2 AM (2.5 µM) at 37°C for 45 min. After addition of 1/15 volume of ACD and 
apyrase (0.1 U/mL ADPase), platelets were centrifuged from plasma, washed and 
resuspended in Hepes buffer pH 7.45 [10 mM Hepes, 136 mM NaCl, 2.7 mM KCl, 2 mM 
MgCl2, 0.1% glucose and 0.1% bovine serum albumin (BSA)], as described.
43
 Washed 
Fura-2-loaded platelets were diluted in Hepes buffer pH 7.45 to 1×10
8
 platelets/mL. 
Changes in cytosolic [Ca
2+
]i were measured by ratio fluorometry under stirring; [Ca
2+
]i-
time integrals were measured to quantify prolonged Ca
2+
 responses.
44
 
Changes
 
in [Ca
2+
]i in mouse platelets were measured as published.
45
 Briefly, the 
washed platelets (5.0×10
8
/mL) were incubated with OG-BAPTA AM (1 µM) and Fura red 
AM (1.25 µM) for 30 min at 37°C, and subsequently resuspended at 2.5×108/mL in 
Hepes buffer pH 7.45, containing BSA (5 mg/mL), CaCl2 (1 mM), apyrase (0.02 U/mL) 
and probenecid (1.75 mM). Platelets were stimulated by addition of thrombin (4 nM) 
and/or ADP (20 µM), and ratiometric changes in [Ca2+]i were then determined.
45
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In permeabilized human platelets, InsP3-induced Ca
2+
 mobilization from internal 
stores was measured, using an earlier established procedure.
27
 Washed human platelets 
were resuspended in Ca
2+
-free Hepes buffer pH 7.45 containing 0.1 mM EGTA (1.5×10
9
 
platelets/mL). The cells were diluted in ATP-regenerating medium, preincubated for 15 
min with (ant)agonist, stimulated with ADP, and then permeabilized with 15 µg/mL 
saponin in the presence of 1 µM free Fluo-3. After 10 min of stirring, free [Ca2+] was 
adjusted to 300 nM with a CaCl2 stock solution, after which InsP3 was added. 
Fluorescence intensities were continuously recorded at 488 nm excitation and 526 nm 
emission wavelengths using an SLM-Aminco DMX-1100 spectrofluorometer. Calibrations 
were performed by adding excess amounts of CaCl2 or EGTA/Tris; levels of [Ca
2+
] were 
calculated from the binding equation of Fluo-3 for Ca
2+
.
27
 Ultra-pure calcium-free water 
was used for preparation of all buffers and (ant)agonists. 
Measurement of cytosolic cAMP and InsP3 
Intracellular levels of cAMP and InsP3 in resting and activated platelets were measured 
as described.
27
 Basal concentrations were 2.59±0.17 and 0.96±0.08 pmol/108 platelets 
(n=6), respectively. 
Measurement of SERCA activity 
Decay constants of [Ca
2+
]i decreases following peak values were determined by mono-
exponential fitting of 2-s data points. SERCA activity in saponin-permeabilized platelets 
was determined by measuring fluorescence accumulation due to cleavage of the Ca
2+
-
ATPase substrate, 3-O-methylfluorescein phosphate.
46
 SERCA activity represented the 
ATP- and thapsigargin-sensitive phosphatase activity. 
Measurement of Akt activation 
Akt activation was measured by western blot analysis, using a phosphoserine-473 Akt 
polyclonal antibody (Biosource International) to detect active Akt kinase, as well as a 
separate Akt polyclonal antibody (Cell Signaling Technology) to determine total Akt, as 
described.
19
 
Thrombin generation 
For thrombin generation measurements, human or mouse blood was collected in 1/10 
volume of 129 mM trisodium citrate. Isolated PRP was centrifuged twice at 2700 g for 10 
min to prepare platelet-poor plasma. The PRP was diluted to the desired platelet count 
with autologous PPP. 
Normalized PRP (1.5×10
8
 platelets/mL) was preincubated with inhibitors (15 min), 
and platelets were activated as required. Thrombin generation was initiated in PRP with 
tissue factor (1 pM final concentration) at 37°C and measured according to the 
thrombogram method.
47
 Briefly, PRP samples (4 volumes) were pipetted into a 
polystyrene 96-wells plate (Immulon 2HB, Dynex Technologies), already containing 1 
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volume of buffer A (20 mM Hepes, 140 mM NaCl, 5 mg/mL BSA and 6 pM tissue factor). 
Coagulation was started by adding 1 volume of buffer B (2.5 mM Z-GGR-AMC, 20 mM 
Hepes, 140 mM NaCl, 100 mM CaCl2 and 60 mg/mL BSA). Fluorescence accumulation 
was measured with a Fluoroskan Ascent well-plate reader (Thermolab Systems), 
equipped with thrombinoscope software (Synapse). 
Flow cytometry 
Washed platelets (1.0×10
8
/mL) were resuspended in citrate-anticoagulated, fibrin-
depleted plasma.
5
 Coagulation was triggered with CaCl2 (16.6 mM) and tissue factor (0.5 
pM, f.c.). After 10 min of activation, exposure of PS was determined by flow cytometry 
using FITC-labeled annexin A5. 
Statistical analysis 
Statistical analysis was performed with the Students t-test, using the statistical package 
for social sciences (SPSS 11.0). Data are presented as means±SEM, unless indicated 
otherwise. 
Results 
Autocrine and added ADP increases and prolongs thrombin receptor-induced Ca
2+
 
responses via P2Y12 receptor stimulation 
Previously, the selective P2Y12 antagonist, cangrelor (AR-C69931MX, AR-C), was used 
to demonstrate that autocrine produced ADP stimulates the procoagulant activity of 
thrombin-stimulated platelets exclusively via P2Y12 receptors; the selective P2Y1 
antagonist MRS2179 was without influence here.
5
 This procoagulant effect of P2Y12 was 
proposed to result from synergy with signaling via the platelet thrombin receptors. To 
investigate how autocrine ADP contributes to the Ca
2+
 response induced by thrombin, 
Fura-2-loaded human platelets were stimulated with low or high thrombin concentrations 
(0.5-20 nM), and the effects of pre- or post-addition of AR-C or MRS2179 were 
examined. As shown in Figure 1, AR-C pretreatment lowered the Ca
2+
 signal at all 
thrombin doses. The effect of AR-C was marked in showing a persistent reduction of 30-
50% (p<0.05) of the later phase of the Ca
2+
 response, such in contrast to MRS2179. 
Interestingly, also late addition of AR-C, i.e. when given after the initial Ca
2+
 peak, 
resulted in nearly immediate abolition of the remaining part of the Ca
2+
 signal, which then 
reached the level as in platelets preincubated with AR-C. In the experiments, a 
concentration of 2-5 µM AR-C was sufficient for maximal reduction of the Ca2+ response, 
while higher concentrations of 10-30 µM did not give additional effects (not shown). In 
marked contrast, post-addition of MRS2179 did not affect the thrombin-induced Ca
2+
 
response (Fig. 1). 
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Figure 1. Autocrine ADP and P2Y12 prolong thrombin-induced Ca
2+
 responses. Fura-2-loaded 
platelets were activated with thrombin (0.5, 4 or 20 nM) in the presence of 1 mM CaCl2. Vehicle 
solution (black lines) or AR-C (10 µM, grey lines) was added at 10 min before thrombin or shortly 
after thrombin (arrows). Dotted lines indicate effect of MRS2179 (100 µM) addition. Traces are 
representative for 3 or more experiments.  
 
 
To determine if the P2Y12 contribution to the thrombin-evoked Ca
2+
 response was 
limited by incomplete or impaired secretion, we determined how it was influenced by pre- 
or post-addition of AR-C using platelets that were co-stimulated with thrombin (4 nM) and 
ADP (20 µM). Again, AR-C – when given before or after the agonists – greatly 
suppressed the late phase of the [Ca
2+
]i increase (Fig. 2A). Here, an AR-C concentration 
of 10-30 µM was needed for optimal effect (not shown). As a comparison, the general 
PI3-K inhibitor wortmannin was given after thrombin + ADP; wortmannin had a slower 
but similar type of effect as AR-C (Fig. 2B). 
To quantify the contribution of P2Y12 to the Ca
2+
 response in platelets stimulated with 
4 nM thrombin with/without ADP, we measured not only [Ca
2+
]i peaks but also changes 
in [Ca
2+
]i-time integrals, which reflect both the extent and duration of the [Ca
2+
]i 
increase.
9
 Platelet pretreatment with AR-C reduced the Ca
2+
 peak (-9%) and the Ca
2+
 
integral (-34%) after thrombin stimulation (Table 1). Extra addition of MRS2179 was 
without effect, thus excluding a contribution of P2Y1 receptors. Co-stimulation with 
thrombin and ADP increased both the Ca
2+
 peak (+19%) and the Ca
2+
 integral (+35%) in 
comparison to thrombin alone. Importantly, pretreatment with AR-C reversed both 
parameters to the same level as seen with thrombin alone. 
Chapter 4 
 50 
Thrombin + ADP
Time (s)
[C
a
2
+
] i
 (
n
M
)
0
200
400
600
800
100 s
AR-C
AR-C
Thrombin + ADP
Time (s)
[C
a
2
+
] i
 (
n
M
)
0
200
400
600
800
100 s
WT
WT
A
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. P2Y12 prolongs thrombin-induced Ca
2+
 responses partly via PI3-K signaling. Fura-2-
loaded platelets were activated with 4 nM thrombin + 20 µM ADP in the presence of 1 mM CaCl2. 
(A) Effect of pre- or post-addition of vehicle (black lines) or AR-C (30 µM, grey lines) on the Ca2+ 
response. (B) Effect of pre- or post-addition of wortmannin (WT 200 nM, dotted lines) on the Ca
2+
 
response. Traces are representative for 3 or more experiments. 
 
 
 
Table 1. Contribution of P2Y12 signaling to thrombin- and ADP-induced Ca
2+
 responses. 
Agonist Antagonist Peak (nM) 
(% versus thrombin) 
Integral (nM x s) 
(% versus thrombin) 
Thrombin Vehicle 646 ± 38 (100%) 40173 ± 3032 (100%) 
 AR-C 591 ± 69 (91%)* 26513 ± 2660 (66%)* 
 AR-C + MRS2179 648 ± 142 (100%) 29064 ± 4098 (72%)** 
Thrombin + ADP Vehicle 767 ± 131 (119%) 54149 ± 7418 (135%)* 
 AR-C 603 ± 103 (93%)* 25762 ± 2784 (64%)* 
 AR-C + MRS2179 565 ± 131 (87%)* 23744 ± 3421 (59%)* 
 
Fura-2-loaded platelets (1×10
8
/mL) were preincubated with vehicle, AR-C (30 µM), and/or 
MRS2179 (100 µM) for 10 min. Changes in [Ca2+]i were measured after activation with 4 nM 
thrombin ± 20 µM ADP in the presence of 1 mM CaCl2. Data show [Ca
2+
]i peak levels and [Ca
2+
]i-
time integrals over 5 min; 
*
p<0.05, **p<0.1 (n=3-5).  
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The thrombin receptors PAR1 and PAR4 have been implicated in early and late 
stages of thrombin-induced human platelet activation, respectively. To investigate 
whether PAR1 alone or in combination with PAR4 co-signals with P2Y12, platelets were 
stimulated with the PAR1 agonist SFLLRN (15 µM) ± the PAR4 agonist AYPGKF (200 
µM). In either case, AR-C (but not MRS2179) suppressed the Ca2+ integral with a similar 
degree; 38±1% and 37±1% (n=3). Thus, the P2Y12-dependent part of the Ca
2+
 signal 
with thrombin does not rely on PAR4 activation.  
Together, these results demonstrate that both autocrine released and externally 
added ADP reinforce the thrombin receptor-induced Ca
2+
 responses by a moderate 
increase of the first Ca
2+
 peak and a more marked increase of the later Ca
2+
 signal. 
Further, the strong inhibitory effect of post-added AR-C indicates that long-term signaling 
via P2Y12 receptors is needed for the prolonged thrombin-induced Ca
2+ 
signal. 
P2Y12 stimulation increases thrombin-induced Ca
2+
 mobilization from internal 
stores 
In order to prevent response variation due to incomplete or impaired ADP secretion, 
subsequent experiments were carried out by co-stimulation of platelets with fixed 
concentrations of thrombin and ADP. Since ADP was proposed to trigger unspecified 
Ca
2+
 entry channels,
24
 we measured its contribution to thrombin-induced Ca
2+
 signals in 
the presence or absence of external CaCl2. Typically, ADP increased and prolonged the 
Ca
2+
 response in either case (Fig. 3). In comparison to the condition where P2Y12 activity 
was fully blocked (+AR-C), ADP increased the thrombin-induced Ca
2+
 integral with 
93±16% or 76±10% in the presence of EGTA or CaCl2, respectively (Fig. 3). This 
suggested that P2Y12 primarily stimulated mobilization of Ca
2+
 from internal stores, and it 
only secondarily enhanced store-regulated Ca
2+
 entry in the presence of CaCl2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. P2Y12 enhances thrombin-induced Ca
2+
 responses independent of Ca
2+
 entry. Fura-
2-loaded platelets were preincubated with vehicle or AR-C (30 µM), and stimulated with thrombin (4 
nM) ± ADP (20 µM) in the presence of either 1 mM CaCl2 or 1 mM EGTA. Data are presented as 
normalized Ca
2+
-time integrals (5 min) relative to the condition of AR-C + thrombin; *p<0.05 (n=4-6). 
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P2Y12 stimulation increases InsP3 receptor function via PKA 
By linking to Gi, P2Y12 inhibits adenylyl cyclase and causes inactivation of cAMP-
dependent protein kinase A (PKA).
14,25
 Knowing that PKA-induced phosphorylation of 
platelet InsP3 receptors inhibits their Ca
2+
 channel function,
26
 we determined how P2Y12 
signaling affects InsP3-induced mobilization of Ca
2+
 from intracellular stores. Using 
saponin-permeabilized platelets, the Ca
2+
 release was measured in response to a sub-
optimal dose of InsP3.
27
 Platelet activation with ADP had a clear stimulating effect on the 
InsP3-induced Ca
2+
 release, while AR-C completely antagonized this effect (Fig. 4A). In 
marked contrast, preincubation with the PI3-K inhibitor wortmannin was ineffective. 
Further experiments confirmed the sensitivity of InsP3-induced Ca
2+
 mobilization for 
modulation of PKA activity. Platelets were therefore pretreated with the PKA inhibitors, 
KT5720 and H89.
28
 Following saponin permeabilization, this resulted in increased InsP3-
induced Ca
2+
 release with either inhibitor, with an EC50 of 1 µM KT5720 and 4 µM H89. 
Pretreatment with an optimal dose of 2.5 µM KT5720 doubled the Ca2+ release with ADP 
(Fig. 4B). Conversely, pretreatment with the PKA-stimulating agent  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. P2Y12 enhances InsP3-induced Ca
2+
 mobilization in saponin-permeabilized platelets. 
Washed platelets in ATP-regenerating medium were stimulated with ADP (20 µM), as indicated, and 
permeabilized with saponin in the presence of Fluo-3. After adjustment of the free Ca
2+
 level to 300 
nM, InsP3 (100 nM) was added, and Ca
2+
 mobilization was measured. (A) Platelets were pretreated 
with vehicle, AR-C (30 µM) or wortmannin (WT, 200 nM) for 5 min, and then activated with ADP. (B) 
Platelets were pretreated with KT5720 (2.5 µM), PGE1 (10 µM) or heparin (20 µg/mL). Traces of 
InsP3-induced increases in [Ca
2+
]i are from representative experiments out of three or more 
performed. Values are percentages of maximal InsP3-induced Ca
2+
 mobilization compared to control 
condition; *p<0.05 compared to control (n=3-8). 
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prostaglandin E1 (IC50 0.5 µM) more than halved this Ca
2+
 release. In control 
experiments, saponin-permeabilized platelets were treated with heparin, which was used 
here as an established InsP3 receptor.
29
 Heparin completely inhibited all InsP3-induced 
Ca
2+
 mobilization (Fig. 4B). Note that no thrombin was used in this experimental set. As 
an alternative way to reduce cAMP, platelets were preincubated with the Gz-coupled 
agonist, adrenaline.
27
 Similarly to P2Y12/Gi-mediated inhibition of adenylate cyclase, this 
treatment resulted in a 61±10% increase of InsP3-induced Ca
2+
 mobilization. Together, 
these results show that P2Y12 receptor activation, by lowering cAMP and PKA activity, 
can enhance the Ca
2+
-mobilizing function of the InsP3 receptors. 
P2Y12 stimulation increases Ca
2+
 mobilization via both PKA and PI3-K pathways 
Effects of PKA inhibition were also measured on Ca
2+
 responses of non-permeabilized, 
Fura-2-loaded platelets. Pretreatment of platelets with an optimal dose of 10 µM H89 
resulted in an overall increase in Ca
2+
 integral with thrombin alone, but not with thrombin 
+ ADP (Fig. 5). Accordingly, with H89 present, the contribution of ADP/P2Y12 to the 
thrombin-induced Ca
2+
 integral reduced by 47%. Basically similar results were obtained 
with KT5720, but these were difficult to quantify because this compound strongly 
interfered with Fura-2 fluorescence (not shown). The ADP/P2Y12 effect on the thrombin-
induced Ca
2+
 response was independent of integrin signaling, since in platelets treated 
with the αIIbβ3 antagonist, tirofiban, it changed insignificantly from 176% to 167-170%. 
The contribution of PI3-K was further examined using two structurally distinct 
inhibitors, wortmannin and LY294002.
21
 In the presence of ADP/P2Y12 activity, 
wortmannin or LY294002 suppressed the thrombin-induced Ca
2+
 integral with an IC50 of  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. P2Y12 enhances thrombin-induced Ca
2+
 responses via both PKA and PI3-K. Fura-2-
loaded platelets in 1 mM EGTA were preincubated with vehicle, AR-C (30 µM), H89 (10 µM) and/or 
wortmannin (WT, 200 nM), as indicated. Platelets were activated with 4 nM thrombin in combination 
with either 30 µM AR-C or 20 µM ADP, as in Fig. 3. Data are presented as normalized [Ca2+]i-time 
integrals relative to the condition of AR-C + thrombin. *p<0.05 compared to respective control (n=5-
6).  
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about 10 nM and 1 µM, respectively, which is in accordance with the known affinity of 
these compounds for the PI3-K catalytic subunits. At these concentrations (required for 
notable inhibition of Akt phosphorylation, see below), wortmannin and LY294002 
reduced the Ca
2+
 integral with 24.4±4.1% and 24.0±1.7% (n=3), respectively. In contrast, 
when AR-C was present and P2Y12 was not active, these compounds influenced the 
thrombin-induced Ca
2+
 mobilization insignificantly with <6% (p=0.34). Figure 5 shows 
that wortmannin, at a maximally effective dose of 200 nM, suppressed the thrombin + 
ADP response with 35±3.4%. Notably, when combined with H89 to block PKA, 
wortmannin treatment almost completely abolished the stimulating effect of ADP (Fig. 5). 
In other words, combined antagonism of PKA and PI3-K was sufficient to nearly 
completely block the ADP/P2Y12 effect on thrombin-induced Ca
2+
 mobilization. 
P2Y12 stimulation increases Ca
2+
 mobilization via prolonged phospholipase C 
activity 
The PI3-K pathway might enhance Ca
2+
 mobilization by reducing Ca
2+
 removal via 
SERCA inhibition, in a way similar as proposed for pancreatic acinar cells.
30
 In platelets, 
the SERCA inhibitor thapsigargin prolonged the thrombin-induced Ca
2+
 response, and 
abolished the effects of ADP, AR-C and wortmannin on this response (Fig. 6A, B). 
Wortmannin pretreatment did not change the decay rate of the Ca
2+
 signal with thrombin 
+ ADP. Direct measurement of SERCA activity in saponin-permeabilized platelets 
showed that neither AR-C nor wortmannin decreased this activity with <3%. Together, 
this indicates that ADP/P2Y12 activity prolongs Ca
2+
 mobilization in a way that requires 
normal SERCA activity. However, the data do not provide evidence for a direct effect of 
P2Y12/PI3-K on SERCA activity in platelets. 
If PI3-K does not affect Ca
2+
 reuptake, it may enhance or prolong the activation of 
phospholipase C, in particular its γ-isoforms which partly rely on PIP3 formation.
31
 To 
explore this possibility, platelets were stimulated with thrombin + ADP, after which 
phospholipase C-inhibiting agents were added. Post-addition of the phospholipase C 
inhibitor U73122 completely abrogated the prolonged phase of the Ca
2+
 response, while 
the control substance U73343 was ineffective (Fig. 6C, D). As U73122 can have non-
specific effects, control experiments were performed with other phospholipase C 
inhibitors, ET-18-OCH3 and manoalide. Similarly, post-addition of these compounds 
blocked the prolonged phase of the Ca
2+
 response (Fig. 6D). As mentioned above, a 
similar but slower effect was obtained by post-addition of wortmannin (Fig. 2B). To 
confirm that PI3-K contributes to late phospholipase C activation, levels of InsP3 were 
measured in platelets stimulated for 5 min with thrombin + ADP. This stimulation resulted 
in a 1.73±0.16 fold increase in InsP3, which was significantly reduced to 1.43±0.20 fold in 
the presence of wortmannin (p=0.02, n=6). Together, these results indicate that the 
ADP/P2Y12-dependent prolongation of the Ca
2+
 response relies on both phospholipase C 
and PI3-K activity. 
Dual P2Y12 signaling in thrombin-stimulated platelets 
 55 
Time (s)
[C
a
2
+
] i
 (
n
M
)
0
200
400
600
800
Control
U73122
100 s
[C
a
2
+
] i
 (
%
 o
f 
c
o
n
tr
o
l)
0
50
100
C
on
tr
ol
U
73
12
2
U
73
34
3
E
T-
18
-O
C
H
3
M
an
oa
lid
e
*
*
*
Time (s)
[C
a
2
+
] i
 (
n
M
)
0
200
400
600 Thrombin + TG
+ AR-C
+ ADP
+ WT + ADP
50 s
[C
a
2
+
] i
 t
im
e
-i
n
te
g
ra
l 
(%
 v
s
. 
T
h
ro
m
b
in
/A
D
P
)
0
100
200
300
WT - + +
TG
*
- - +
-
+
Thrombin + ADP
A B
C D
 
Figure 6. Contribution of SERCA and phospholipase C to P2Y12-dependent prolongation of 
Ca
2+
 responses. (A, B) Fura-2-loaded platelets were preincubated with vehicle, AR-C (30 µM) or 
wortmannin (WT, 200 nM) for 10 min, as indicated. Platelets then were stimulated with thrombin (4 
nM) ± ADP (20 µM) in the presence or absence of thapsigargin (TG, 2 µM). Bars show quantitative 
effect of wortmannin relative to thrombin + ADP. (C, D) Fura-2-loaded platelets were stimulated with 
thrombin and ADP as above. At 60 s after activation (arrow), the following substances were added: 
vehicle (control), U73343 (2 µM), U73122 (2 µM), ET-18-OCH3 (40 µM) or manoalide (10 µM). Bars 
give Ca
2+
 levels, relative to thrombin + ADP, measured at 60 s after addition of indicated substance. 
Representative Ca
2+
 traces are shown (n=3-5). 
The PI3-Kβ and not the PI3-Kγ isoform mediates the P2Y12 effect on thrombin-
evoked Ca
2+
 responses 
In man and mouse, the PI3-Kβ (p110β) and PI3-Kγ (p110γ) isoforms are involved in 
P2Y12-dependent platelet aggregation.
19,21,32
 To examine how these isoforms contribute 
to the Ca
2+
 signal, the PI3-Kβ selective inhibitor TGX221 21 was used and platelets from 
p110γ-/- mice, lacking active PI-3Kγ. It was established that, in murine platelets, TGX221 
dose-dependently inhibited PI3-K-dependent phosphorylation of Akt; full inhibition was 
achieved at a concentration of 0.5 µM (not shown, but see below). Typically, platelets 
from wildtype p110γ+/+ and knockout p110γ-/- mice showed a similar enhancement with 
ADP of the thrombin-induced Ca
2+ 
response, which was always inhibited by AR-C (Fig. 
7A). In either genotype, this enhancement also antagonized by the general PI3-K 
inhibitor LY294002 (Fig. 7B), and by the PI3-Kβ specific inhibitor TGX221 (Fig. 7C). 
Similar results were obtained with human platelets, showing that pretreatment with 
TGX221 was almost as active as wortmannin in suppressing the  
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Figure 7. Unchanged contribution of P2Y12 to Ca
2+
 responses in PI3-Kγ deficient platelets. 
Washed platelets, obtained from p110γ+/+ and p110γ-/- mice, were loaded with Ca2+ indicator dyes. 
Changes in [Ca
2+
]i were monitored after preincubation of the platelets with inhibitor (10 min), and 
stimulation with thrombin alone (4 nM) or in combination with ADP (20 µM). (A) Effect of AR-C (10 
µM) preincubation on Ca2+ response. (B) Effect of general PI3-K inhibitor LY294002 (LY, 25 µM) on 
Ca
2+
 response. (C) Effect of PI3-Kβ inhibitor TGX221 (TGX, 0.5 µM) on Ca2+ response. Graphs are 
representative and show fold increases in [Ca
2+
]i after agonist stimulation. Bars give [Ca
2+
]i-time 
integrals, expressed relative to values with thrombin + ADP (n=4, duplicate experiments). 
 
thrombin + ADP-induced Ca
2+
 response (Fig. 8A). On the other hand, pretreatment with 
the PI3-Kγ-specific inhibitor, AS252424,21 was without effect. As protein kinase B/Akt is a 
downstream mediator of PI3-K in platelets,
33,34
 effects of the isoform-specific inhibitors 
were examined on thrombin + ADP-induced Akt activation. In platelets that were 
stimulated with thrombin alone or in combination with ADP, Akt was phosphorylated at its 
activation site of Ser
473
, peaking after 5-10 min. This phosphorylation was completely 
absent in the presence of the P2Y12 antagonist AR-C, regardless of whether ADP was 
added or not (Fig. 8B, C). Furthermore, pretreatment with LY294002 or TGX221 caused 
complete inhibition of the thrombin + ADP-evoked Ser
473
 phosphorylation of Akt (Fig. 
8D). Apparently, in thrombin-stimulated platelets, Akt phosphorylation and activation is 
completely dependent on autocrine produced or externally added ADP, via stimulation of 
the P2Y12 and PI3-Kβ pathway These results not only show that the regulatory role for 
PI3-K in P2Y12 signaling is conserved in mouse and human platelets, but also highlight 
the importance of the PI3-Kβ isoform. 
The PI3-Kβ and not the PI3-Kγ isoform mediates P2Y12-dependent procoagulant 
activity of mouse and human platelets 
Prolonged elevation in [Ca
2+
]i can signal for surface exposure of PS, thus facilitating 
platelet-dependent thrombin generation.
9
 It was thus studied whether the P2Y12/PI3-Kβ 
pathway contributed to thrombin generation. In PRP from wildtype and  
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Figure 8. PI3-K β-isoform mediates P2Y12-dependent enhancement of platelet activation by 
thrombin. (A) Human, Fura-2-loaded platelets were preincubated with vehicle, wortmannin (WT, 
200 nM), TGX221 (TGX, 0.5 µM) or AS252424 (AS, 1 µM). Cells were then stimulated by thrombin 
(4 nM) and ADP (20 µM). Effects are shown of preincubation on Ca2+-time integrals (n=4-6, relative 
to thrombin + ADP). (B-D) Washed platelets were preincubated with AR-C (10 µM), LY294002 (LY, 
25 µM) or TGX221 (TGX, 0.5 µM) for 10 min. Platelets remained then unstimulated (rest), or were 
stimulated with thrombin ± ADP (as above), then boiled in the presence of reducing buffer. Equal 
volumes of platelet samples were analyzed for Akt activation by western blot. Images are from one 
representative of four independent experiments. Bars show density of Akt phosphorylation on Ser
473
 
(n=4). 
 
p110γ-/- mice, lacking PI3-Kγ, thrombin generation was induced by triggering with tissue 
factor/CaCl2. In either genotype, activation with ADP via P2Y12 resulted in a quite similar 
increase in thrombin generation (Fig. 9A, B). In PRP from all mice, TGX221 partly 
antagonized the stimulating effect of ADP, reducing the rate of thrombin generation by 
~25%. 
Similar experiments were conducted with human PRP. Also in the human system, 
ADP enhanced the thrombin generation triggered by tissue factor/CaCl2 in a way 
inhibitable by AR-C (Fig. 10A). Pretreatment of PRP with wortmannin or TGX221 
reduced the initial rate of thrombin generation about half as effective as AR-C (Fig. 10B, 
C). In contrast, pretreatment with the PI3-Kγ inhibitor AS252424 was without any effect. 
Controls showed that neither wortmannin nor TGX221 affected the thrombin generation 
in the presence of AR-C (not shown). With only wortmannin present, the PKA inhibitor 
H89 further reduced the rate of thrombin generation with another 25%, thus pointing to  
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Figure 9. PI3-K β-isoform mediates P2Y12-dependent stimulation of coagulation in wildtype 
and PI3-Kγ deficient mice. PRP from (A) p110γ+/+ or (B) p110γ-/- mice was pretreated with vehicle, 
AR-C (30 µM) or TGX221 (TGX, 0.5 µM) and activated with ADP. Coagulant activity was measured 
by the thrombin generation assay, after triggering with tissue factor/CaCl2. Representative thrombin 
generation curves are given for wildtype and p110γ-/- PRP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. PI3-K β-isoform mediates P2Y12-dependent stimulation of coagulation and PS 
exposure. Human PRP was preincubated with vehicle, wortmannin (WT, 200 nM), AR-C (30 µM), 
TGX221 (TGX, 0.5 µM) or AS252424 (AS, 1 µM), and then activated with ADP (20 µM). Thrombin 
generation was measured by triggering with tissue factor/CaCl2. (A) Traces are representative 
thrombin generation curves, showing treatment effects of AR-C, WT and TGX221. (B) Panel shows 
initials part of the same thrombin generation curves. (C) Bars show preincubation effects on initial 
rates (5 min) of thrombin generation (n=3-5). (D) Human platelets in fibrin-depleted human plasma 
were preincubated with inhibitors and activated with tissue factor/CaCl2. After 10 min, FITC-labeled 
annexin A5 was added, and fractions of PS-exposing platelets were determined by flow cytometry 
(n=3-5). 
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additional involvement of PKA. To assess more directly the role of the P2Y12/PI3-Kβ 
pathway in procoagulant activity, effects of ADP were examined on PS exposure in PRP 
that was triggered with tissue factor/CaCl2. Plasma was depleted from fibrinogen to 
prevent formation of clots. Flow cytometric analysis using FITC-labeled annexin A5 
(detecting exposed PS) showed that ADP increased the fraction of PS-exposing platelets 
by 70% (Fig. 10D). Wortmannin pretreatment almost fully antagonized this increase, 
while TGX221 pretreatment was somewhat less inhibitory, and AS252424 was 
ineffective. Taken together, these results suggest that in both mouse and human 
platelets, the β but not the γ PI3-K isoform contributes to platelet procoagulant activity 
following P2Y12 stimulation. 
Discussion 
The present results highlight the importance of the ‘weak’ agonist, ADP, as a key platelet 
activator that is effective at low and high thrombin concentrations as well as under 
coagulant conditions, where thrombin is generated in situ. We find that (autocrine) ADP, 
acting via P2Y12, enhances and extends the thrombin-induced platelet activation by 
increasing Ca
2+
 mobilization from internal stores, without directly affecting a specific Ca
2+
 
entry channel, as was previously suggested. This potentiation by P2Y12 signaling is 
conserved between platelets from man and mouse, and thus is irrespective of the 
different thrombin receptor types employed by these species. The data are well 
compatible with the earlier findings that P2Y12 activates platelets mostly or exclusively 
via Gi,
14,25
 whereas thrombin and P2Y1 stimulate the Gq pathway, which is directly 
coupled to Ca
2+
 mobilization.
35
 The present results are also in agreement with another 
paper, showing that P2Y12 activation enhances the Ca
2+
 response induced by thrombin 
receptor-activating peptide.
36
 Thus, in the presence of thrombin, the Gi signaling 
pathway via P2Y12 provides platelets with a mechanism to extend their activation. 
Platelet and mature megakaryocytic InsP3 receptors are sensitive to small changes in 
cAMP levels and ensuing PKA activation.
27,28
 This sensitivity is likely regulated by PKA 
phosphorylation sites, present in the type-I InsP3 receptor Ca
2+
 channels, which control 
the Ca
2+
-mobilizing properties of platelets.
26
 The current data indicate that ADP, acting 
via P2Y12 and Gi, can down-regulate adenylyl cyclase and hence PKA with consequently 
increased Ca
2+
 mobilization. This pathway still operates in the presence of thrombin, e.g. 
exemplified by the fact the PKA inhibitor H89 reinforces the thrombin-induced Ca
2+ 
response when P2Y12 is active. 
In addition, this study demonstrates an important role for PI3-K in the P2Y12-
dependent enhancement of thrombin receptor signaling, which is most prominent in the 
late stage of the Ca
2+
 response and is quite substantial in longer-term Ca
2+
 integrals. 
This long Ca
2+
 signal is shortened by PI3-K inhibition with wortmannin or LY294002. It 
apparently does not implicate modulation of the InsP3 receptor Ca
2+
 channels, as the 
InsP3-induced Ca
2+
 mobilization is not affected by PI3-K inhibition. As wortmannin and 
the prototype PI-3K inhibitor,
21
 LY294002, had similar shortening effects on the Ca
2+
 
Chapter 4 
 60 
response evoked by thrombin + ADP, we do not have evidence that LY294002 may 
affect this response in an aspecific way, as was proposed for smooth muscle cells.
37
 
Platelets from PI3-Kγ deficient mice exhibited unchanged Ca2+ response and 
procoagulant activity, while the PI3-Kβ inhibitor TGX221 suppressed this response in 
both wildtype and deficient platelets. Similarly, in human platelets, TGX221 but not the 
PI3-Kγ specific inhibitor, AS252424, antagonized the P2Y12-dependent part of the Ca
2+
 
response, indicating that PI3-Kβ is the main isoform in Ca2+ signal modulation via P2Y12. 
Examination of targets downstream of P2Y12 revealed a clear role for PI3-Kβ in the 
regulation of Akt activation, in platelets stimulated with thrombin + ADP. This agrees well 
with the earlier finding, in mouse platelets, that Akt is activated downstream of Gi and 
G12/13.
33,38
 However, under the present conditions of thrombin + ADP receptor 
stimulation, we could not confirm that also PI3-Kγ contributes to Akt activation19 or to 
Ca
2+
 mobilization.
32
 
The mechanism whereby PI3-Kβ enhances Ca2+ signaling is not entirely clear. Its 
effect relies on SERCA activity, as it disappears in the presence of thapsigargin. 
However, in contrast to a report on pancreatic acinar cells, where PI3-K inhibition 
increased Ca
2+
 mobilization via SERCA activation,
30
 PI-3K inhibition did not alter SERCA 
activity in platelets. This suggests that not the Ca
2+
 reuptake itself is controlled by PI3-K, 
but a different process which is still dependent on normal Ca
2+
-ATPase function. 
A remarkable finding is that the persistent effect of P2Y12 on Ca
2+
 mobilization relies 
on prolonged phospholipase C activation. Similarly to AR-C, late application of each of 
the three phospholipase C inhibitors, U73122, ET-18-OCH3 or manoalide, rapidly 
abolished the remaining Ca
2+
 response. Late application of wortmannin to block PI3-K 
had a similar though slower effect. That PI3-K contributes to phospholipase C activity 
was further confirmed by the finding that treatment with wortmannin suppressed the 
cytosolic InsP3 level in thrombin + ADP stimulated platelets. Knowing that the PI3-Kβ 
isoform is responsible for a considerable part of the PIP3 formed in platelets,
21
 this may 
suggest that the PIP3 produced by this isoform leads to the plasma membrane binding 
and, hence, activation of PH domain-containing phospholipase Cγ. Indeed, thrombin (via 
ADP?) has been shown to provoke activation of phospholipase Cγ along with 
phospholipase Cβ isozymes.39 A similar mechanism of prolonged Ca2+ signaling by PIP3 
and membrane translocation of phospholipase Cγ has been proposed for other cell 
types.
31
 
In experiments where thrombin is induced in situ by activation of PRP with tissue 
factor and CaCl2, we find that the P2Y12/PI3-K pathway significantly enhances the 
activation state and, hence, the procoagulant activity of platelets. Experiments with 
inhibitors and PI3-Kγ deficient mice, indicated that especially the PI3-Kβ isoform is 
involved. Flow cytometry further indicated that the PI3-K pathway increased the fraction 
of platelets with PS exposure under these conditions. Since PS exposure is a strongly 
Ca
2+
-dependent response, that in turn mediates thrombin generation, this indicates that 
P2Y12 signaling via PI3-Kβ plays a regulating role in the positive feedback loop of 
thrombin-induced platelet activation, platelet procoagulant activity, and new thrombin 
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formation. These data thereby support the earlier finding that ADP enhances the 
procoagulant activity of platelets via the P2Y12 receptors.
5,22,23
 
The present results significantly extend the earlier work where the interaction of 
P2Y12 with P2Y1 signaling was investigated.
25,40
 We find that P2Y12 enhances the 
thrombin-induced Ca
2+
 response in a way not only involving adenylyl cyclase/PKA 
inhibition, but also by PI3-K stimulation. P2Y12 appears to increase the InsP3 receptor 
function via PKA inhibition. This effect is further enlarged by a PI3-Kβ-dependent 
prolongation of phospholipase C activation and InsP3 production (see scheme in 
supplementary Fig. S1). The data thereby reveal a novel function for the β-isoform of 
PI3-K. Earlier, this isoform has been linked to shear-dependent activation of platelets, 
regulating the stability of platelet adhesion and aggregation.
20,21
 We now advocate that 
PI3-Kβ also plays a role in the prolongation of thrombin-induced Ca2+ signaling via 
P2Y12. 
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Abstract 
Integrin αIIbβ3 mediates adhesion and aggregation of platelets via binding of fibrinogen. 
Integrin αIIbβ3 inhibitors not only affect these responses, but also suppress the ability of 
platelets to support thrombin generation. We hypothesized that αIIbβ3 antagonists affect 
platelet procoagulant activity through displacement of its main ligand, fibrinogen, with as 
a result abrogated outside-in signaling by the integrin. The structurally different integrin 
blockers, abciximab, eptifibatide and tirofiban reduced and delayed tissue factor-induced 
generation of thrombin in plasma at a similar extent, provided that platelets were present. 
This reduction was accompanied by a potent decrease in phosphatidylserine exposure 
on the platelet surface. Isolated platelets stimulated with thrombin and convulxin 
responded by binding of fibrin(ogen), a prolonged rise in cytosolic Ca
2+
 and surface 
exposure of phosphatidylserine. All these responses were suppressed by αIIbβ3 
inhibition and they were also greatly reduced in platelets from a patient with 
Glanzmann’s thrombasthenia, lacking αIIbβ3. Stimulation of outside-in integrin signaling 
in platelets spread on fibrinogen potentiated the thrombin-induced Ca
2+
 rises and 
increased the exposure of PS. Also this response was essentially absent in Glanzmann 
platelets. Inhibitor studies showed that phosphoinositide 3-kinase was involved in the 
platelet procoagulant response, likely in part via P2Y12 receptor signaling. Together, 
these results indicate that outside-in signaling by fibrin(ogen)-occupied integrin αIIbβ3 
contributes to PS exposure by maintaining a high Ca
2+
 signal in stimulated platelets. 
Introduction 
The major platelet integrin, αIIbβ3 (glycoprotein IIb/IIIa), plays a key role in the adhesion 
and aggregation of platelets. Platelet activation by agonists like ADP, thrombin and 
collagen results in a conformational change of αIIbβ3, which increases its affinity for 
ligands such as fibrinogen and von Willebrand factor. This integrin inside-out signaling 
relies on association of the β3-chain with the actin-binding proteins talin and kindlin-3,1,2 
and is a premise for platelet-platelet interactions and hence aggregate formation.
3,4
 
Conversely, fibrinogen binding, particularly under conditions favoring αIIbβ3 clustering, 
induces outside-in signaling of the integrin itself, through a pathway involving complex 
formation and activation of the protein tyrosine kinases, Src, Syk and FAK.
5,6
 In 
synergism with ADP-induced signaling via P2Y12 receptors, outside-in signaling also 
leads to activation of phosphoinositide 3-kinase (PI3-K) and to an increased intracellular 
Ca
2+
 level in a not well understood way.
7
 The result of integrin αIIbβ3 activation and 
signaling is cytoskeletal reorganization, granule secretion and lamellipod formation, with 
as physiological consequence, spreading of platelets at an integrin-adhesive surface and 
contraction of platelets within a clot.
8
 Recently, it was described that αIIbβ3 outside-in 
signaling also leads to continuous shedding of microparticles from both suspended and 
spreading platelets.
9
 
In addition to forming aggregates, platelets have a procoagulant role in supporting 
thrombin generation and coagulation.
10,11
 Previous studies have shown that integrin 
αIIbβ3 antagonists not only inhibit platelet aggregation but also thrombin generation and 
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procoagulant activity.
12-15
 Several mechanisms have been proposed to be responsible 
for this anticoagulant effect of integrin αIIbβ3 blockade. These include: inhibition of 
microparticle formation,
12,16,17
 displacement of binding of prothrombin to αIIbβ3,18 
reduced binding of factor V(a) to platelets,
19,20
 and a diminishing effect on platelet 
activation and surface exposure of procoagulant phosphatidylserine (PS).
19,20
 However, 
several papers demonstrate that integrin αIIbβ3 inhibitors, at concentrations that 
completely block platelet aggregation, show distinct and even opposing effects on 
platelet procoagulant activity.
17,21
 Furthermore, recent observations indicate that the 
activation of αIIbβ3 reverses in platelets under coagulant conditions.22 This raises the 
question whether and how the αIIbβ3 inhibitors interact with platelets to modulate their 
coagulant activity. 
Here we hypothesized that αIIbβ3 antagonists affect platelet procoagulant activity 
through displacement of its main ligand, fibrinogen, with as a result abrogated outside-in 
signaling by the integrin. Procoagulant activity under thrombin-generating conditions was 
assessed from the ability of platelets to expose PS. As elevation in cytosolic Ca
2+
 is a 
key trigger for PS exposure,
23
 this platelet response was also studied. The results point 
to a hitherto unrecognized signaling role of integrin αIIbβ3 towards procoagulant activity, 
which is dependent on ligandation with fibrinogen or fibrin. 
Materials and methods 
Materials 
Human α-thrombin came from Enzyme Research Laboratories (Swansea, UK). Fura-2 
and Fluo-4 acetoxymethyl esters were from Molecular Probes (Leiden, NL); recombinant 
human tissue factor from Dade Behring (Marburg, Germany); and human thrombin 
calibrator from Thrombinoscope (Maastricht, NL). Apyrase, bovine serum albumin (BSA), 
human and bovine fibrinogen (fraction 1, type III) and wortmannin were from Sigma (St. 
Louis, MO, USA). Cangrelor (AR-C69931MX, AR-C) was kindly provided by The 
Medicine Company (Parsippany, NJ, USA). Fluorescent thrombin substrate, Z-Gly-Gly-
Arg aminomethyl coumarin (Z-GGR-AMC) and PAR1 peptide SFLLRN were from 
Bachem (Bubendorf, Switzerland). Ancrod came from NIBSC (Hertfordshire, UK); 
fluorescein isothiocyanate (FITC)-labeled annexin A5 from PharmaTarget (Maastricht, 
NL); FITC-labeled mAb against platelet-bound human fibrinogen from WAK Chemie 
Medical (Steinbach, Germany). Procoagulant phospholipid vesicles (PS : phosphatidyl 
choline : phosphatidyl ethanolamine 1 : 3 : 1; mol/mol/mol) were prepared, as 
described.
24
 Convulxin was purified to homogeneity from the venom of Crotalus durissus 
terrificus (Latoxan, France).
25
 Abciximab (reopro) was from Centocor (Leiden, NL); 
tirofiban (aggrastat) from Merck (Haarlem, NL); and eptifibatide (integrilin) from 
GlaxoSmithKline (Zeist, NL). 
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Platelet preparation and isolation 
Blood was taken from healthy volunteers and collected into 1/10 volume of 129 mM 
trisodium citrate. Blood was also taken from a patient with Glanzmann’s thrombasthenia, 
with known deficiency in integrin αIIbβ3.26 PRP was obtained by 15 min centrifuging at 
240 g. Platelet-free plasma (PFP) was obtained by centrifuging twice at 2630 g for 10 
min. Platelet count in PRP was determined with a thrombocounter (Coulter Electronics, 
Luton, UK) and normalized with autologous PFP. To prepare washed platelets, blood 
was collected into 1/6 volume of acid-citrate glucose solution (ACD, 80 mM trisodium 
citrate, 52 mM citric acid and 180 mM glucose). 
Human citrate-anticoagulated plasma was treated with ancrod (1.3 IU/mL) to achieve 
partial depletion of fibrinogen. Remaining fibrinogen content in the plasma was 
approximately 0.5 mg/mL. 
Thrombin generation measurements 
Normalized PRP (1.5×10
8
 platelets/mL) or PFP supplemented with phospholipid vesicles 
(10 µM) were preincubated with indicated inhibitors; platelets in PRP were pre-activated 
as required. Thrombin generation was initiated with tissue factor/CaCl2 and measured at 
37°C according to the thrombogram method, as described previously.
13
 Briefly, plasma 
samples (4 volumes) were pipetted into a polystyrene 96-wells plate (Immulon 2HB, 
Dynex Technologies), already containing 1 volume of buffer A (20 mM Hepes, 140 mM 
NaCl, 5 mg/mL BSA and 6 pM tissue factor). Coagulation was started by adding 1 
volume of buffer B (2.5 mM Z-GGR-AMC, 20 mM Hepes, 100 mM CaCl2 and 60 mg/mL 
BSA). Fluorescence accumulation was measured with a Fluoroskan Ascent well-plate 
reader, equipped with Thrombinoscope software. 
Flow cytometry 
Washed platelets (1.0×10
8
 platelets/mL) were resuspended in buffer or ancrod-treated 
citrate plasma.
27
 Platelets were preincubated with inhibitors, and activated as required. 
For experiments with plasma, coagulation was triggered with tissue factor (2 pM) and 
CaCl2 (16.6 mM). For experiments with platelets in Hepes buffer, activation was with 
PAR1 agonist SFLLRN (15 µM) or thrombin (10 nM) in combination with convulxin (50 
ng/mL). After 15 min of activation, platelet surface characteristics were determined by 
flow cytometry using FITC-labeled annexin A5 or FITC-labeled mAb against platelet-
bound human fibrinogen. 
Cytosolic Ca
2+
 measurements 
To evaluate changes in cytosolic free Ca
2+
, PRP was incubated with Fura-2 
acetoxymethyl ester (2.5 µM) at 37°C for 45 min, under standardized conditions.
28
 Fura-
2-loaded platelets were washed in the presence of apyrase (0.1 U/mL ADPase), and 
finally resuspended in Hepes buffer pH 7.45 (10 mM Hepes, 136 mM NaCl, 2.7 mM KCl, 
2 mM MgCl2, 0.1% glucose and 0.1% BSA) at a concentration of 1.0×10
8
 platelets/mL. 
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Before start of measurements, platelets were incubated with inhibitors or vehicle solution 
and 2 mM CaCl2. Nanomolar changes in cytosolic [Ca
2+
]i were measured by ratio 
fluorometry at 37°C.
29
 Platelet suspensions were slowly stirred. 
Single cell activation measurements 
Glass coverslips were coated with 25 µL fibrinogen solution (1 mg/mL) during 10 min, 
and rinsed with saline. Washed platelets in Hepes buffer pH 7.45 (1.0×10
8
 platelets/mL) 
were allowed to adhere to fibrinogen-coated coverslips for 30 min. After 5-10 min, non-
adherent platelets were removed by rinsing with Hepes buffer. Platelets were pre-loaded 
with Fura-2, as appropriate. The adhered platelets were stimulated with thrombin (10 
nM) in Hepes buffer containing CaCl2 (2 mM). Phase contrast images and fluorescence 
ratio images, indicating cytosolic Ca
2+
 levels (Fura-2) or PS exposure (FITC-labeled 
annexin A5), were taken using a dual camera imaging system, controlled by Visitech 
software, as described before.
30
 
Statistics 
Significance of differences was determined with the Mann-Whitney U test or the 
independent samples t test, as appropriate, using the statistical package for social 
sciences (SPSS 15.0, Chicago, IL). 
Results 
Similar effects of various integrin αIIbβ3 inhibitors on thrombin generation in 
platelet-rich plasma 
Integrin αIIbβ3 blockers were suggested to have different effects on platelet-dependent 
coagulation.
17,21
 To examine this in more detail, we compared the three integrin inhibitors 
that currently are in clinical use: the human/mouse chimeric monoclonal antibody 
fragment abciximab (also inhibiting αvβ3), the peptide compound eptifibatide, and the 
non-peptide compound tirofiban. At physiological extracellular Ca
2+
 concentrations, these 
compounds inhibit SFLLRN (PAR1)-induced aggregation in PPACK-anticoagulated PRP 
with IC50 values of 5 µg/mL, 0.5 µg/mL and 0.1 µg/mL, respectively.
31
 This is in 
accordance with the known difference in affinities of the compounds for αIIbβ3.32 We 
investigated the effect of these inhibitors on thrombin generation in PRP, triggered with 
tissue factor/CaCl2. All three inhibitors suppressed and delayed the formation of thrombin 
to a similar (lowest) level of about 20 nM thrombin (Fig. 1A). With all inhibitors, the effect 
was dose-dependent (Fig. 1B). Half-maximal reduction in thrombin peak height was 
achieved at approximately 2 µg/mL (abciximab), 1 µg/mL (eptifibatide) and 0.1 µg/mL 
(tirofiban). Hence, in comparison to platelet aggregation (under non-coagulant 
conditions), the integrin inhibitors did not completely suppress thrombin generation, and 
slightly higher concentrations were needed for a half-maximal effect. To determine 
whether this inhibiting effect is specific and solely  
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Figure 1. Antagonism of αIIbβ3 suppresses thrombin generation in the presence of platelets. 
Human PRP (1.0×10
8
 platelets/mL, f.c.) or PFP supplemented with phospholipid vesicles (PV 10 
µM, f.c.) was preincubated with vehicle, abciximab (0.5-20 µg/mL), eptifibatide (0.5-20 µg/mL) or 
tirofiban (0.1-5 µg/mL) for 20 min. Thrombin generation was measured after triggering with tissue 
factor (1 pM) and CaCl2 (16.6 mM). (A) Representative thrombin generation traces with PRP, 
showing the comparable inhibitory effect of integrin blockers in the presence of platelets. (B) Dose-
dependent effect of integrin inhibitors on thrombin peak height. Data are relative to the control 
condition with vehicle (mean±SEM, n=3-5). 
 
dependent on platelets, thrombin generation was measured in plasma in which 
phospholipids vesicles provided the procoagulant surface. As shown in Fig. 1B, none of 
the αIIbβ3 inhibitors did influence thrombin peak levels, even not at the highest doses 
applied, thus demonstrating that they do not affect the coagulation process as such. 
Fibrinogen binding to integrin αIIbβ3 leads to increased PS exposure 
It has been reported that particularly antibody-based αIIbβ3 inhibitors suppress platelet 
PS exposure in response to thrombin with/without collagen.
19-21,33
 Flow cytometry was 
applied to determine how the reducing effect of αIIbβ3 inhibitors on in situ thrombin 
generation is related to PS exposure of platelets. For practical reasons, citrate-
anticoagulated plasma was treated with the snake venom ancrod, resulting in partial 
defibrination with a fibrinogen level below the threshold for macroscopic fibrin clot 
formation (<1 mg/mL). Control experiments where this plasma was reconstituted with 
platelets indicated that the integrin blockers still caused normal suppression of tissue 
factor/CaCl2-induced thrombin generation, in spite of the fact that no massive clots were  
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Figure 2. Antagonism of αIIbβ3 reduces PS exposure of platelets activated in the presence or 
absence of plasma. Platelets reconstituted with defibrinated plasma or platelets in Hepes buffer pH 
7.45 were preincubated with vehicle, abciximab (10 µg/mL), eptifibatide (10 µg/mL) or tirofiban (1 
µg/mL). (A) The plasma was triggered with tissue factor and CaCl2 for 15 min for in situ thrombin 
generation. Flow cytometry was used to determine: (i) platelet binding of fibrinogen with FITC-anti-
human fibrinogen, and (ii) platelet exposure of PS with FITC-labeled annexin A5. (B) Platelets in 
Hepes buffer were stimulated with thrombin (10 nM) + convulxin (50 ng/mL) in the presence of 
CaCl2 (2 mM) for 15 min. Flow cytometry was used as above. Shown are representative histograms 
of annexin A5 and anti-fibrinogen fluorescence (grey: non-activated, black: activated platelets); M2 
indicates the population positively stained. Bars indicate percentages of PS-exposing platelets 
relative to the vehicle condition. Data are mean±SEM (n=3-6); *p<0.05 vs. vehicle. 
 
formed (data not shown). At 15 min after addition of tissue factor/CaCl2, binding of 
fibrin(ogen) to platelets was determined using a fluorescent-labeled mAb against 
platelet-bound fibrinogen (which also detects fibrin). Increased fibrin(ogen) binding was 
observed in the whole platelet population (Fig. 2A). Labeling with FITC-annexin A5 
showed that the majority of platelets stained positively and hence exposed PS. 
Preincubation of the reconstituted PRP with abciximab (10 µg/mL) decreased the 
amount of PS-exposing platelets to 41±6.3% of control (Fig. 2A). Eptifibatide (10 µg/mL) 
and tirofiban (1 µg/mL) each reduced the fraction of PS-exposing platelets to about 20% 
of control. Furthermore, αIIbβ3 blockade reduced the binding of fibrin(ogen) to platelets 
to 51±3.2%. Flow cytometry further indicated that the integrin blockers had a reducing, 
though less predominant, effect on microparticle formation (not shown), but this was not 
further investigated. Together, these results suggest that the suppressive effect of 
integrin inhibitors on thrombin generation was particularly due to reduced PS exposure 
by platelets. This by implication points to a reducing effect of integrin inhibitors on the 
activation process of platelets to PS exposure. 
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In suspensions of washed platelets, PS exposure can be achieved by stimulation with 
a combination of thrombin and collagen receptor agonists.
23
 Suspended platelets were 
therefore stimulated with thrombin (activating PAR1 and PAR4) and convulxin 
(stimulating the GPVI receptor for collagen) in the presence of CaCl2. After 15 min of 
activation, this resulted in a fraction of 35±2.9% PS-exposing platelets (Fig. 2B). Staining 
with anti-fibrinogen mAb indicated that the majority of the platelets bound fibrin(ogen), 
which was secreted by the platelets themselves. Also in this case, platelet pretreatment 
with integrin inhibitors resulted in a markedly reduced fraction of PS-exposing platelets, 
reaching 65% (abciximab) to 50% (eptifibatide or tirofiban) of the control condition (Fig. 
2B). 
These results suggest that the activation of platelets leads to fibrinogen secretion 
which, by binding to integrin αIIbβ3, induces outside-in signaling towards enhanced PS 
exposure. This scheme was tested by determining the effect of fibrinogen addition on PS 
exposure to platelets that were stimulated with thrombin and collagen receptor agonists. 
To prevent fibrinogen degradation and clot formation, the cells were incubated with the 
PAR1 agonist SFLLRN (instead of thrombin) plus convulxin. As indicated in Fig. 3, 
addition of purified bovine fibrinogen caused a dose-dependent, stimulating effect on PS 
exposure, reaching a fraction of >70% PS-exposing platelets at the highest dose tested 
(2 mg/mL). Importantly, pretreatment with tirofiban (Fig. 3) or other integrin inhibitors (not 
shown) reversed the stimulating effect of fibrinogen on PS exposure. Comparable results 
were obtained by addition of purified human fibrinogen; in this case, fractions of PS-
exposing platelets dose-dependently increased to 146±19% (0.1 mg fibrinogen/mL) and 
193±14% (2 mg fibrinogen/mL, n=3) of the control condition. Accordingly, fibrinogen 
interaction with αIIbβ3 appears to result in enhancement of PS exposure at the platelet 
surface. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Fibrinogen stimulates PS exposure of activated platelets. Washed platelets in Hepes 
buffer pH 7.45 were incubated with vehicle, tirofiban (1 µg/mL) and/or fibrinogen (0.1-2 mg/mL) for 
20 min at 37°C. Platelets were then activated with SFLLRN (15 µM) + convulxin (50 ng/mL) in the 
presence of CaCl2 (2 mM). After 15 min, FITC-labeled annexin A5 was added, and fractions of PS-
exposing platelets were determined by flow cytometry. Data are means±SEM (n=3); *p<0.05 vs. 
vehicle. 
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Integrin αIIbβ3 outside-in signaling maintains high cytosolic Ca2+ levels and 
stimulates PS exposure 
In platelets stimulated with potent agonists, a sustained rise in cytosolic Ca
2+
 is required 
for PS exposure.
10
 However, various papers indicate that αIIbβ3 blockade does not 
change platelet Ca
2+
 responses.
20,33
 We reasoned that αIIbβ3 signaling may contribute 
to prolongation rather than to initialization of the platelet Ca
2+
 signal. To study this, 
suspensions of Fura-2 loaded platelets were stimulated with thrombin and convulxin, and 
levels of cytosolic Ca
2+
 were monitored for up to 15 min by ratio fluorometry. Note that 
this method relies on ratio measurements of fluorescence at 340 nm and 380 nm 
excitation. Hence, it is not affected by changes in the absolute amount of fluorescence, 
e.g. due to aggregation of platelets or bleaching of fluorescence. In the absence of 
inhibitors, thrombin/convulxin-stimulated platelets showed a strong initial increase in 
cytosolic Ca
2+
, which was followed after 3 min by a sustained high Ca
2+
 level,  
 
 
 
 
Figure 4. Integrin αIIbβ3-enhanced Ca2+ signaling increases PS exposure in activated 
platelets. Fura-2 loaded platelets were preincubated with vehicle, eptifibatide (10 µg/mL) or 
tirofiban (1 µg/mL), as in Fig. 2B. Platelets were activated with thrombin (10 nM) + convulxin (50 
ng/mL) in the presence of CaCl2 (2 mM). (A) Traces of changes in cytosolic Ca
2+
 in suspensions of 
platelets, representative for 3 or more experiments with platelets from different donors. (B) 
Averaged cytosolic Ca
2+
 peak levels and end levels (15 min) of suspensions of platelets. Fractions 
of PS-exposing platelets (black bars) were determined in 15 min samples, using flow cytometry and 
FITC-annexin A5 label. (C) Time effect of addition of integrin antagonist on PS exposure. Platelets 
in Hepes buffer pH 7.45 were stimulated as for panel B at t=0. Aliquots were treated with eptifibatide 
(10 µg/mL) or tirofiban (1 µg/mL), either before (t=-10 min) or after (t=1 to 10 min) stimulation with 
thrombin + convulxin. Fractions of PS-exposing platelets were determined in 15 min samples by 
flow cytometry with FITC-annexin A5. Data are relative to the control condition without antagonist. 
Means±SEM (n=3-5); *p<0.05 vs. vehicle. 
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persisting at 450 nM during 15 min (Fig. 4A). Preincubation of the platelets with 
eptifibatide or tirofiban did not influence the initial Ca
2+
 peak level (Fig. 4B). However, 
both inhibitors markedly reduced the late phase (3-15 min) of the Ca
2+
 response (Fig. 
4A, B). After 15 min of activation, the Ca
2+
 level was reduced to 56±10% or 60±8% (n=3-
5) with eptifibatide or tirofiban, respectively, in comparison to the control condition. 
Samples of the Fura-2-loaded platelets were then used for flow cytometric detection of 
FITC-annexin A5 binding. Platelets that were preincubated with eptifibatide or tirofiban 
had a strong reduction in PS exposure (Fig. 4B). 
If integrin signaling contributes to PS exposure only by prolongation of the platelet 
Ca
2+
 signal, also addition of integrin blockers after activation should decrease the 
number of PS-exposing platelets. This was indeed observed (Fig. 4C). Eptifibatide or 
tirofiban added at 1 min (t=1) after thrombin/convulxin still caused a substantial reduction 
in PS-exposing platelets. Addition of the inhibitors at 5 min or 10 min after activation was 
progressively less effective. These results thus suggest that outside-in signaling via 
integrin αIIbβ3 maintains a high Ca2+ signal in stimulated platelets, which leads to 
exposure of PS at the platelet surface. 
To confirm these data, similar experiments were performed with platelets from a 
patient with Glanzmann’s thrombasthenia, which lack expression of integrin αIIbβ3. The 
platelets showed normal initial Ca
2+
 responses when stimulated with thrombin/convulxin 
(Fig. 5A). However, at later time points (15 min) the cytosolic Ca
2+
 levels declined to 
below 200 nM (Fig. 5B). Furthermore, pretreatment of Glanzmann platelets with tirofiban 
altered neither the late Ca
2+
 signal nor the (low) exposure of PS. 
 
 
 
 
Figure 5. Reduced late Ca
2+
 response and reduced PS exposure in activated Glanzmann 
platelets. Platelets from a Glanzmann patient were loaded with Fura-2, preincubated with vehicle or 
tirofiban (1 µg/mL), and activated with thrombin and convulxin, as described for Fig. 4. (A) Traces of 
changes in cytosolic Ca
2+
 in suspensions of platelets (3 experiments, 1 donor). (B) Averaged 
cytosolic Ca
2+
 peak levels and end levels (15 min) of suspensions of platelets. Fractions of PS-
exposing platelets were determined in 15 min samples, by flow cytometry and FITC-annexin A5 
label. Data are means±SEM, (n=3, 1 donor). 
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Figure 6. Platelet spreading on fibrinogen via αIIbβ3 increases Ca2+ signaling and PS 
exposure in activated platelets. Fura-2 loaded platelets (1.0×10
8
 platelets/mL) pretreated with 
vehicle (control) or tirofiban (1 µg/mL) were allowed to adhere to immobilized fibrinogen for 30 min. 
Cells were then stimulated with thrombin (10 nM) for another 10 min, as indicated. Fluorescence 
changes were monitored by advanced microscopy and ratio fluorometry. (A) Representative phase 
contrast images of platelets on fibrinogen (35×40 µm), and Ca2+ traces from single platelets (2 cells 
per condition). (B) Platelets on fibrinogen were scored for elevation in Ca
2+
 (>100 nM) and for 
staining with FITC-annexin A5. Figure bars give fractions of high Ca
2+
 and PS-exposing platelets. 
Data are means±SEM (n=4-6); *p<0.05 vs. control. 
Immobilized fibrinogen triggers αIIbβ3 outside-in signaling and enhances PS 
exposure of platelets 
As another way to study the involvement of integrin signaling in PS exposure, platelets 
were allowed to spread on fibrinogen, which is a classical reaction directed by αIIbβ3 
outside-in signaling.
4
 Loading of the platelets with Fura-2 made it possible to follow the 
changes in cytosolic Ca
2+
. Under control conditions, the platelets slowly developed 
filopodia and lamellipodia, which was accompanied by only incidental spiking rises in 
Ca
2+
 (Fig. 6A, upper panel). Addition of thrombin to platelets that were spreading on 
fibrinogen for 30 min, stimulated the formation of lamellipodia. Thrombin addition further 
resulted in persistent rises in Ca
2+
 in most of the platelets (Fig. 6A, middle panel). 
Pretreatment with tirofiban reduced the thrombin-induced spreading and caused a non-
continuous but spiking Ca
2+
 signal in the majority of the cells (Fig. 6A, lower panel). The 
platelets were then stained with FITC-annexin A5 to determine PS exposure. A fraction 
of 12±4% platelets showed PS exposure after 30 min spreading and subsequent  
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Figure 7. Involvement of αIIbβ3 in spreading and PS exposure of activated platelets. Washed 
platelets (1.0×10
8
 platelets/mL) from control subjects or a Glanzmann patient were pretreated with 
vehicle or tirofiban (1 µg/mL) and allowed to adhere to immobilized fibrinogen for 30 min. Platelets 
were then stimulated with thrombin (10 nM) for another 10 min. (A) Representative phase contrast 
(120x120 µm) and fluorescence images (FITC-annexin A5, 150x150 µm) after 10 min of activation. 
(B) Averaged size of arbitrarily selected platelets after 10 min of activation (n=6 per donor). (C) 
Fractions of PS-exposing platelets. Means±SEM (n=3-6); *p<0.05 vs. vehicle.  
 
stimulation with thrombin (Fig. 6B). In contrast, thrombin addition to non-spread platelets 
(5 min adhesion) resulted in only 2.5±0.4% of PS-exposing platelets. Furthermore, 
presence of tirofiban during the spreading also decreased the fraction of PS-exposing 
platelets to 2.0±0.4%. 
In a subsequent set of experiments, the extent of spreading of platelets from control 
subjects and a Glanzmann patient was compared for the tendency to PS exposure. 
While almost all platelets from control subjects spread in response to thrombin, about 
10% became annexin A5-positive (Fig. 7). Tirofiban treatment inhibited spreading and 
PS exposure. Platelets from the Glanzmann patient hardly spread on the fibrinogen 
surface, and were very low in PS exposure. Together, these data are compatible with the 
scenario that αIIbβ3 outside-in signaling, induced by spreading on fibrinogen, enhanced 
thrombin-evoked Ca
2+
 rises which increase the tendency to expose PS. 
A final set of experiments was designed to determine by which signaling pathway 
αIIbβ3 evoked enhanced PS exposure. This was tested for platelets in partially 
defibrinated plasma, where thrombin was generated in situ with tissue factor. Possible 
involvement of PI3-K signaling was tested by pretreatment of the platelets with 
wortmannin. PI3-K inhibition decreased the fraction of PS-exposing platelets from 38% to 
8%, i.e. similar to the effect of tirofiban (Fig. 8A). As also secreted ADP can contribute to  
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Figure 8. Roles of PI3-K and ADP in integrin αIIbβ3-stimulated PS exposure. Platelets 
reconstituted in defibrinated plasma were preincubated with vehicle, tirofiban (1 µg/mL), wortmannin 
(200 nM) or cangrelor (AR-C, 10 µM). The plasma was triggered with tissue factor and CaCl2 for 15 
min for inducing in situ thrombin generation. Flow cytometry was used to measure: (A) PS exposure 
FITC-labeled annexin A5; (B) binding of fibrinogen with FITC-anti-human fibrinogen mAb. 
Means±SEM (n=3); *p<0.05 vs. vehicle. 
 
platelet procoagulant activity via P2Y12 receptors and PI3-K,
27,34,35
 the contribution of this 
pathway was also studied. Platelets were preincubated with the P2Y12 blocker cangrelor 
(AR-C), which reduced the amount of PS-exposing platelets to 21%, that is less than 
seen with tirofiban or wortmannin (Fig. 8A). Platelet-fibrin(ogen) binding was measured 
to test whether wortmannin and cangrelor affected the occupancy of αIIbβ3 under these 
conditions. In contrast to tirofiban, neither of the compounds affected the fibrin(ogen) 
binding (Fig. 8B). Accordingly, these results indicate that the PI3-K pathway plays an 
important role in the integrin αIIbβ3-mediated signaling to PS exposure, and that part of 
this integrin signal relies on P2Y12 via ADP secretion. 
Discussion 
This paper provides new insight into the mechanism by which integrin αIIbβ3 antagonists 
affect platelet-dependent procoagulant activity and thrombin generation. Various lines of 
evidence demonstrate that binding of ligand, i.e. fibrin(ogen), to αIIbβ3 via the classical 
pathway of outside-in signaling enhances exposure of PS on platelets that are 
(co)stimulated either by in-situ generated thrombin in plasma, or by purified thrombin in a 
plasma-free system. We show that: (i) in suspended platelets, the presence of fibrinogen 
stimulates long-term Ca
2+
 signal generation and PS exposure, in a way fully inhibitable 
by abciximab, eptifibatide and tirofiban; (ii) spreading of platelets over fibrinogen 
increases the thrombin-induced Ca
2+
 signal along with PS exposure; (iii) these 
fibrinogen-dependent potentiating effects are absent in platelets from a patient with 
Glanzmann’s thrombasthenia; (iv) blockade of PI3-K antagonizes the integrin-dependent 
procoagulant response to a larger extent than ADP receptor blockade. Furthermore, the 
data show that the procoagulant effect of integrin signaling is independent of thrombin 
(i.e. fibrin formation), as also PAR1 (SFLLRN) and GPVI (convulxin) signaling synergizes 
with fibrinogen-induced integrin signaling in prolongation of the Ca
2+
 signal and 
increased exposure of PS. Together, the current results provide a mechanistic 
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explanation for the earlier described (variable) effect of integrin inhibitors on the 
development of procoagulant activity.
14,19-21,33
 
Earlier work demonstrated that αIIbβ3 outside-in signaling caused shedding of 
microparticles from platelets even without added agonist.
9
 Together with the present 
results it seems that outside-in signaling is an ongoing event in platelets that are in 
continuous presence of the αIIbβ3 ligand, fibrinogen. Likely, fibrin(ogen)-mediated 
outside-in signaling also contributes to the microparticle formation from platelets in 
clotting plasma, given the reported suppressive effect of integrin inhibitors.
12
 However, 
this was not investigated. On the other hand, it is clear that with various other agonists 
that stimulate platelet procoagulant activity (collagens, Ca
2+
 ionophores), PS exposure is 
mostly associated with microparticle formation.
10,36,37
 
Few reports indicate that integrin inhibition or Glanzmann’s thrombasthenia has no 
effect on the procoagulant activity of platelets stimulated with collagen alone.
21,38
 This 
does not contrast to the present concept, since GPVI stimulation causes a potent and 
prolonged Ca
2+
 signal in platelets which, by itself, is a sufficient trigger for PS 
exposure.
39
 
A number of other studies failed to detect effects of αIIbβ3 antagonists on Ca2+ 
responses in collagen- and/or thrombin-stimulated platelets.
20,21,33
 Also a reducing effect 
of fibrinogen on Ca
2+
 signaling via store-mediated Ca
2+
 entry was described.
26
 However, 
in all these cases only initial Ca
2+
 signals were studied, which also in the current setting 
are not affected by αIIbβ3 inhibition. One study reports long-term inhibition by abciximab 
(but curiously not by other integrin inhibitors) on collagen/thrombin-induced Ca
2+
 
responses only under conditions of stirring.
21
 This clearly is compatible with the present 
findings, since stirring likely is increasing the ligand-integrin receptor interaction. In this 
context, it is worth mentioning that, under shear, αIIbβ3 is considered to evoke Ca2+ 
signaling and provoke microparticle release, in a way inhibitable by abciximab.
17,40
 
Current data with the PI3K inhibitor wortmannin indicated that this pathway, known to 
be triggered by αIIbβ3 signaling,6 is implicated in the generation of platelet procoagulant 
activity. A feasible mechanism is that the formation 3-phosphorylated phosphoinositide 
(PIP3) in the plasma membrane by PI3-K stimulates the activation of phospholipase Cγ 
isoforms and, hence, increases Ca
2+
 mobilization, as in other cell types.
41
 Indeed, it has 
been demonstrated that platelet phospholipase Cγ2 is phosphorylated following αIIbβ3 
activation.
40
 Part of the PI3K-dependent events may involve αIIbβ3-mediated ADP 
secretion and autocrine P2Y12 receptor signaling, as apparent from the inhibitory effect of 
cangrelor. Recently, we reported that PI3K-dependent phospholipase C activation 
contributes to P2Y12-mediated procoagulant activity.
42
 Additional study will be necessary 
to fully elucidate this interplay between integrin and P2Y12 effects. 
A striking observation was that not all platelets that extensively spread on the 
fibrinogen surface showed PS exposure upon stimulation with thrombin. This has been 
reported earlier,
43
 and is in line with the observation that only part of the platelets in a 
thrombus show this response.
22
 In the latter study the PS-exposing platelets were shown 
to have inactivated αIIbβ3 integrins. Given the current findings, this points to an 
interesting negative feedback loop: fibrinogen binding to activated αIIbβ3 leads to 
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increased PS exposure, but once (procoagulant) platelets have reached this activation 
state, the integrins will be switched off and the outside-in signaling stops. 
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Abstract 
In vivo thrombosis models have shown that the intrinsic coagulation pathway, initiated by 
factor XII, plays an important role in the thrombotic process. In the present study we 
show that in plasma, fibrillar type I collagens caused a dose-dependent shortening of the 
clotting time initiated by factor XIIa. In vitro, type I collagen bound factor XII and 
increased its proteolytic activity. In the presence of platelets, collagen potently enhanced 
thrombin generation via the combined activation of factor XII and glycoprotein VI. Under 
flow conditions, collagen surfaces promoted the formation of thrombi rich in fibrin(ogen) 
and phosphatidylserine-exposing platelets. Thrombus formation and procoagulant 
activity were markedly reduced, when factor XIIa was blocked or when factor XII or XI 
were absent. Furthermore, formation of procoagulant thrombi was also dependent on 
glycoprotein VI signaling, as this response was greatly diminished with platelets deficient 
in LAT or phospholipase Cγ2. In contrast, blockade of the tissue factor/factor VIIa 
pathway had no or minimal effect. Together, these results point to a dual role of collagen 
in thrombus formation: initiation of coagulation via factor XII activation, and stimulation of 
glycoprotein VI signaling via LAT and PLCγ2, to provide a procoagulant membrane 
surface for massive fibrin formation and clotting. 
Introduction 
Vascular injury leads to exposure of hemostatic subendothelial components, such as 
tissue factor and collagen to the blood stream. Until recently, exposure of tissue factor 
was considered to be the principal way of activation of the coagulation cascade. In the 
extrinsic coagulation pathway, tissue factor complexes with circulating factor (F)VII(a), 
which leads via a multistep cascade of activated serine proteases to formation of 
thrombin and fibrin.
1
 Exposed collagen was considered solely to function as a substrate 
for platelet adhesion and activation via the glycoprotein VI (GPVI) receptor, causing 
powerful signaling events.
2
 
The intrinsic (blood-borne) coagulation pathway is initiated by activation of FXII 
(Hageman factor), which results in sequential activation of FXI and FIX. For long, the 
physiological importance of this pathway has remained obscure, in part because the 
initial trigger in vivo was not known. However, in vitro, FXII undergoes powerful activation 
upon exposure to negatively charged materials like kaolin, glass or ellagic acid. This type 
of activation forms the basis of a widely used coagulation test, the activated partial 
thromboplastin time (aPTT). Early evidence suggests that vascular polyanionic 
components like cerebroside sulfates and glycosaminoglycans can promote FXII 
activation.
3,4
 In addition, vascular collagens have also been proposed to play a role in 
FXII activation and coagulation.
5,6
 Other papers at that time, however, stipulated 
absence of effect or even inhibition of FXII activation by collagens.
7,8
 
Recent developments of in vivo mouse thrombosis models have led to increasing 
recognition of the importance of FXII in thrombus formation and coagulation. In a number 
of models where the thrombotic process was induced by collagen exposure due to 
vascular damage, the absence or inhibition of FXII had a marked antithrombotic effect.
9
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Furthermore, in a middle cerebral artery model of ischemia-reperfusion injury, FXII 
deficiency diminished thrombus formation and reduced infarction volume in the brain 
vessels.
10
 Interestingly in the same models, also FXI deficiency led to thrombosis 
protection.
10,11
 We have suggested that platelet activation is implicated in the FXII-
dependent thrombus formation, but the mechanism remained unclear.
9
 
The immunoglobulin collagen receptor, GPVI, in association with the FcR γ-chain co-
receptor, activates platelets via a tyrosine phosphorylation chain involving sequential 
activation of Src and Syk kinases. This initiates a downstream signaling cascade via the 
adapter protein LAT and the key effector enzyme, phospholipase Cγ2 (PLCγ2).2,12 We 
and others have shown that collagen-induced signaling from GPVI to PLCγ2 plays a 
controlling role in flow-mediated platelet thrombus formation both in vivo and in vitro.
13-15
 
Furthermore, this pathway stimulates platelet procoagulant activity, converting platelets 
into cells exposing phosphatidylserine (PS), at which coagulation factors bind and 
become activated.
14,16
 
Here, we hypothesized that collagen has a more extended role in thrombus and clot 
formation next to stimulating platelet GPVI, i.e. by triggering the intrinsic pathway of 
coagulation via activation of FXII. This hypothesis is tested in the present study using 
both human and mouse blood. 
Methods 
Materials 
Fibrillar type I Horm (type I/H) collagen was from Nycomed (Munich, Germany); fibrillar 
type I equine (type I/E) collagen from Merck, fibrillar type I bovine (type I/B) collagen 
from Sigma and bovine type I collagen purified (type I/P), as described.
17
 Collagen 
preparations were checked on protein contamination by gel-electrophoresis and dialyzed 
against collagen buffer. Prekallikrein and high molecular weight kininogen came from 
Enzyme Research Laboratories (South Bend, IN). Corn trypsin inhibitor (CTI) and 
recombinant human FXII from Haematologic Technologies (Essex, VT); recombinant 
human tissue factor from Dade Behring (Marburg, Germany); and human FXII-deficient 
plasma from George King Bio-Medical (Overland Park, KS). Active-site inactivated FVIIa 
(FVIIai) was kindly provided by Novo Nordisk (Malov, Denmark); Oregon Green 
(OG)488-labeled annexin A5, Alexa Fluor (AF)546-labeled fibrinogen, and AF633-
labeled streptavidin were from Molecular Probes (Leiden, The Netherlands); thrombin 
substrate, Z-Gly-Gly-Arg aminomethyl coumarin (Z-GGR-AMC) from Bachem 
(Bubendorf, Switzerland); the FXIIa substrate, Pefachrome FXIIa (5963), from 
Pentapharm (Basel, Switzerland). Preparation of procoagulant phospholipid vesicles (PS 
: phosphatidylcholine : phosphatidylethanolamine 1 : 3 : 1; mol/mol/mol) is described 
elsewhere.
18
 The preparation of biotin-labeled anti-FXII mAb (F3 against human/mouse 
FXII) is as described.
19
 Anti-PLCγ2 mAb DN84 was from DNAX Research Institute (Palo 
Alto, CA), anti-phosphotyrosine 4G10 mAb from Upstate Biotechnology (Bucks, United 
Kingdom), and FITC-anti-GPIbβ Xia.C3 mAb from Emfret (Würzburg, Germany). Anti-
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GPVI JAQ1 mAb was a kind gift of Dr. Nieswandt (Virchow Research Centre, Würzburg, 
Germany). Human thrombin calibrator came from Thrombinoscope (Maastricht, The 
Netherlands). FITC-labeled avidin was from Vector Laboratories (Burlingame, CA). Other 
materials including collagenase from C. histolyticum were from Sigma (St. Louis, MO). 
Animals 
Animal experiments were approved by the local animal experimental committees. 
Control C57Bl/6 mice were obtained from Charles River (Maastricht, The Netherlands). 
Mice homozygously deficient in LAT or PLCγ2 were bred from heterozygotes with a 
C57Bl/6 background.
20,21
 Mice homozygous for null mutations in the FXI or FXII gene 
were generated, as described.
22,23
 The animals were crossbred for >10 generations at a 
C57Bl/6J background. Per experimental set, wildtypes, heterozygotes and homozygotes 
from the same breeding were used; all animals were genotyped. Blood cell counts of all 
animal types were in the normal range. 
Blood collection 
Human blood was taken from healthy volunteers, who gave full informed consent; 
subjects were free from medication for at least two weeks. Blood was collected by freely 
dripping into 1/10 vol. 129 mM trisodium citrate (first 2 mL removed). Mouse blood, 
drawn from animals under anesthesia, was collected into the same citrate solution.
14
 
Platelet-rich plasma (PRP) and platelet-free plasma (PFP) were freshly prepared, as 
described for human and mouse systems.
24,25
 Note that PFP was centrifuged twice at 
1500 g for 4 minutes to remove all platelets. Platelet count was checked with a 
thrombocounter (Coulter Electronics, Luton, United Kingdom). 
Clotting times and factor levels 
Clotting times were measured with a KC-4A coagulometer at 37°C. Normalized human 
PRP (2×10
8
 platelets/mL) was used or PFP supplemented with 10 µM procoagulant 
phospholipid vesicles. Tubes were pre-rinsed with saline containing 1% BSA. Plasma 
samples were preincubated with collagen or tissue factor for 5 minutes, after which 
coagulation was triggered by addition of CaCl2 (16.6 mM, f.c.). 
Coagulation times (aPTT, PT) in mouse plasma were determined as described 
previously.
9
 Levels of coagulation factors in plasma from wildtype, FXI
-/-
 and FXII
-/-
 mice 
were determined with an automated blood coagulation system (BCS; Dade Behring), 
using reagents and protocols for human plasma. No significant difference in factor levels 
was found between wildtype and factor-deficient mice, except for the factor that was 
knocked out. Platelet-free plasma from mice deficient in LAT or PLCγ2 had normal 
coagulation profiles. 
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Thrombin generation 
Thrombin generation was measured in citrate-anticoagulated human or mouse PRP 
(1×10
8
 platelets/mL, f.c.) or in PFP supplemented with phospholipid vesicles (4 µM), 
basically as before.
26
 Briefly, plasmas were preincubated with inhibitors and treated with 
collagen or right vehicle for 10 minutes. Samples (4 vol.) were pipetted into a polystyrene 
96-wells plate (Immulon 2HB, Dynex Technologies, Chantilly, VA), already containing 1 
vol. of buffer A (20 mM Hepes, 140 mM NaCl and 0.5% BSA). Assays were run in 
Immulon 2HB polystyrene well-plates, as these showed minimal levels of contact 
activation. Tissue factor was only added if indicated. Coagulation was started by adding 
1 vol. of buffer B (2.5 mM Z-GGR-AMC, 20 mM Hepes, 140 mM NaCl, 100 mM CaCl2 
and 6% BSA). First-derivative curves of accumulation of fluorescence in human plasma 
were converted into nM thrombin using a human calibrator. Thrombin levels in mouse 
plasma are shown as arbitrary activity units (AAU), since substrate cleavage rate by 
murine thrombin is unknown. Samples were run at least in duplicate. Controls were 
carried out with FVIIai, which is effective in both human and mouse plasma, to check for 
residual contribution of the extrinsic coagulation pathway. 
Binding and activation of factor XII 
Coverslips were spotted with a fibrillar type I collagen (1 µg), washed and blocked with 
1% BSA. Coverslips were incubated for 10 minutes with FXII in the presence or absence 
of prekallikrein/high molecular weight kininogen. After three wash steps with PBS, 
coverslips were stained with biotinylated anti-FXII mAb (1:50) or biotinylated control IgG, 
followed by AF633-streptavidin (1:200) or FITC-labeled avidin (1:200). Negative controls 
were run by omission of anti-FXIIa mAb and positive controls by (strept)avidin pre-
blocking. Fluorescence images were recorded by two-photon laser scanning microscopy 
at fixed settings of laser power, gain and pinhole.
27
 
Enzymatic activity of FXIIa was measured with Pefachrome FXIIa in Hepes buffer pH 
7.45. Purified FXII (7.5 µg/mL), prekallikrein (2.5 µg/mL) and high molecular weight 
kininogen (3.5 µg/mL) were incubated in the presence or absence of collagens or 
platelets for 15 minutes. After addition of 0.8 mM Pefachrome FXIIa, the increase in 
absorption at 405 nm was determined at 37˚C. 
Thrombus and clot formation under flow 
For thrombus formation, coverslips were coated with a fibrillar type I collagen (10 mm
2
 by 
25 µL application of a 50 µg/mL solution) and blocked with Hepes buffer pH 7.45 (5 mM 
Hepes, 136 mM NaCl, 2.7 mM KCl, 0.42 mM NaH2PO4, 2 mM MgCl2 and 1% BSA). 
Uncoated coverslips were blocked with the same BSA-containing buffer. The coverslips 
were placed onto a transparent, 50 µm-deep parallel-plate flow chamber, and the 
chamber was pre-rinsed with BSA-containing buffer. Chambers were then co-infused 
with citrate-anticoagulated blood (1 vol.) and isotonic CaCl2/MgCl2 solution (110 mM 
NaCl, 13.3 mM CaCl2 and 6.7 mM MgCl2; 1 vol.). This resulted in physiological free Ca
2+
 
and Mg
2+
 concentrations of ~2 mM each. Blood samples were pre-incubated for 15 
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minutes with indicated inhibitor. After 4-6 minutes of flow (shear rate 150-1000 s
-1
), flow 
chambers were rinsed with Hepes buffer pH 7.45 containing 2 mM CaCl2, 1 U/mL 
heparin. Fluorescent probe was present in blood or in rinse buffer (0.5 µg/mL OG488-
annexin A5 or 200 µg/mL AF546-fibrinogen). Bright-field phase contrast and non-
confocal fluorescent images were recorded, using equipment described before.
14
 
Confocal fluorescence images were recorded using a Nikon Eclipse E600 microscope 
equipped with C1 confocal scanning head. Scanning was at 50 lines per second and 2× 
Kalman averaging. Images were processed with ImagePro software. 
Immunoprecipitation and western blotting 
Washed platelets (5×10
8
 platelets/mL) were stimulated with 10 µg/mL type I collagens 
for 90 s in the presence of EGTA to prevent aggregation. Activated platelets were lysed, 
and PLCγ2 was immunoprecipitated using anti-PLCγ2 mAb, as described.28 
Immunoprecipitated proteins were separated by gel electrophoresis, subjected to 
western blotting, probed for phospho-tyrosine and re-probed for PLCγ2.29 
Statistics 
Significance of differences was determined with the Mann-Whitney U test or the 
independent samples t test, as appropriate, using the statistical package for social 
sciences (SPSS 11.0, Chicago, IL). Size distribution of platelet thrombi was evaluated by 
χ2 analysis. 
Results 
Collagen stimulates clotting and thrombin generation by activation of FXII 
It was investigated how collagen affects the coagulation process independently of tissue 
factor. First, clotting times were measured in citrate-anticoagulated human plasma 
following activation with CaCl2 but no tissue factor. Figure 1A shows that type I collagen 
Horm (type I/H), in a dose-dependent way, significantly shortened the clotting time of 
plasma in comparison to vehicle (collagen buffer added at same volumes). At 40 µg/mL 
collagen, the clotting time was reduced from >500 to ~200 seconds, with either 
phospholipid vesicles or platelets present as procoagulant lipid surface. Similar results 
were obtained with a range of purified fibrillar type-I collagens from various sources, i.e. 
types I/E, I/B and I/P (data not shown, but see below). Treatment of these preparations 
with collagenase from C. histolyticum abolished the collagen effect on clotting time, thus 
demonstrating that it was not caused by impurities in the collagens. Markedly, collagen 
was unable to shorten the clotting time in FXII-deficient human plasma, while its effect 
was completely blocked by the FXII inhibitor, CTI (IC50 15 µg/mL), again in the presence 
of phospholipid vesicles or platelets (Figure 1A). On the other hand, with tissue factor 
present which by itself shortened clotting times, CTI had no additional effect in neither 
normal nor FXII-deficient plasma. 
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Figure 1. Collagen enhances coagulation in the absence of platelets and tissue factor. Human 
plasma containing phospholipid vesicles (PFP + PV) or platelets (PRP) was pretreated with CTI (50 
µg/mL) or FVIIai (5 µg/mL), as indicated. Pre-incubation was with collagen buffer (vehicle control) or 
collagen type I Horm (type I/H); activation was with CaCl2 (16.6 mM). Tissue factor (1 pM) was only 
added, where indicated. (A) Dose-dependent shortening by collagen (standard 40 µg/mL) of 
coagulation time in control plasma (circles) and FXII-deficient plasma (triangles). Note marked effect 
in the absence of tissue factor (closed symbols) vs. presence of tissue factor (open symbols). (B) 
Increased thrombin generation by collagen I/H (5 µg/mL) in the presence of phospholipid vesicles or 
platelets (no tissue factor added). Bars give thrombin peak height, normalized to the control 
condition with collagen buffer. Other collagens had similar effects. Means±SEM (n=3-5), *p<0.05 vs. 
control, 
#
p<0.05 vs. condition with collagen. 
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Thrombin generation experiments were carried out to confirm the procoagulant effect 
of type I collagens. Polystyrene (Immulon 2HB) well plates were used in this case, as 
this material has a minimal contribution to contact activation. In the presence of 
phospholipids (without added tissue factor), collagen (EC50 2 µg/mL) markedly shortened 
the lag-time and increased the peak height of thrombin generation, while CTI treatment 
abrogated all thrombin generation (Figure 1Bi). Collagen also potentiated thrombin 
generation in the presence of platelets (Figure 1Bii). This ability was only little influenced 
by the tissue factor inhibitor, FVIIai (5 µg/mL, i.e. sufficient to block 1 pM tissue factor), 
and it was greatly but not completely antagonized by CTI. Again this collagen effect was 
abolished by pretreatment with collagenase from C. histolyticum. Together, these data 
demonstrate that collagen can markedly increase the thrombin generation process via 
activation of FXII, both in the presence and absence of platelets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Collagen binds FXII and enhances FXII activation. (A) Effect of collagen on FXII 
activation. FXII (7.5 µg/mL) was incubated at 37°C with prekallikrein (PK, 2.5 µg/mL), high 
molecular weight kininogen (HK, 3.5 µg/mL), type I/H collagen (5 µg/mL) and CTI (50 µg/mL), as 
indicated. Cleavage rate of Pefachrome FXIIa substrate (0.8 mM) was determined as ∆ mOD/min. 
(B-C) Binding of FXII to collagen. Coverslips containing various fibrillar type I collagens were 
incubated with FXII ± PK/HK (concentrations as above) for 10 minutes, and after extensive rinse 
stained with biotin-labeled anti-FXII mAb and FITC-avidin. Controls were coverslips coated with 
collagen type I/H that were: (i) stained without anti-FXII mAb (negative control), (ii) incubated with 
heat-treated FXII (5 minutes at 56°C), or (iii) stained with biotin control IgG. Confocal images 
(180×180 µm) were analyzed for staining intensity of collagen fibers. Data are from independent 
measurements (means±SEM, n=3-4, *p<0.05 vs. condition without collagen). 
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Collagen binds and activates factor XII 
The effect of collagen on FXII activation was studied in a test system with purified 
coagulation factors. This purified system was used, because we observed that the 
commercially available peptide-based FXII substrates and FXII active-site inhibitors are 
non-selective towards FXII in the presence of coagulating plasma. With high molecular 
weight kininogen and prekallikrein, preparations of human FXII slowly cleaved 
chromogenic substrate for FXIIa, most likely due to kallikrein-mediated auto-activation. 
However, in the presence of fibrillar collagen this chromogenic activity was markedly 
increased (Figure 2A). The activity was completely inhibited by CTI, thus demonstrating 
specificity for FXIIa. 
As these results suggested that the binding of FXII to collagen enhances its 
activation by prekallikrein/kininogen, Biacore experiments were performed with collagen-
coated microchips. Human FXII showed dose-dependent reversible binding to the chips 
(not shown), confirming a direct interaction. However, data analysis was hampered by 
complex, high background binding of FXII to the chip material, which precluded 
establishment of binding parameters. In an alternative approach, FXII-collagen 
interaction was determined by immunofluorescence detection. Coverslips containing 
immobilized type I collagens were incubated with purified FXII and immuno-stained for 
this factor. Two-photon scanning fluorescence microscopy showed marked staining 
which was completely restricted to the collagen fibers and was not affected by the  
 
 
Figure 3. FXII and platelet GPVI contribute to collagen-dependent thrombin generation in 
mouse. Thrombin generation was measured in PRP from wildtype mice, treated with vehicle 
(control; collagen buffer) or collagen type I/H (5 µg/mL), and triggered with CaCl2. Plasmas were 
preincubated with FVIIai (5 µg/mL), CTI (50 µg/mL) and/or JAQ1 mAb (40 µg/mL). Thrombin 
generation curves were determined (A) in the absence or (B) presence of tissue factor (1 pM). 
Thrombin levels are given as arbitrary activity units (AAU). Means±SEM (n=4), *p<0.05 vs. control, 
#
p<0.05 vs. condition with collagen. 
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presence of prekallikrein/kininogen (Figure 2B). Importantly, fibrillar type-I collagens from 
all sources (type I/H, I/E, I/B and I/P) showed a similar degree of FXII binding (Figure 
2C). In comparison, there was no staining on non-fibrillar collagens or after collagenase 
treatment; nor when anti-FXII mAb was omitted or if FXII was heat-treated. These results 
strongly suggest that the fluorescence was due to binding of FXII to the collagen fibers. 
Together, these results indicate that FXII can be activated following binding to collagen, 
and that this activation contributes to thrombin and fibrin clot formation. 
Collagen-dependent thrombus formation under flow and coagulation involves FXII 
The availability of mice lacking FXII enabled us to study more directly how FXII 
contributes to thrombus formation. Also in PRP of wildtype mice, collagen type I/H 
markedly increased thrombin generation triggered by CaCl2 (Figure 3A). Similarly, type 
I/B and I/P collagens (5 µg/mL) increased the thrombin peak height to ~225%. As with 
human PRP, the effect of collagen was partly inihibited by CTI (IC50 10 µg/mL) but not by 
FVIIai; the remainder was blocked by anti-GPVI mAb JAQ1 (Figure 3A). In the presence 
of tissue factor, collagen still enhanced thrombin generation, but this effect was now only 
sensitive to blockade of GPVI by JAQ1 but not to CTI (Figure 3B). This suggested that, 
without tissue factor, the collagen-induced effect on thrombin generation is mediated by 
coagulation activation via FXII as well as platelet activation via GPVI, whereas in the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Deficiency in FXII or FXI abolishes collagen enhancement of thrombin generation. 
Plasmas (PFP) from FXII
+/+
, FXII
-/-
 and FXI
-/-
 mice were supplemented with washed platelets, pooled 
from wildtype C57Bl/6 mice (1×10
8
 platelets/mL, f.c.). Samples were pre-treated with collagen buffer 
(vehicle control), collagen type I/H (5 µg/mL) and/or FVIIai (5 µg/mL), as indicated. (A) Thrombin 
generation was triggered by addition of CaCl2. Shown are thrombograms and thrombin peak 
heights, expressed as arbitrary activity units (AAU). (B) Thrombin peak heights, after triggering with 
1 pM tissue factor (no FVIIai). Means±SEM (n=4-5), *p<0.05 vs. control. 
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presence of tissue factor, only GPVI contributes to the response. These results are 
hence in line with those observed in human PRP. 
Subsequently, the effect of FXII or FXI deficiency on thrombin generation was 
examined. Plasmas from wildtype, FXII
-/-
 and FXI
-/-
 mice were reconstituted with pooled 
wildtype platelets to avoid variation in platelet responsiveness. Thrombin generation 
curves showed that collagen provoked a marked increase in thrombin peak height in 
FXII
+/+
 plasma, while this effect was completely abolished in plasmas from FXII
-/-
 or FXI
-/-
 
animals (Figure 4A). On the contrary, with tissue factor added, wildtype and factor 
deficient plasmas did not differ in thrombin generation profile (Figure 4B). 
To study the importance of FXII-dependent thrombin generation at physiological flow 
conditions, blood from the mice was recalcified and perfused over collagen fibers at a 
moderate shear rate of 1000 s
-1
. Earlier studies with tissue factor present have shown  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Blockage of FXII or platelet GPVI suppresses collagen-dependent thrombus and 
clot formation. Blood from wildtype mice was flowed over type I/H collagen under coagulant 
conditions by 4-minutes co-perfusion with isotonic CaCl2/MgCl2 at 1000 s
-1
. Blood was pretreated 
with vehicle (control), CTI (50 µg/mL), JAQ1 mAb (40 µg/mL) or FVIIai (5 µg/mL), as indicated. No 
tissue factor was added. (A) Staining of thrombi with OG488-annexin A5 added during perfusion 
(0.5 µg/mL). Representative experiment for 3 performed. (B) Projected confocal stacks (180×180 
µm, z=50 µm) co-stained with AF546-fibrinogen and OG488-annexin A5. Right panels are side 
views, indicating averaged thrombus height. (C) Phase contrast images (120×120 µm) after 4 
minutes of flow. Control coverslips without collagen (uncoated) did not show platelet or fibrin 
deposition. Histograms show surface area coverage of thrombi, and frequency distribution of the 
feature sizes, i.e. single platelets, small and larger aggregates (numbers of platelets per feature are 
indicated). Means±SEM (n=4-5), *, # p<0.05 vs. vehicle control (# for χ2 test). 
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that such a flow protocol resulted in massive formation of fibrin-containing thrombi on 
collagen.
27
 For the present purpose, the flow system was extensively pre-rinsed with 1%  
BSA to prevent unspecific contact activation, and no tissue factor was added. At first, 
OG488-annexin A5 was added to wildtype mouse blood (0.5 µg/mL), to monitor 
procoagulant, PS-expressing platelets. Perfusion of recalcified blood resulted in rapid 
platelet adhesion and aggregation. Initially only platelets on collagen bound OG488-
annexin A5, but after several minutes, once fibrin fibers were formed, also aggregates 
started to bind annexin A5, thus resulting in a strong increase in overall fluorescence 
(Figure 5A). Fluorescence accumulation was markedly suppressed in the presence of 
CTI, and was virtually absent with the anti-GPVI mAb JAQ1 present as well. 
Two-color confocal images of wildtype thrombi, formed in the presence of AF546-
fibrinogen and OG488-annexin A5, showed massive staining of aggregates for 
fibrin(ogen) and annexin A5 (Figure 5B). The labeling of both fibrin(ogen) and annexin 
A5 was markedly reduced in the presence of CTI; and even more with JAQ1 mAb 
present, then leaving only single platelets and small platelet clusters at the collagen 
surface. With CTI or CTI/JAQ1, thrombus volume (per 1000 µm3), as measured from 
fibrinogen staining, reduced from 143±22 to 20.3±9 or 5.9±1.8 µm3, respectively. This 
was also clear from phase-contrast images taken at the end of perfusion: with CTI 
present, surface area coverage of thrombi on collagen reduced from 39% to 13%, and it 
further reduced to 7% with CTI/JAQ1 (Figure 5C). Morphometric analysis of thrombus 
size showed that CTI and JAQ1 abolished the formation of large (fibrin-containing) 
aggregates, again leaving only single platelets and small clusters. In contrast, addition of 
FVIIai to wildtype blood did not affect thrombus formation. Importantly, platelet thrombi 
were only detected at sites of collagen coating; hence, no platelets or fibrin were present 
at uncoated coverslips (Figure 5C). Staining of the thrombi on coverslips for FXII showed 
marked fluorescence of the collagen fibers, but not of the platelet aggregates (data not 
shown). 
Subsequent flow studies were carried out with blood from factor XII deficient mice. In 
comparison to wildtype blood, thrombus formation and platelet procoagulant activity 
(OG488-annexin A5 binding) were significantly reduced in the absence of FXII (Figure 
6A). Only small aggregates were left that stained for annexin A5 at sites of contact with 
collagen (Figure 6B). Also fibrin formation was greatly reduced. A similar set of results 
was observed using FXI
-/-
 blood: thrombus formation and PS exposure reduced to a 
similar degree as with FXII
-/-
 blood (Figure 6). 
Additional experiments showed that CTI or FVIIai did not further reduce thrombus 
formation with FXII
-/-
 blood. Addition of CTI or FVIIai changed the surface area coverage 
of thrombi from 40.7±4.5% to 40.5±1.6% or 38.5±3.8%; and slightly reduced surface 
area coverage by PS-exposing platelets from 12.2±4.6% to 9.6±4.6% or 8.3±0.7%, 
respectively (n=3-5). To determine whether remaining PS exposure was due to GPVI-
induced platelet activation, the  FXII
-/-
 blood was treated with blocking anti-GPVI mAb 
JAQ1. This resulted in elimination of large platelet aggregates, fibrin formation and PS 
exposure, although individual platelets still adhered (Figure 6A). Together, these results 
suggest that flow over collagen triggers the FXII-driven intrinsic pathway of coagulation  
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Figure 6. Deficiency in FXII or FXI impairs collagen-dependent formation of thrombi and 
clots. Blood from FXII
-/-
 or FXI
-/-
 mice or wildtypes was flowed over collagen under coagulant 
conditions for 4 minutes (see Figure 5). Thrombi were post-stained with OG488-annexin A5. Blood 
was pretreated with JAQ1 mAb (40 µg/mL), as indicated. (A) Representative phase contrast and 
fluorescent images (175×225 µm). (B) Surface area coverage of thrombi (□) and PS-exposing 
platelets (■); lower panel shows frequency distribution of the feature sizes. Means±SEM (n=5-7), *, # 
p<0.05 vs. corresponding wildtype (
#
 for χ2 test). 
 
and, thereby, promotes thrombus formation and PS exposure, under conditions where 
the tissue factor/FVIIa pathway is inactive. 
Collagen-dependent thrombus formation and coagulation under flow also relies on 
platelet signaling by LAT and PLCγ2 
In flow-mediated thrombus formation on collagen type I fibers, GPVI-induced platelet 
activation causes PS exposure via signaling to the LAT adapter protein and PLCγ2. With 
tissue factor present, this pathway strongly promotes the coagulation process.
27
 Mice 
heterozygously or homozygously deficient in LAT or PLCγ2 were used to determine the 
contribution of GPVI signaling to the FXII-dependent coagulation pathway. To determine 
the activity of GPVI signaling, platelets from these mice were stimulated with collagen, 
PLCγ2 was immunoprecipitated, and precipitates were assessed for tyrosine 
phosphorylation by western blot analysis. In comparison to wildtype platelets, tyrosine 
phosphorylation of PLCγ2 was unchanged in platelets from heterozygous LAT+/- or 
PLCγ2+/- mice; however, it was markedly decreased by homozygous deficiency in LAT 
(Figure 7A). These results were confirmed by analysis of total collagen-induced tyrosine 
phosphorylation, giving a strong reduction in LAT
-/-
 and PLCγ2-/- platelets but not in LAT+/- 
and PLCγ2+/- platelets (not shown, but see Ref.30). 
Flow experiments of recalcified blood (no tissue factor) from heterozygous LAT
+/-
 and 
PLCγ2+/- mice over collagen resulted in normal formation of large platelet/fibrin thrombi,  
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Figure 7. Deficiency in LAT or PLCγ2 impairs collagen-dependent thrombus formation and 
platelet procoagulant activity. (A) Effect of collagen type I/H (10 µg/mL) on tyrosine 
phosphorylation of PLCγ2 in platelets from wildtype mice or mice (heterozygously) deficient in 
LAT or PLCγ2. PLCγ2 was immunoprecipitated, western blots were stained for anti-
phosphotyrosine (p-Tyr), then reprobed with anti-PLCγ2 mAb (representative for 3 sample sets). 
(B) Blood from wildtype or deficient mice was flowed over collagen for 4 minutes; platelet-fibrin 
thrombi were post-stained with OG488-annexin A5 (see Figure 5). Shown are representative 
phase contrast and fluorescent images (180×180 µm). (C) Surface area coverage of thrombi (□) 
and PS-exposing platelets (■). Means±SEM (n=4-5), *p<0.05 vs. corresponding wildtype. 
 
again staining strongly for OG488-annexin A5 (Figure 7B). However, with blood from 
LAT
-/-
 mice, both thrombus formation and PS exposure were significantly, yet 
incompletely reduced in comparison to corresponding wildtype blood (Figure 7C). With 
PLCγ2-/- blood, large thrombi were no longer formed, while the collagen surface was 
covered with small platelet aggregates and a few single PS-exposing platelets. Essential 
the same results were obtained with blood from mice lacking the Fc receptor-γ chain (not 
shown). Together, these results indicate that signaling to PLCγ2 via LAT is essential for 
massive thrombus formation on collagen under conditions of flow and FXII-dependent 
coagulation. 
Finally, to confirm the importance of this signaling pathway in collagen-dependent 
coagulation, thrombin generation experiments were performed using PRP from LAT
-/-
 
and PLCγ2-/- mice. In wildtype PRP, collagen (5 µg/mL) increased the thrombin peak 
height to 209±34% (mean±SEM, n=4), and this collagen effect was reduced to 114±9% 
or 127±7% in LAT-/- or PLCγ2-/- PRP, respectively. In wildtype PRP, addition of CTI 
caused a partial reduction of the collagen effect to a peak height of 122±21% of the 
control value. In contrast, CTI did not change the collagen effect on thrombin peak in 
Collagen and factor XII in thrombus formation 
 97 
PRP from LAT
-/-
 (111±20%) or PLCγ2-/- (106±14%) mice. Accordingly, collagen-
enhanced thrombin generation requires platelet stimulation via LAT and PLCγ2 as well 
as FXII activation. 
Discussion 
In this paper we have defined a novel role for type I collagen by triggering the intrinsic 
pathway of coagulation via FXII and FXI activation; this pathway operates jointly with the 
platelet-stimulating effect of collagen via GPVI signaling. Evidence for this collagen 
function comes from data that collagen: a) shortens plasma clotting times in a FXII-
dependent way; b) enhances thrombin generation via FXII, and c) stimulates flow-
dependent thrombus formation under coagulant conditions. These collagen effects are 
detected in both the presence and absence of platelets, and in human as well as mouse 
plasma systems. With platelets present, collagen has an additional effect by causing 
signaling via GPVI to activation of LAT and PLCγ2. Earlier work has shown that GPVI 
activation causes a potent rise in cytosolic Ca
2+
 concentration and exposure of PS, 
which mediates platelet-dependent coagulant activity.
14,26
 The present data hence point 
to a second potentiating role of collagen in thrombus formation, by also triggering the 
contact-dependent coagulation system via FXII. This dual thrombogenic effect of 
collagen can explain why collagen exposure is such an efficient trigger for thrombus 
formation in many in vivo thrombosis models.
2,31
 From in vivo (staining) and in vitro 
studies it is already known that type I next to type III collagen is most thrombogenic. 
Earlier work has demonstrated a key role of murine FXII and FXI in several models of 
experimental thrombosis.
9,32
 The present findings not only confirm this, but also provide 
a mechanistic explanation. The proposed scheme is that collagen activates FXII and FXI, 
which provides sufficient amounts of activated coagulation factors to start thrombin 
generation. Platelets exposing PS, also formed on collagen, then provide the necessary 
surface for propagation of the coagulation process. Our data indicate that such a process 
is operative under flow conditions, since the formation of thrombi composed of 
fibrin(ogen)-binding and PS-exposing platelets under flow was highly sensitive to 
blockage/absence of FXII or FXI and by blockage/absence of platelet GPVI activation. 
The similarity in effects of FXII and FXI deficiency is in agreement with in vivo 
measurements of murine thrombus formation.
33
 In line with this also is a recent study 
showing that in human plasma FXII is the main activator of FXI.
34
 
Blood and plasma can contain trace amounts of (blood-borne) tissue factor, which for 
instance has been identified at the surface of (activated) platelets.
35,36
 In the present 
experiments, tissue factor blocking with FVIIai had sometimes a small inhibitory effect, 
which however contrasted with the much larger inhibition by CTI or the absence of FXII. 
Hence, these results point to a strong role of the intrinsic coagulation pathway that is 
independent of tissue factor activity. Conversely, procoagulant effects of collagen – i.e. 
those independent of platelet activation – were not observed in the presence of 
picomolar concentrations of tissue factor. Together, this suggests that under 
physiological conditions the FXII-stimulating role of collagen becomes most relevant  
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Figure 8. Proposed dual role of collagen in thrombus formation. Collagen binds and facilitates 
FXII activation, which results in sequential activation of FXI and FIX. Platelets adhere to collagen 
and are activated via their GPVI receptors. Subsequent signaling via LAT and PLCγ2 results in Ca2+ 
mobilization and a PS-exposing membrane surface. This procoagulant surface allows formation of 
coagulation factor complexes for massive generation of FXa and thrombin. Jointly, these pathways 
lead to rapid formation of platelet-fibrin clots, under conditions where tissue factor is limitedly 
available. 
 
when the local tissue factor activity is limited. While the role of platelets in particular is to 
provide a procoagulant membrane surface, our results do no exclude a contribution of 
other platelet-derived products, such as polyphosphates, to thrombus formation.
37
 
The marked effects of type I collagens on the FXII-dependent clotting time and on 
thrombin generation suggested that collagen is capable to bind FXII and/or 
kininogen/prekallikrein. We indeed detected significant binding of FXII to fibrillar type I 
collagens, and this binding was not increased by kininogen/prekallikrein. Although the 
FXII binding site within the collagen sequence still needs to be identified, our results 
show that binding is accompanied by an enhanced activation of FXII in the presence of 
kininogen/prekallikrein. 
Although the role of FXII in murine in vivo thrombosis models is well established, its 
relevance in clinical studies is equivocal. Several studies involving individuals with FXII 
levels within the broad normal range, report an association between low levels of FXII(a) 
and an increased risk on cardiovascular disease.
19,38-40
 However, the correlation was 
absent in individuals with FXII levels below 10% of normal.
39
 This indicates that is 
unclear whether low FXII levels are the cause or consequence of cardiovascular disease 
and therefore FXII may be more a risk marker than a risk factor.
41
 On the other hand, 
FXII deficiency is not related to bleeding, meaning that it is dispensable for normal 
hemostasis in both man and mice. Consequently, the intrinsic pathway of coagulation 
can be an attractive target for the treatment of thrombotic disease.
33
 While it still remains 
to be established how the protective effect of FXII deficiency in mice translates to the 
human situation, the present results yet lead to a better understanding of the mechanism 
of FXII activation.   
In summary, the present results point to a dual role of exposed collagen in thrombus 
formation and coagulation (Figure 8). Collagen activates platelets via the GPVI-LAT-
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PLCγ2 signaling pathway, causing platelet aggregation and exposure of procoagulant 
PS. In addition, collagen binds FXII and enhances its activation, which via FXI results in 
the activation of other coagulation factors. This function of collagen may serve to backup 
and enhance the extrinsic tissue factor/FVIIa pathway. 
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Thrombosis as well as hemostasis rely on platelet activation and on fibrin clot formation 
by activation of the coagulation cascade. In the classical concept, platelets stimulate the 
coagulation process when activated by the combination of thrombin and collagen. 
Together, these agonists induce exposure of phosphatidylserine (PS) at the platelet 
surface, which mediates the local assembly and activation of coagulation factors 
provoking activation of factor X and prothrombin.
1
 In earlier work, this procoagulant effect 
of platelet activation in response to thrombin and collagen could be linked to signaling via 
the PAR1/4 and glycoprotein VI receptors, respectively.
2,3
 However, given the extensive 
interplay of platelet activation and coagulation, it is quite likely that also other platelet 
agonists than thrombin and collagen, and other sets of platelet receptors, regulate the 
development of platelet procoagulant activity. This was the underlying hypothesis of the 
present thesis, where we aimed to study new interaction mechanisms of platelet 
signaling and coagulation. The results show a novel role of ADP signaling via the P2Y12 
receptor in the stimulation of PS exposure. Furthermore, we describe that also outside-in 
signaling by integrin αIIbβ3 leads to stimulation of platelet procoagulant activity. Third, 
we report on an additional role of collagen by enhancing the factor XII pathway of 
coagulation in the stimulation of platelet-dependent thrombus formation. These findings 
may identify new antithrombotic targets for remedying cardiovascular diseases. 
P2Y12 signaling pathways leading to procoagulant activity 
The role of ADP and its receptors, P2Y1 and P2Y12, in platelet aggregation is well 
established. Chapters 3 and 4 of this thesis describe that ADP receptor stimulation also 
has another role, namely enhancement of platelet procoagulant activity. This appeared 
from the ability of ADP to enhance thrombin generation in coagulating plasma. The data 
show that ADP, produced by platelets in an autocrine way, is responsible for a 
considerable part of the thrombin-induced exposure of procoagulant phosphatidylserine 
(PS) at the platelet surface. In addition, co-stimulation of platelets with ADP and thrombin 
further enhances the PS exposure. Thus, in thrombin-stimulated platelets ADP release 
provides a positive feedback loop by enhancing PS exposure and thereby the process of 
thrombin generation. These observations are in general agreement with those of other 
studies.
4-6
  
As thrombin is always present at sites of vascular injury, it was of interest to study the 
synergistic effects of ADP and thrombin in more detail. By using specific antagonists of 
the P2Y1 and P2Y12 receptors, it appeared that the synergistic effect of ADP on the 
activation of platelets by thrombin relies exclusively on P2Y12 receptor function. In further 
experiments, we unraveled the signaling pathways downstream of the P2Y12 receptor 
that are responsible for the enhanced PS exposure and subsequent thrombin 
generation. Background knowledge was that platelet PS exposure is considered to be 
the result of a prolonged elevation in cytosolic free Ca
2+
 level. Further, it is known that 
P2Y12 signaling does contribute to the ADP-induced Ca
2+
 response.
7
 In Chapter 3 it is 
shown that this P2Y12 signal is relevant even in the presence of the potent platelet 
activator thrombin. Since the thrombin receptor PAR4 also prolongs the Ca
2+
 response, it 
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was important to compare the contribution of P2Y12 activation to this response in 
platelets stimulated with PAR1 agonist alone or with a combination of PAR1 and PAR4 
agonists. In either case, P2Y12 inhibition resulted in a quite similar reduction of the Ca
2+
 
signal in platelets. Hence it was concluded that upon thrombin stimulation, particularly 
PAR1 signaling synergizes with P2Y12 in prolonged Ca
2+
 elevation. 
Subsequent work presented in Chapter 4 indicated that the P2Y12-dependent effect 
involves two parallel signaling pathways. This is summarized in Figure 1. On the one 
hand, P2Y12 inhibits adenylyl cyclase activity via Gi, which suppresses cAMP-dependent 
protein kinase A (PKA) activation. This protein kinase can phosphorylate and thereby 
inactivate the platelet inositol 1,4,5-triphosphate (IP3) receptors.
8
 It is known that 
epinephrine, which inhibits adenylyl cyclase via Gz, antagonizes the PKA-dependent 
phosphorylation and inactivation of IP3 receptors, and hence increases the IP3 receptor-
mediated Ca
2+
 release from intracellular stores.
9
 By analogy, the results in Chapter 4 
indicate that P2Y12-induced inhibition of PKA also increases Ca
2+
 mobilization from 
internal stores. The second P2Y12-dependent signaling pathway again acts via Gi, but 
not via adenylyl cyclase. This pathway appears to be mediated by activation of 
phosphoinositide 3-kinase (PI3-K), which produces phosphatidylinositol 3,4,5 
triphosphate (PIP3) and increases the activation of phospholipase C isoforms. The  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Synergy of platelet signaling induced by P2Y12 and thrombin receptors. Thrombin 
receptors (PAR1/4) couple to Gq. This leads to phospholipase Cβ (PLCβ) activation, IP3 formation 
and Ca
2+
 release from intracellular stores. Autocrine produced ADP binds to the P2Y1 and P2Y12 
receptors. P2Y1 also couples to Gq, but this effect is overruled by thrombin signaling. In contrast, 
P2Y12 activates Gi and prolongs the thrombin-induced Ca
2+
 response via two pathways. First, it 
increases IP3 receptor function via PKA inhibition. Second, it activates phosphoinositide 3-kinase 
(PI3-K) which results in phospholipase C(γ) activation and extended IP3 formation. Thus P2Y12 
prolongs the mobilization of Ca
2+
 and this sustained Ca
2+
 signal will result in PS exposure and 
subsequent thrombin formation at the platelet surface. For further details, see text.  
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consequence is an increase and extension of the production of IP3 and, consequently, a 
prolongation of the Ca
2+
 signal. By which molecular mechanism PI3-K becomes 
activated via Gi is still unknown. 
The following data sets confirmed this dual model of P2Y12 signaling via adenylate 
cyclase inhibition and PI3-K activation: a) combined inhibition of PKA and PI3-K was 
needed to antagonize the prolonged P2Y12-induced Ca
2+
 response; b) IP3 receptor 
function, which is affected by PKA activation, became increased in the presence of ADP 
and this increase was abolished by inhibition of P2Y12 but not of PI3-K; c) phospholipase 
C inhibition, in a similar way as PI3-K blockage, reduced the prolonged phase of the 
Ca
2+
 response; and d) phospholipase C-dependent IP3 formation was decreased upon 
PI3-K blockage. In support of these results, others have demonstrated that P2Y12 can 
potentiate the P2Y1-induced Ca
2+
 response via inhibition of adenylyl cyclase and 
activation of PI3-K.
10
 These authors also reported that Src kinases negatively regulate 
the PI3-K-dependent pathway of P2Y12. In this thesis, we could not confirm such a role 
for Src kinases in P2Y12 signaling with thrombin present. Furthermore, we found that 
thrombin overruled effects of P2Y1 on the Ca
2+
 response, most likely because thrombin 
receptors similarly as P2Y1 signal via the Gq and G13 proteins. Confirmative evidence 
that the procoagulant effect of ADP proceeds via the two above-mentioned P2Y12-
mediated pathways came from thrombin generation experiments. Here all stimulatory 
effects of ADP were abolished in the combined presence of PKA and PI3-K inhibitors. 
Platelets contain a number of class I isoforms of PI3-K, namely α, β, δ and γ.11 It is 
nowadays well established that the PI3-Kβ and PI3-Kγ isoforms play a role in integrin 
αIIbβ3 activation and hence in the stabilization of platelet aggregation.12,13 By using 
platelets from mice deficient in PI3-Kγ and using isoform-specific inhibitors directed 
against the catalytic subunit of PI3-K, we investigated which isoform is involved in the 
prolonged Ca
2+
 response and procoagulant activity downstream of P2Y12. Selective 
inhibition of PI3-Kβ reduced the Ca2+ response and PS exposure following platelet 
stimulation with thrombin/ADP. However, platelets from mice deficient in PI3-Kγ or 
platelets treated with PI3-Kγ inhibitor were unchanged in Ca2+ response and 
procoagulant activity. This is in contrast with a report by Lian et al. showing a mildly 
impaired Ca
2+
 response with ADP or thrombin in platelets from mice deficient in PI3-Kγ.14 
However, the response was further suppressed by the general PI3-K inhibitor, 
LY294002, which is compatible with our finding that mainly PI3-Kβ is contributing to the 
Ca
2+
 response downstream of P2Y12. Once mice lacking PI3-Kβ become available, it will 
be important to confirm the key importance of this PI3-K isoform in platelet procoagulant 
activity. 
Another novel observation presented in Chapter 4 is that the PI3-Kβ isoform is fully 
responsible for phosphorylation of the downstream target Akt1/2 (protein kinase B). 
Interestingly, we did not find evidence for a role of PI3-Kγ herein, such as proposed by 
others.
15
 Our data are in agreement with other studies, showing that in thrombin-
stimulated platelets the phosphorylation and activation of Akt is completely dependent on 
autocrine ADP release and on P2Y12 activity.
16-18
 Accordingly, most studies stipulate that 
Akt is activated downstream of Gi (P2Y12) and not Gq (P2Y1, PARs).  
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In cell types other than platelets, the PIP3 formed by PI3-K activity plays a role in the 
docking and activation of PH domain-containing phospholipase Cγ and Akt isoforms to 
the plasma membrane.
19
 Given the evidence, described above, that also in platelets PI3-
K activity increases phospholipase C activation and enhances Ca
2+
 signaling, a similar 
docking mechanism may be applicable for the ADP/P2Y12 activation pathway. This would 
imply an involvement of phospholipase Cγ in this pathway, since it contains PH domains 
for interaction with PIP3, such in contrast to the G protein-coupled phospholipase Cβ 
isoforms. There is early evidence that thrombin stimulation leads to activation of the 
phospholipase Cγ1 isoform;20 based on the present results it is likely that this thrombin 
effect relies on autocrine production of ADP and P2Y12 signaling. 
Following PI3-K activation, the formed PIP3 has been shown to lead to membrane 
attachment and phosphorylation of platelet Akt.
21
 Although studies with mouse platelets 
have demonstrated the importance of Akt in platelet aggregation, fibrinogen binding and 
granule secretion,
18,22
 it is has not been investigated whether Akt isoforms play a role in 
the procoagulant response (PS exposure) of platelets. Until recently, not much was 
known about the actual effectors of Akt. A newly discovered target is GSK3β, which is 
phosphorylated by Akt, and then acts as a positive regulator of platelet function.
23
 Thus, 
if GSK3β indeed appears to be the main effector of Akt in platelets, it may play a role in 
the P2Y12-mediated procoagulant response. 
Function of integrin αIIbβ3 outside-in signaling in procoagulant 
activity 
In addition to mediating platelet aggregation, integrin αIIbβ3 must play a role in platelet 
procoagulant activity, as various groups describe that αIIbβ3 antagonists suppress 
thrombin generation in platelet-rich plasma.
24-27
 However, besides the proposal that 
αIIbβ3 may act as a receptor for prothrombin,28 little was known about the precise action 
mechanism of these integrin blockers. We reasoned that this inhibiting effect implicates 
that the blockers interfere with the binding of fibrinogen to activated αIIbβ3 and, hence, 
with so-called outside-in signaling evoked by this integrin. Therefore we investigated 
whether and how αIIbβ3 outside-in signaling affects platelet procoagulant activity. 
Chapter 5 gives supportive evidence for this concept. It appeared that fibrinogen-
dependent outside-in signaling via αIIbβ3 promotes a late phase of the Ca2+ response 
induced by strong agonists, which results in a significant enhancement of PS exposure. 
Strikingly, integrin αIIbβ3 antagonists did not affect the initial Ca2+ response (<5 min after 
activation), but markedly reduced the Ca
2+
 level in a later phase. The experiments with 
αIIbβ3 antagonists were confirmed by using platelets from a Glanzmann patient, which 
lack functional integrin αIIbβ3. The patient’s platelets showed reduced Ca2+ signaling 
paralleled by a decreased PS exposure. 
There is limited literature, reviewed elsewhere,
29
 indicating that the pathway of αIIbβ3 
outside-in signaling is reminiscent to that evoked by glycoprotein VI, which potently 
causes PS exposure. Clustering of αIIbβ3 caused by fibrinogen binding leads to 
activation of Src kinase and recruitment of Syk kinase.
30
 Since phospholipase Cγ2 is a  
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Figure 2. Pathway of integrin αIIbβ3 outside-in signaling leading to enhanced PS exposure in 
activated platelets. Fibrinogen binding to integrin αIIbβ3 prolongs the Ca2+ signal in activated 
platelets most probably via activation of phosphoinositide 3-kinase (PI3-K) and a phospholipase Cγ 
(PLCγ) isoform. This proposed pathway shows resemblance to the glycoprotein VI (GPVI) pathway 
induced by collagen. Outside-in signaling via αIIbβ3 thereby enforces PS exposure in (thrombin) 
activated platelets. 
 
substrate of Src kinase, it is proposed that this kinase, together with Syk and Btk kinases 
and the signaling components SLP76 and Vav, phosphorylates and activates 
phospholipase Cγ2 downstream of αIIbβ3 (Figure 2).29 This integrin pathway 
distinguishes from the glycoprotein VI pathway by not including the adaptor proteins LAT 
and Gads.
29
 It is unclear why. In addition, the results presented in Chapter 5 show that 
integrin αIIbβ3 enhances PS exposure via PI3-K activation, which is only partly 
dependent on ADP secretion and subsequent P2Y12 receptor activity. A similar 
mechanism as discussed above can be applied here; PI3-K-dependent formation of PIP3 
leads to activation of phospholipase Cγ with Ca2+ mobilization as a result (Figure 2). 
However, it remains to be determined how the integrin-mediated late Ca
2+
 response is 
influenced by PI3-K. Together, we demonstrated that the stimulating effect of 
glycoprotein VI and thrombin receptor activation on PS exposure is enforced by outside-
in signaling via αIIbβ3, likely through synergistic activation of phospholipase Cγ (Figure 
2). 
A recent paper describes that αIIbβ3 blockade might inhibit platelet PS exposure by 
potentiating phospholipid translocase and attenuating scramblase activity, although no 
mechanistic explanation for this observation was given.
31
 It is difficult to speculate on an 
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integrin-mediated regulation of scramblase activity at present, since the putative enzyme 
involved is still unknown. Current attention focus on the actin cytoskeleton-binding 
proteins, talin and kindlin-3, which bind to the β-integrin tails and play an important role in 
αIIbβ3-dependent outside-in signaling.32-34 Whether and how these proteins are 
implicated in the platelet procoagulant response requires further study. 
These αIIbβ3-mediated outside-in signaling effects on procoagulant activity may 
interfere or overlap with the procoagulant effects of P2Y12 stimulation as described 
above. Because this ADP receptor potently activates αIIbβ3, it can be hypothesized that 
subsequent integrin outside-in signaling adds to the P2Y12-mediated PS exposure. In 
Chapter 4 it is shown that αIIbβ3 blockers do not influence the (initial) P2Y12-dependent 
Ca
2+
 signal, which seems to preclude a contribution of outside-in signaling. However, it 
should be noted that integrin effects on the late Ca
2+
 response were not assessed in this 
chapter. 
Integrin αIIbβ3 is a relatively often used target for antithrombotic therapy. Currently, 
three αIIbβ3 antagonists have been approved for clinical application, i.e. the chimeric 
antibody abciximab, and the small molecules, eptifibatide and tirofiban. However, their 
clinical use is restricted due to limitations in efficacy leading to increased mortality and 
adverse effects of bleeding.
35,36
 These antagonists have proved benefits in patients 
undergoing percutaneous coronary intervention and in high risk patients with acute 
coronary syndromes. An explanation for the insufficient safety of αIIbβ3 blockers is that 
they might act as ligand-mimetics by resembling the RGD sequence of fibrinogen and, 
hence, cause a conformational change of αIIbβ3 followed by outside-in signaling.37-39 As 
a ‘milder’ integrin blocker, single-chain antibodies have been developed that bind 
specifically to the activated form of αIIbβ3. This activation-specific blockade of integrin 
αIIbβ3 does neither induce conformational changes nor outside-in signaling and reduces 
bleeding complications.
40
 In the perspective of this thesis, where we show that αIIbβ3 is 
not only essential for platelet aggregation but also for procoagulant activity and hence 
coagulation, this dual function of αIIbβ3 may provide an explanation for the bleeding 
complications caused by high levels of αIIbβ3 inhibitors. 
Roles of collagen and factor XII in thrombus formation  
Collagen, exposed in damaged vessels, activates platelets via the glycoprotein VI 
receptor, which effectively leads to procoagulant activity (PS exposure).
3
 Old data 
suggested that collagen by itself can activate the coagulation system, perhaps via the 
contact activation pathway involving factor XII.
41
 However, these data were not uniformly 
supported and appeared to be dependent on the collagen preparation used.
42
 In the later 
literature, the increased procoagulant activity with collagen was supposed to be a 
platelet-dependent phenomenon.
43
 In Chapter 6 it is shown that type I collagen fibers 
markedly enhance thrombin generation and shorten the clotting time independently of 
platelets under conditions where tissue factor activity is limited. Typically, corn trypsin 
inhibitor, which is a specific blocker of factor XII activity, abolishes this stimulating effect 
of collagen both in the presence and absence of platelets. Complementary results were 
Chapter 7 
 110 
obtained with mice deficient in factor XII. In plasma from these mice, the stimulating 
effect of collagen on thrombin and clot formation has largely disappeared, and corn 
trypsin inhibitor is no longer effective. Together, this indicates that collagen stimulates 
the intrinsic pathway of coagulation via activation of factor XII. Supportive evidence 
comes from fluorescence experiments demonstrating the binding of labeled factor XII to 
collagen fibers. Furthermore, enzymatic studies showed that collagen enhanced the 
cleavage of a specific chromogenic substrate for activated factor XII in reaction mixtures 
where the presence of factor XII, prekallikrein and high molecular weight kininogen is 
required. 
By using a flow model where shear-dependent thrombus formation was induced 
under coagulant conditions, it was shown that in the absence of factor XII smaller and 
instable thrombi were formed. Evidence for the physiological relevance of these findings 
was provided by the study of Renné et al., who show defective thrombus formation in 
mice lacking factor XII by means of three in vivo models of arterial thrombosis.
44,45
 With 
the present results, we have identified collagen as a key initiator of factor XII-driven 
thrombin formation. Note that this function is dependent on the availability of tissue 
factor, since with high (picomolar) tissue factor concentrations thrombus and clot 
formation are no longer limited in the absence of factor XII activation and, hence, are 
driven by the faster onset of the extrinsic coagulation pathway. 
In addition, collagen has a well-known second function in thrombus formation, i.e. by 
providing a surface for platelet adhesion and activation through glycoprotein VI.
46
 In 
blood from mice lacking LAT or phospholipase Cγ2, we made the novel observation that 
GPVI signaling synergizes with the collagen-induced activation of factor XII for optimal 
thrombus and clot formation. Autocrine ADP/P2Y12- and αIIbβ3-dependent effects will 
enforce this process (see above). Another way, via which activated platelets can 
promote the contact activation pathway is by releasing polyphosphates,
47
 but this was 
not investigated. 
In several in vivo mouse thrombosis models (e.g., using ligation-induced and ferric 
chloride-induced injury) collagen exposure is known to be a determining factor in the 
thrombus-forming process. Also in these in vivo models collagen was found to activate 
platelets via the glycoprotein VI pathway, as evidenced by experiments with mice lacking 
glycoprotein VI, the FcR γ-chain or one of the downstream signaling proteins.48-52 
However, the collagen dependency of these in vivo models suggests that the factor XII 
pathway of coagulation may also play a role herein. Indeed, defective thrombus 
formation in factor XII-deficient mice was detected in all in vivo models known to be 
dependent on collagen exposure.
44
 
It should be noted that a number of other in vivo thrombosis models rely more 
strongly on tissue factor activity, particularly those using laser-induced and Bengal rose-
induced injury.
51
 In these models it has been reported that thrombin inhibition is more 
effective than glycoprotein VI blockage.
53
 This is compatible with the present in vitro 
results indicating that under such conditions factor XII plays only a minor role, as it is 
overruled by the presence of tissue factor. Tissue factor is located in the (damaged) 
vessel wall, but it is also detected on microparticles and leukocytes in the circulating  
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Figure 3. Dual role of collagen in coagulation-dependent thrombus formation. Upon vascular 
damage exposed collagen activates platelets via glycoprotein VI (GPVI) and thereby induces 
surface exposure of PS. Under conditions where tissue factor is limited, collagen additionally 
stimulates factor XII activation and triggers the intrinsic pathway of coagulation. Formation of 
thrombin is propagated at the PS-exposing platelet surface and both pathways are needed for 
optimal thrombus and clot formation. See text for further details.  
 
blood.
54
 In the experiments presented in Chapter 6 circulating tissue factor did not 
appear to play a significant role, as evidenced by the limited effect of factor VIIa inhibition 
on thrombus formation and thrombin generation. Recently, it was postulated that 
platelets can bind tissue factor in a way cross-linked by protein disulfide isomerase, likely 
at sites of high vascular damage.
55-57
 On the other hand, platelets are known to release 
high amounts of tissue factor pathway inhibitor.
58
 Together, this suggests that the relative 
role of collagen and thus factor XII is depending on both the type and the severity of 
vascular injury and, perhaps, the platelet activation state. Obviously, in vivo 
experimentation is needed to confirm this. 
As summarized in Figure 3, the data of this thesis (Chapter 6) indicate that collagen 
has two functions in the formation of thrombin and stable thrombi. It makes platelets 
procoagulant by activating the glycoprotein VI signaling pathway and, under conditions 
where tissue factor is limited or inhibited, collagen supports factor XII activation and 
triggers the intrinsic pathway of coagulation. In this scheme, the relative availability of 
collagen and tissue factor thus determines whether thrombin is generated via factor XII 
or via factor VII. 
Although factor XII appears to play an important role in several mouse thrombosis 
models, and there is no evidence that this factor acts differently in mice and man,
44
 
clinical studies are not unambiguous on its (patho)physiological function.
59
 There is 
conflicting evidence regarding the function of human factor XII in arterial thromboembolic 
disease, most likely due to heterogeneity between the patients with factor XII deficiency. 
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Recent studies debate whether increased or decreased levels of plasma factor XII or 
XIIa contribute to the risk of cardiovascular disease.
60,61
 Likely the new evidence with 
mouse models will stimulate further clinical studies. Considering that venous thrombi 
consist of predominantly red blood cells and fibrin and relatively little platelets (Chapter 
2), it is likely that coagulation factor deficiencies have an impact on the risk of venous 
thrombosis. But also for venous thromboembolic disease, the role of factor XII is 
indistinct.
59
 
Factor XII activation sequentially cleaves and activates factor XI. Chapter 6 shows 
that the stimulating effect of collagen on thrombin formation requires the presence of 
factor XI. Furthermore, shear-dependent thrombus formation with blood from factor XI 
deficient mice is decreased to a similar extent as with factor XII deficient blood. This is 
compatible with in vivo evidence that factor XI and factor XII deficient mice are 
comparably protected from arterial or venous occlusion.
44,62,63
 Together this raises the 
possibility that, in mice, factor XII exerts all or most of its procoagulant effect via 
activation of factor XI. A striking difference with man is that the phenotypes of factor XII- 
and XI-deficient mice are highly similar with no abnormality of hemostasis, whereas 
factor XI-deficient, but not factor XII-deficient patients, experience a mild bleeding 
disorder. Species differences can be an explanation for this. An alternative explanation 
concerns the factor XII-dependent formation of kininogen hydrolysis products, which 
have anticoagulant effects.
64,65
 Thus factor XII-deficient individuals lack both 
procoagulant and anticoagulant effects, while factor XI-deficient individuals only lack the 
procoagulant component what possibly results in a bleeding tendency.
64
 In contrast to 
factor XII, various studies do address a clear association between high factor XI plasma 
levels and increased risk of arterial/venous thrombosis in humans.
59
  
Clinical implications 
In this thesis we have identified several novel pathways implicated in platelet 
procoagulant activity and coagulation, namely activation steps involving the P2Y12 ADP 
receptor, integrin αIIbβ3 and factor XII (Figure 4). Signaling by ADP via P2Y12 and by 
fibrinogen via integrin αIIbβ3 appears to prolong the rise in intracellular Ca2+ level in 
platelets, which results in PS exposure and thrombin formation on the platelet surface. 
Collagen, in addition to its established procoagulant effect via GPVI signaling, can also 
directly stimulate thrombin generation and coagulation by facilitating the activation of 
factor XII. This pathway is considered to be important when tissue factor is limitedly 
present. 
Clinical inhibition of integrin αIIbβ3 gives a high risk of adverse bleeding 
complications (see above). Less complete suppression of platelet activation is achieved 
by blocking only specific pathways leading to αIIbβ3 activation. Inhibition of platelet 
P2Y12 receptors provides a way to do so. Similarly to integrin inhibition, blocking of P2Y12 
suppresses both platelet aggregation and platelet procoagulant activity. This sheds a 
new light on the action mechanism of existing medication directed against this receptor. 
Currently used in the clinic is clopidogrel, a thienopyridine that after metabolic activation  
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Figure 4. Novel pathways identified that promote platelet procoagulant activity and 
coagulation. It is already known that thrombin and collagen stimulate the procoagulant response of 
platelets which then promotes again the generation of thrombin on the platelet surface. Tissue 
factor is thereby an important initiator of the coagulation pathway. Now an additional role of collagen 
was identified in that it activates factor XII which triggers the intrinsic pathway of coagulation. 
Furthermore, P2Y12 signaling and integrin αIIbβ3 outside-in signaling in platelets were found to play 
an important role in platelet procoagulant activity. Feed-forward loops are not indicated. These 
newly identified components could be interesting targets for future antithrombotic therapy.   
 
irreversibly antagonizes platelet P2Y12 receptors. Although clopidogrel treatment causes 
significant benefit in patients suffering from cardiovascular diseases, there appears to be 
a striking response variability among patients.
66,67
 Various mechanisms responsible for 
clopidogrel non-responsiveness, inappropriately called ‘resistance’, have been identified: 
i.e. inadequate (hepatic) production of the active metabolite, polymorphisms of the 
platelet receptor, and increased turnover of platelets. Intervention with clopidogrel 
resulted in a low bleeding risk, probably because of incomplete inhibition of P2Y12 
receptors in many of the patients.
67
 This differs from the situation in patients completely 
lacking the P2Y12 receptors, who have slightly prolonged bleeding times. In Chapter 3 it 
is shown that the thrombogram method of measuring thrombin generation is suitable for 
assessing the variability of responsiveness of patients to clopidogrel, even though only a 
limited number of subjects was included in this study. 
Current attention regarding P2Y12 inhibitors focuses on the thienopyridine prodrug 
prasugrel, which results in a more potent antiaggregatory effect than clopidogrel, with 
rapid onset and long duration.
68
 The active metabolite of prasugrel has also been 
demonstrated to inhibit platelet procoagulant activity via P2Y12.
69
 In addition to prasugrel, 
the direct reversible P2Y12 antagonists AZD6140 and cangrelor (AR-C69931MX) are 
currently in phase 3 clinical trials. Similarly to prasugrel, these antagonists show a more 
rapid onset of action and greater degree of platelet inhibition than clopidogrel, but with so 
far no significant increase in bleeding.
66,70,71
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An attractive new target for antithrombotic therapy is PI3-Kβ, as this signaling protein 
plays a role not only in P2Y12- and, likely, integrin-dependent procoagulant activity but 
also in the glycoprotein VI-dependent procoagulant response.
72
 Inhibition of this PI3-K 
isoform may be a novel effective approach, especially because this enzyme functions to 
enhance (rather than to allow) a number of platelet responses, including platelet 
procoagulant activity and aggregation. 
With respect to the coagulation system, antagonists of factor XII may be beneficial in 
reducing thrombus and clot formation without affecting the coagulation system as a 
whole. Experiments with mice indicated that factor XII deficiency results in instable 
thrombi that tend to embolize. Future studies designed to monitor effects of embolization 
throughout the body will be necessary to gain further insight into the safety and efficacy 
of factor XII as an antithrombotic target. Hopefully the research described in this thesis 
will provide handles for the search for new antithrombotic targets with higher efficacy and 
safety for patients.  
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Interaction mechanisms of platelets and coagulation 
Hemostasis is a process which functions to arrest bleeding after vascular damage by 
inducing the formation of a clot. When the hemostatic balance is disturbed in intact 
vessels, thrombosis may occur with vascular occlusion as a result. Platelets play an 
important role in hemostasis as well as thrombosis. The classical concept of thrombus 
formation starts from the premise that after vascular injury, platelets adhere to 
components of the vessel wall, such as collagen, that become exposed to the blood after 
endothelial damage. Platelets also bind to each other and form a platelet plug or platelet 
aggregate. Subsequent activation of the coagulation cascade by tissue factor results in 
the formation of thrombin and fibrin, the latter stabilizing the platelet aggregate 
(thrombus). However, recently it was demonstrated that platelet activation and 
coagulation are interdependent processes and occur nearly simultaneously. Activated 
platelets can stimulate the coagulation cascade by exposing phosphatidylserine (PS) on 
their surface, on which coagulation factors can assemble and become activated. This 
greatly accelerates the formation of thrombin. The procoagulant response of platelets 
especially occurs upon activation with a combination of thrombin and collagen, and is 
due to a prolonged elevation in the intracellular calcium level of the platelets. 
Considering the extensive interplay of platelet activation and coagulation, it is likely that 
also other interaction mechanisms are involved in these two processes. The studies in 
this thesis confirm this notion. 
In chapter 1 the main physiological activators of platelets are described, as well as 
the receptors and signaling pathways that are relevant for this thesis. Thrombin has an 
important function in coagulation, but is also a potent activator of platelets. It binds to the 
Gq-coupled receptors PAR1 and PAR4, resulting in the activation of the enzyme 
phospholipase Cβ. This leads to calcium mobilization from the internal stores and a 
subsequent rise in the intracellular calcium level. Activated platelets secrete positive 
mediators, like adenosine-diphosphate (ADP), which in turn will activate other platelets. 
Secreted ADP binds to the Gq-coupled receptor P2Y1 and to the Gi-coupled receptor 
P2Y12. The P2Y12 receptor inactivates the enzyme adenylate cyclase and activates 
phosphoinositide 3-kinase (PI3-K). In this chapter it is also described that collagen 
activates platelets via glycoprotein (GP) VI. This collagen receptor activates for instance 
phospholipase Cγ2, with again a rise in the intracellular calcium level as a consequence. 
The fibrinogen receptor integrin αIIbβ3 is also able to induce signaling upon interaction 
with the ligand. This so-called ‘outside-in’ signaling leads to activation of phospholipase 
Cγ2 as well. 
Platelets play an important role in arterial thrombosis, while venous thrombosis is 
associated with high coagulation activity. Since platelet activation and coagulation are 
cooperative processes, in chapter 2 the contribution of platelets to the development of 
venous thrombosis is discussed. How platelets affect the thrombin generation and 
coagulation process is investigated in the next chapters. 
In chapter 3 it is described that ADP is involved in the procoagulant response of 
platelets. The results show that ADP promotes the generation of thrombin in coagulating 
platelet-rich plasma. The ADP produced and secreted by platelets, appeared to be 
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responsible for a considerable part of the thrombin-induced PS exposure. By using 
specific inhibitors of the ADP receptors, it is demonstrated that the procoagulant effect of 
ADP relies on P2Y12 receptor function. Signaling via this receptor causes an elevation in 
the intracellular calcium level which results in PS exposure and subsequent formation of 
thrombin. The effect of treatment with clopidogrel, directed against the P2Y12 receptor, 
was assessed in patients with an increased thrombotic risk. Platelet activation processes 
were determined as well as the capability of activated platelets to stimulate thrombin 
generation by using the thrombogram method. It is shown that clopidogrel incompletely 
suppresses the contribution of P2Y12 to the platelet procoagulant response.  
As it appeared that activation of the P2Y12 receptors enhances the procoagulant 
activity of platelets, the underlying signaling mechanism is investigated in chapter 4. It is 
demonstrated that ADP, via the P2Y12 receptors, synergizes with thrombin to mobilize 
calcium from the internal stores. This synergistic effect of the P2Y12 receptors is 
mediated via two distinct signaling pathways. On the one hand, P2Y12 inhibits adenylyl 
cyclase, which prevents the formation of cyclic AMP and the activation of protein kinase 
A. This is in accordance to the literature, where protein kinase A is described to inhibit 
the function of the inositol 1,4,5 triphosphate receptors that are responsible for calcium 
mobilization. On the other hand, it was found that the P2Y12 receptors activate PI3-K that 
leads to the recruitment of phospholipase C isoforms. Phospholipase C then triggers a 
calcium response via the formation of inositol 1,4,5-triphosphate. By using either mice 
deficient in the PI3-Kγ isoform or a specific inhibitor of the PI3-Kβ isoform, it is shown 
that only the β-isoform is involved in the elevated calcium response. Together these 
results indicate that the P2Y12 receptors enhance the platelet stimulating effect of 
thrombin by an increased and prolonged elevation of the calcium response, thereby 
facilitating the coagulation process.   
Stimulation of platelets leads to activation of integrin αIIbβ3 which enables platelets 
to aggregate. As integrin αIIbβ3 antagonists not only inhibit platelet aggregation but also 
thrombin generation and procoagulant activity, in chapter 5 the signaling mechanism by 
which αIIbβ3 is able to contribute to the coagulation process is investigated. Binding of 
fibrinogen to activated platelets appeared to stimulate the late phase of the calcium 
response, resulting in enhanced PS exposure and thrombin generation. Experiments 
with inhibitors indicate that this response is due to activation of PI3-K, which in part relies 
on ADP secretion and P2Y12 receptor function. It is known that Src kinases and PI3-K, 
both activated downstream of integrin αIIbβ3, recruit and activate phospholipase C 
isoforms. Therefore, it is likely that this enzyme is involved in the calcium signaling 
pathway evoked by integrin αIIbβ3.  
In chapter 6 it is hypothesized that collagen has an additional function in coagulation 
beyond activating platelets via GPVI. Under conditions where tissue factor is limitedly 
present, type I collagen appeared to stimulate the coagulation process, independent of 
platelets, by activating factor XII. It is demonstrated that collagen is able to bind and 
activate factor XII. Furthermore, collagen stimulates the formation of thrombin in platelet-
rich plasma via the combined activation of factor XII and GPVI on platelets. Thrombus 
formation and procoagulant activity were measured in studies where coagulating blood 
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was perfused over a collagen surface under physiological shear conditions. Here 
collagen promoted the formation of large thrombi rich in fibrin and PS-exposing platelets. 
Thrombus formation and procoagulant activity were greatly reduced with blood deficient 
in factor XII or FXI.  The formation of procoagulant thrombi was also dependent on 
glycoprotein VI signaling, as this response was greatly diminished with platelets deficient 
in the signaling proteins LAT or phospholipase Cγ2. These findings demonstrate that 
collagen plays a dual role in thrombus formation under coagulant conditions. Firstly, 
collagen activates platelets via the GPVI-LAT-phospholipase Cγ2 signaling pathway 
which results in platelet aggregation and PS exposure. Secondly, collagen binds and 
activates factor XII and thereby initiates the coagulation cascade. The latter is especially 
important when tissue factor is limitedly available. 
In chapter 7 the findings presented in this thesis are discussed in the light of relevant 
literature and their possible clinical significance is proposed. In addition to thrombin and 
collagen, ADP, via the P2Y12 receptor, and fibrinogen, via integrin αIIbβ3, contribute to 
the formation of procoagulant platelets by which the generation of thrombin in plasma is 
promoted. Collagen can also directly stimulate coagulation by facilitating the activation of 
factor XII. All together, the studies in this thesis may add to the current knowledge on the 
interaction mechanisms of platelets and coagulation and possibly provide handles for the 
development of new strategies for the treatment of cardiovascular diseases.       
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Interactiemechanismen tussen bloedplaatjes en stolling 
Onder normale condities wordt het bloed in de circulatie vloeibaar en stromend 
gehouden. Bij vaatwandbeschadiging zorgt een proces, genaamd hemostase, ervoor dat 
het bloedverlies stopt door middel van activering van het stollingssysteem. Bij verhoogde 
hemostase activiteit in een intact bloedvat krijgt de stolling de overhand, hetgeen kan 
leiden tot verstopping van het bloedvat oftewel trombose. Gebleken is dat bloedplaatjes 
een belangrijke rol spelen bij zowel hemostase als trombose. Het klassieke concept van 
trombusvorming gaat er vanuit dat bij vaatwandbeschadiging de plaatjes eerst gaan 
hechten aan componenten die vrijkomen bij het verdwijnen van de endotheellaag in de 
vaatwand, zoals collageen. Plaatjes hechten ook aan elkaar en vormen daarmee een 
plaatjesprop of plaatjesaggregaat. Bij vasculaire beschadiging zal vervolgens 
weefselfactor vrijkomen, dat de stolling activeert waardoor uiteindelijk trombine en fibrine 
gevormd worden. Het fibrinenetwerk zorgt voor stabilisatie van het plaatjesaggregaat 
(trombus). Sinds kort zijn er echter aanwijzingen dat de activering van plaatjes en de 
stolling vrijwel gelijktijdig optreden en daarmee nauw met elkaar verbonden zijn. 
Geactiveerde plaatjes kunnen zelf ook de stolling stimuleren door het fosfolipide 
fosfatidylserine (PS) op hun membraan te exposeren. Aan dit geëxposeerde PS binden 
stollingsfactoren die vervolgens een interactie met elkaar aangaan, waardoor de vorming 
van trombine aanzienlijk versneld wordt. Deze stollingsbevorderende (procoagulante) 
respons treedt onder meer op wanneer plaatjes geactiveerd worden door de combinatie 
van trombine en collageen, en deze is het gevolg van een langdurige stijging van het 
intracellulair calciumniveau in de cellen. Gezien de sterke mate van verwevenheid van 
plaatjesactivering en stolling veronderstelden we dat er ook nog andere 
interactiemechanismen tussen deze twee processen moeten zijn. De studies in dit 
proefschrift geven aan dat dit inderdaad het geval is. 
In hoofdstuk 1 wordt kort ingegaan op de belangrijkste fysiologische activatoren van 
plaatjes en op de receptoren en signaleringsroutes die relevant zijn voor dit proefschrift. 
Trombine speelt een belangrijke rol in de stolling, maar is daarnaast ook een sterke 
activator van plaatjes. Het bindt aan de Gq-gekoppelde receptoren PAR1 en PAR4 wat 
resulteert in de activatie van het enzym fosfolipase Cβ. Dit leidt tot mobilisatie van 
calcium vanuit de interne opslagplaatsen, waardoor het intracellulaire calciumniveau 
stijgt. Geactiveerde plaatjes scheiden stoffen uit, waaronder adenosine-difosfaat (ADP), 
die zelf weer activerend werken op andere plaatjes. Eenmaal vrijgekomen bindt ADP 
aan de Gq-gekoppelde receptor P2Y1, alsook aan de Gi-gekoppelde receptor P2Y12. De 
P2Y12 receptor inactiveert het enzym adenylaatcyclase en activeert tegelijkertijd het 
fosfoinositide 3-kinase (PI3-K). In dit hoofdstuk is ook beschreven dat collageen de 
plaatjes activeert door middel van glycoproteïne (GP) VI. Deze collageenreceptor leidt 
tot de activering van onder meer het enzym fosfolipase Cγ2, met als gevolg weer een 
stijging van het intracellulair calciumniveau. De fibrinogeenreceptor integrine αIIbβ3 kan 
ook signaleren na interactie met ligand. Deze zogenaamde ‘outside-in’ (buiten-binnen) 
signalering leidt eveneens tot een bepaalde mate van activering van fosfolipase Cγ2. 
Plaatjes spelen een grote rol in arteriële trombose, terwijl het stollingssysteem 
veeleer de overhand heeft in veneuze trombose. Uitgaande van recente bevindingen dat 
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de activering van plaatjes en van stolling gelijktijdig optreden, is in hoofdstuk 2 
bediscussieerd dat plaatjes ook een rol moeten hebben bij het ontstaan van veneuze 
trombose. In hoofdstukken daarna zijn een aantal mechanismen bestudeerd, waardoor 
plaatjes de stolling kunnen beïnvloeden. 
Hoofdstuk 3 beschrijft dat ook ADP een rol heeft in de procoagulante respons van 
plaatjes. De resultaten tonen aan dat ADP de vorming van trombine stimuleert in stollend 
plaatjes-rijk plasma. Het ADP dat door plaatjes geproduceerd werd, bleek 
verantwoordelijk voor een aanzienlijk deel van de PS-expositie van plaatjes, die met 
trombine gestimuleerd waren. Met behulp van specifieke remmers van de twee ADP-
receptoren kon aangetoond worden dat het procoagulante effect van ADP verloopt via 
de P2Y12 receptor. Signalering via deze receptor leidt tot een verhoogde stijging van het 
intracellulair calciumniveau, als gevolg waarvan PS-expositie kan plaatsvinden en er 
meer trombine gegenereerd wordt. In patiënten met een verhoogd tromboserisico is 
bestudeerd wat de gevolgen waren van medicatie met clopidogrel, gericht tegen de 
P2Y12 receptoren. Hier werd onder meer gebruik gemaakt van de trombogram-methode 
waarbij trombinegeneratie gemeten wordt. De resultaten tonen aan dat bij veel patiënten 
clopidogrel inname leidt tot een incomplete onderdrukking van de bijdrage van P2Y12 
aan de procoagulante plaatjesrespons. 
Aangezien activering van de P2Y12 receptoren een duidelijk stimulerend effect bleek 
te hebben op het stollingsbevorderend vermogen van plaatjes, is in hoofdstuk 4 het 
signaleringsmechanisme hiervan in plaatjes onderzocht. Aangetoond is dat trombine en 
ADP, via P2Y12 receptoren, synergistisch werken bij het vrijzetten van calcium uit de 
interne opslagplaatsen. Verder bleek de bijdrage van de P2Y12 receptoren te verlopen 
via twee afzonderlijke maar complementaire signaleringswegen. Enerzijds remt P2Y12 
het adenylaatcyclase, waardoor geen cyclisch AMP gevormd wordt en het 
proteïnekinase A inactief blijft. Dit komt goed overeen met de literatuur, waarin 
beschreven is dat proteïnekinase A de werking vermindert van inositol 1,4,5-trifosfaat-
receptoren, die zorgen voor calcium mobilisatie. Anderzijds vonden wij dat de P2Y12 
receptoren PI3-K activeren, hetgeen zorgt voor de rekrutering van fosfolipase C 
isovormen. Fosfolipase C produceert inositol 1,4,5-trifosfaat met uiteraard een 
calciumrespons als gevolg. Door gebruik te maken van muizen die deficiënt waren in de 
isovorm PI3-Kγ en van een remmer van de isovorm PI3-Kβ kon aangetoond worden dat 
alleen de β isovorm een rol speelt bij de verhoogde calciumrespons. Samengevat laten 
deze resultaten zien dat de P2Y12 receptoren het stimulerende effect van trombine op 
plaatjes versterken door te zorgen voor een verhoogde dan wel verlengde stijging van 
het calciumniveau, waardoor ook de procoagulante respons bevorderd wordt. 
Algemeen bekend is dat stimulering van plaatjes leidt tot activering van integrine 
αIIbβ3, waardoor plaatjes kunnen aggregeren. Omdat blokkering van dit integrine niet 
alleen de aggregaatvorming maar ook de procoagulante plaatjesrespons bleek te 
onderdrukken, is in hoofdstuk 5 onderzocht via welk signaleringsmechanisme αIIbβ3 
hieraan kan bijdragen. De resultaten tonen aan dat de binding van fibrinogeen aan 
geactiveerde plaatjes leidt tot een stimulering van vooral de latere fase van de 
calciumrespons, met als gevolg een uiteindelijk verhoogde PS-expositie en 
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trombinevorming. Experimenten met remmers gaven aan dat hieraan signalering via PI3-
K ten grondslag ligt, die ten dele via ADP en de P2Y12 receptor verloopt. Src kinases en 
PI3-K, beiden geactiveerd door integrine αIIbβ3, zorgen voor de rekrutering en activering 
van fosfolipase C isovormen. Het is daarom aannemelijk dat fosfolipase C een rol speelt 
bij de calciumsignaleringsroute opgewekt door integrine αIIbβ3.  
In hoofdstuk 6 is uitgegaan van de veronderstelling dat collageen de stolling niet 
alleen beïnvloedt door activering van plaatjes via GPVI. Onder condities waarbij 
weefselfactor beperkt aanwezig is, bleek type I collageen de stolling, onafhankelijk van 
bloedplaatjes, te stimuleren door activatie van factor XII. Aangetoond is dat collageen 
ook in staat is om aan factor XII te binden en deze factor vervolgens te activeren. 
Daarnaast is gevonden dat collageen in plaatjes-rijk plasma de trombinevorming 
stimuleert zowel via activering van factor XII als via verhoogde PS-expositie op plaatjes, 
middels GPVI. Door perfusieproeven, waarbij stollend bloed over een 
collageenoppervlak stroomt, is het mogelijk om het trombus-vormende proces en de 
procoagulante activiteit van de plaatjes te bestuderen onder relevante 
stromingscondities. Daarbij bleek dat collageen zorgde voor de vorming van grote trombi 
met veel fibrine en procoagulante plaatjes. Bloed van muizen die deficiënt in factor XII of 
XI waren zorgde voor een duidelijk verminderde trombusvorming en procoagulante 
activiteit. De vorming van procoagulante trombi was bovendien afhankelijk van de mate 
van GPVI signalering, aangezien plaatjes deficiënt in de signaleringseiwitten LAT en 
fosfolipase Cγ2 veel kleinere trombi vormden. Op basis van deze resultaten is 
geconcludeerd dat collageen een dubbele functie heeft in de trombusvorming onder 
stollingscondities: collageen activeert plaatjes via de GPVI-LAT-fosfolipase Cγ2 
signaleringsweg, die leidt tot plaatjesaggregatie en PS-expositie; daarnaast bindt en 
activeert collageen factor XII waardoor het stollingssysteem in werking treedt. Dit laatste 
is met name van belang wanneer weefselfactor slechts beperkt aanwezig is. 
In hoofdstuk 7 zijn de bevindingen van dit proefschrift bediscussieerd op basis van 
de literatuur en is ingegaan op de mogelijke klinische relevantie. Naast trombine en 
collageen zorgen ook ADP, via de P2Y12 receptor, en fibrinogeen, via integrine αIIbβ3, 
voor de vorming van procoagulante plaatjes, als gevolg waarvan de trombinevorming in 
plasma gestimuleerd wordt. Collageen kan bovendien de stolling direct stimuleren door 
activering van factor XII. De studies in dit proefschrift beogen daarmee bij te dragen tot 
een beter begrip van de interactiemechanismen tussen plaatjesactivering en stolling, 
hetgeen wellicht kan leiden tot nieuwe medicatie voor de behandeling van 
cardiovasculaire aandoeningen. 
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